Retinoic acid metabolism blocking agents (RAMBAS) in hyperkeratotic disorders by Verfaille, C.J.
  
 
Retinoic acid metabolism blocking agents (RAMBAS)
in hyperkeratotic disorders
Citation for published version (APA):
Verfaille, C. J. (2007). Retinoic acid metabolism blocking agents (RAMBAS) in hyperkeratotic disorders.
Maastricht: Datawyse / Universitaire Pers Maastricht.
Document status and date:
Published: 01/01/2007
Document Version:
Publisher's PDF, also known as Version of record
Please check the document version of this publication:
• A submitted manuscript is the version of the article upon submission and before peer-review. There can
be important differences between the submitted version and the official published version of record.
People interested in the research are advised to contact the author for the final version of the publication,
or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.
• The final published version features the final layout of the paper including the volume, issue and page
numbers.
Link to publication
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these
rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.
If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above,
please follow below link for the End User Agreement:
www.umlib.nl/taverne-license
Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.
Download date: 04 Dec. 2019
  
 
 
RETINOIC ACID METABOLISM 
BLOCKING AGENTS (RAMBAS) 
IN HYPERKERATOTIC DISORDERS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lay-out: C.J. Verfaille 
Cover illustration: Fiji Mermaid by Takeshi Yamada (see page 239) 
Printing: Datawyse / Universitaire Pers Maastricht 
 
ISBN 978 -90-5278-620-9 
 
© Copyright C.J. Verfaille, Beerse 2007 
All rights reserved. No part of this thesis may be reproduced or transmitted in any form or by any means, 
electronic or mechanical, including photocopying, recording or any information appropriate, without the prior 
written permission of the publishers of the publications.
  
 
 
 
Proefschrift  
 
ter verkrijging van de graad van doctor 
 aan de Universiteit van Maastricht  
op gezag van de Rector Magnificus,  
Prof. Mr. G.P.M.F. Mols 
volgens het besluit van het College van Decanen  
in het openbaar te verdedigen  
op vrijdag 27 april 2007 om 14.00 uur 
 
door 
 
Christel Jeanne Verfaille 
geboren te Menen, België op 19 maart 1969 
UNIVERSITAIRE
PERS MAASTRICHT
P
M
 
RETINOIC ACID METABOLISM 
BLOCKING AGENTS (RAMBAS) 
IN HYPERKERATOTIC DISORDERS 
Promotor 
Prof. Dr. M. Borgers 
Prof. Dr. F.C.S. Ramaekers 
Prof. Dr. P.M. Steijlen  
 
Co-promotor 
Dr. M.A.M. van Steensel 
 
Beoordelingscommissie 
Prof. Dr. J.P.M. Geraedts (voorzitter) 
Prof. Dr. M.J.A.P. Daemen 
Prof. Dr. H. Degreef (Katholieke Universiteit Leuven) 
Prof. Dr. A.P. Oranje (Erasmus MC, Rotterdam) 
Prof. Dr. H. van Loveren 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The work presented in this thesis as well as the printing was financially supported by 
Barrier Therapeutics .  , Geel, Belgium
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Aan mijn ouders 
En mijn familie 
 
Family, family, center of our lifes, 
No one wants a broken circle 
Hands together 
Bound 
(The Innocent Mission) 
 
Abbreviations 
 
ACTH Adrenocorticotropic Hormone 
ADIV Autosomal Dominant Ichthyosis Vulgaris 
AD Atopic Dermatitis  
ADH Alcohol Dehydrogenase 
ALDH Retinal Dehydrogenase 
AE Adverse Event 
All-trans-RA All-trans-Retinoic Acid 
APL Acute Promyelocytic Leukemia 
ARAT Acyl-CoA:Retinol Acyltransferase 
AUC Area under the Curve 
b.i.d. Bis in diem 
BPE Bovine Pituitary Extract 
BSA Bovine Serum Albumine 
CBIE Congenital Bullous Ichthyosiform Erythroderma of Brocq 
CCA Complete Case Analysis 
CRABP Cellular Retinoic Acid Binding Protein 
CRBP Cellular Retinol Binding Protein 
CTCL Cutaneous T-Cell Lymphoma 
CYP Cytochrome P-450 
DR Direct Repeat  
ECG Electrocardiogram 
EGF Epidermal Growth Factor 
ELI Erythrodermic Lamellar Ichthyosis 
ELISA Enzyme-Linked ImmunoSorbent Assay  
FDA U.S. Food and Drug Administration 
FLG Filaggrin Gene 
FSH Follicle-Stimulating Hormone  
HDFa Human Adult Dermal Fibroblasts 
HLA Human Leucocyte Antigen 
HuMVEC Human Micr vascular Endothelial Cells 
IBS Ichthyosis Bullosa of Siemens 
IC50 50% Inhibitory Concentration 
IFN- γ Interferon γ 
IL-1α Interleukin-1α  
ITT Intent-to-Treat 
IU International Units 
i.v. Intravenous 
KRT Keratin Gene 
KSFM Keratinocyte Serum-free Medium 
LI Lamellar Ichthyosis 
LH Luteïnizing Hormone 
LOR Loricrin Gene 
 
o
 LRAT Lecithin:Retinol Acyltransferase 
LSC Liquid Scintillation Counting 
LSGS Low Serum Growth Supplement 
MHC Major Histocompatability Complex 
MRP-8 Migration inhibitory factor-Related Protein 
MTT 3-[4,5-dimethyl-thiazol-2-yl]-2,5-diphenyl tetrazolium bromide 
MVGS Microvascular Growth Supplement 
n-CIE non-Bullous Congenital Ichthyosiform Erythroderma 
NELI Non-Erythrodermic Lamellar Ichthyosis 
NHEK Normal Human Epidermal Keratinocytes 
9-cis-RA 9-cis-Retinoic Acid 
OD Optical Density 
ODC Ornithine Decarboxylase 
PASI Psoriasis Area Severity Index 
PBS Phosphate Buffered Saline 
p.o. Per Os 
PP Per Protocol 
PPAR Peroxisome Proliferator-activated Receptor 
PSORS Psoriasis Susceptibility Locus 
PUVA Psoralen plus UVA-irradiation  
RA Retinoic Acid  
RAL Retinal 
RAMBA Retinoic Acid Metabolism Blocking Agent 
RAR Retinoic Acid Receptor 
RBP Retinol Binding Protein 
RE Retinyl Ester 
RHE Reconstituted Human Epidermis  
ROL Retinol 
RXR Retinoid X Receptor 
SAE Serious Adverse Event 
s.c. Subcutaneous 
SDR Short-chain Dehydrogenase/Reductase 
STS  Steroid Sulfatase 
13-cis-RA 13-cis-Retinoic Acid 
TG-1 Transglutaminase -1 
TGM-1  Transglutaminase-1 gene 
TPA Tetradecanoyl-phorbol-13-acetate 
TR Thyroid Receptor 
TSH Thyroid Stimulating Hormone 
TTR Transthyretin 
UGT2B7 Human Liver Glucuronyl Transferase 
UVA Ultraviolet A 
UVB Ultraviolet B 
VDR Vitamin D Receptor 
XRI X-linked Recessive Ichthyosis 
Contents 
 
 
Chapter 1 General introduction  11 
Hyperkeratotic skin disorders 12 
Ichthyosis 14 
Psoriasis 20 
Acne 22 
Treatment of hyperkeratotic disorders 23 
General treatments 23 
Retinoids 25 
Retinoic Acid Metabolism Blocking Agents 37 
Aim and outline of the thesis 39 
 
Chapter 2 In vitro comparison of 3 generations RAMBAs 55  
Chapter 3 Effects of R115866 on Reconstituted Human Epidermis  69 
Chapter 4 In vivo pharmacology of liarozole  85 
Chapter 5 Topical liarozole in ichthyosis  103 
Chapter 6 Oral liarozole in ichthyosis  119 
Chapter 7 Retinoids and RAMBAs in psoriasis 139 
Chapter 8 Oral R115866 in psoriasis 171 
Chapter 9 Oral R115866 in acne  193 
Chapter 10 General discussion 207 
Summary  221 
Samenvatting  225 
Colour figures 229 
Fiji Mermaid by Takeshi Yamada 239 
Dankwoord 241 
Curriculum vitae 245 
List of publications 248 
 11
 
1  
General Introduction  
Partly based on: 
Verfaille CJ 1,4, van Steensel MAM 2, van de Kerkhof PCM 3 and Steijlen PM 1.  
Use of liarozole in ichthyosis. 
 
 
1 Departments of Dermatology and Molecular Cell Biology, GROW, Maastricht University,  
The Netherlands. 
2 Department of Dermatology, AZM, University Hospital Maastricht, The Netherlands. 
3 Department of Dermatology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands. 
4 Barrier Therapeutics nv, Geel, Belgium 
Submitted 
 
CHAPTER 1 
 12
Hyperkeratotic skin disorders 
The outer layer of the skin, called “the epidermis”, is the largest organ in the human 
body. It is at its thinnest on the eyelids, at .05 mm, and at its thickest on the palms and 
soles at 1.5 mm. As a specialized non-vascularised stratifying epithelium, consisting of 
successive layers (strata) of keratin producing cells (keratinocytes), the epidermis is a 
dynamic, continually renewing structure that functions as an essential barrier to the 
environment. The keratinocytes gradually migrate through the different strata up to the 
surface (keratinocyte maturation) and are sloughed off in a process known as desquama-
tion.1-3 Keratinocyte maturation can be divided into five sequences: 
 
1. The bottom layer of the epidermis, the stratum basale, consists of undifferentiated 
keratinocytes shaped like columns. These cells are attached by hemi-desmosomes 
to a non-cellular basement membrane that separates the epidermis from the under-
lying dermis. In the basal layer, the keratinocytes divide continuously and push al-
ready formed cells into higher layers. Half of these cells progress upwards and dif-
ferentiate, while the other half remain behind to divide again. In addition to the dif-
ferentiating keratinocytes, the stratum basale also houses other cells with stem cell-
like properties, Merkel cells (with apparent sensory functions) and melanocytes 
(pigment producing cells that protect us against ultraviolet radiation damage). 
2. In the middle inner layers, the stratum spinosum (8-10 sheets of keratinocytes with 
limited dividing capacity), the shape of the keratinocytes changes from columnar to 
polygonal. Differentiating keratinocytes synthesize keratins which aggregate to 
form the tonofilaments that make up the cell skeleton. Condensations of these tono-
filaments insert into desmosomes which connect keratinocytes and serve to disperse 
structural stresses through the epidermis. Also found here are bone marrow-derived 
sentinel cells of the immune system called Langerhans cells. 
3. The next layer, the stratum granulosum, consists of 3-5 sheets of non-dividing 
keratinocytes producing granules of a protein called keratinohyalin and enzymes 
which induce degradation of nuclei and organelles. The formation of an anuclear 
keratin layer is called orthokeratosis. Keratohyalin granules mature the keratin and 
provide an amorphous protein matrix for the tonofilaments. Membrane coating 
granules attach to the cell membrane and release impenetrable lipid-containing ce-
ment which contributes to cell adhesion and to the cornified envelope which ulti-
mately will form the epidermal barrier.  
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4. The outermost layer of the epidermis, the stratum corneum, consists of 15-26 layers 
of highly cross-linked dead but biochemically active, flat skin cells or corneocytes 
that are organized into ‘bricks-and-mortar’ arrays and shed about every 2 weeks. 
Corneocytes are afforded extra protection via a uniform peripheral envelope of sev-
eral highly cross-linked, cytosolic proteins, the cornified envelope. The flattened 
sheets are packed with keratin filaments and embedded within a matrix of filaggrin 
and interconnected via junctions (corneo-desmosomes). The stratum corneum is 
important in preventing all manner of agents from entering the skin, including mi-
cro-organisms, water and particulate matter. It also prevents loss of vital body flu-
ids. Barrier function in human epidermis depends on transglutaminase (TGase)-
mediated cross-linking of structural proteins and lipids during this terminal stage of 
keratinocyte differentiation. Such cross-linking yields high molecular mass proteins 
highly resistant to mechanical perturbation and proteolysis. Several mutations in 
genes encoding the barrier’s structural components, its enzymes and lipid process-
ing can result in skin diseases. 
5. Corneocytes are shed from the skin surface. 
 
The dividing basal cell replicates on average every 200 to 400 hours, and the resulting 
cell takes 14 days to differentiate and 14 days to be shed again, which results in a 
normal human epidermal cell turn-over of 28 days. Increased proliferation of the basal 
cells or increased retention of the keratinocytes within the epidermis, or both, results in 
increased thickness of the epidermis, also called ‘hyperkeratosis’, a typical feature of 
keratinisation disorders. Many such diseases have been discovered to date, but this work 
will only focus on 3 of them: ichthyosis, psoriasis and acne. 
 
Genetic abnormalities in structural cytoskeleton proteins or in enzymes responsible for 
the formation of the cornified cell envelope or the metabolism of the intercellular lipids 
are among the main causes of keratinization disorders such as ichthyosis. These, how-
ever, are relatively rare. 
 
Hyperkeratosis as a result of an abnormal cell turnover is much more common. Abnor-
mal cell-turn over is caused by abnormalities in the keratinocyte life-cycle, which may 
or may not be immune-mediated. The best known example is psoriasis, where hyperk-
eratosis is associated with aberrant differentiation and inflammation caused by the 
release of cytokines into the epidermis by keratinocytes and lymphocytes. Mitotic 
activity of basal keratinocytes is increased almost 50-fold, with keratinocytes migrating 
from the basal to the cornified layers in only 3-5 days compared to the normal 28-30 
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days. With hyperproliferation of skin cells, the epidermis becomes thickened or acan-
thotic in appearance and an increase in size of the rete ridges is observed. Abnormal 
keratinocyte differentiation is noted throughout the psoriatic plaques, as manifested by 
the loss of the granular layer. The stratum corneum is also thickened, and the retention 
of cell nuclei in this layer is referred to as parakeratosis. 
 
Hyperkeratosis is also one of the factors involved in the pathogenesis of acne. The 
keratinocytes lining the inside of a hair follicle normally detach from the lining, attach 
to the growing hair and die, while converting themselves into corneocytes and forming 
the hair cuticle. In acne, a number of the keratinocytes in the follicle convert too fast 
(=hyperkeratinization), clumping together instead of attaching to the cuticle. When such 
a clump of keratinocytes blocks the follicle exit, it induces comedogenesis and contrib-
utes to acne. 
Ichthyosis 
‘Ichthyosis’ is a descriptive term used for a clinically and genetically heterogeneous 
group of keratinisation disorders caused by abnormal differentiation and/or desquama-
tion of the epidermis. Ichthyosis is derived from the Greek word ‘ichthys’ which means 
fish, as it is characterized by visible scales all over the body surface and excessively dry 
skin.4 These dermatoses are rarely life-threatening but they can be debilitating, cause 
social isolation and may require life-long treatment. The quality of life of these patients 
is severely affected.5 
 
The group is classified on the basis of clinical appearance and the underlying gene 
defect. Classification has been refined over the years due to spectacular advances in 
molecular genetics. Today, more than 20 different subtypes have been described and as 
more mutations are discovered, more surely will follow over the next years. An over-
view of the molecular genetics and geno/phenotypes of the different ichthyosis subtypes 
described in this thesis is given in Table 1.1. More information on the different ich-
thyosis subtypes can be found in the works of H.Traupe and Judge and Harper.4,6 More 
recently, the molecular genetics have been reviewed by Richard et al. and Segre et al.7,8 
Autosomal dominant ichthyosis vulgaris (ADIV) 
ADIV, with an incidence in 1/250 individuals, is the most common form of ichthyosis. 
Although inherited in an autosomal dominant pattern, it differs in many ways from the 
rest of the ichthyosis. Being a lot milder than the other types, it responds well to hydra-
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tion, lubrication and keratolytics and is considered a separate clinical entity by derma-
tologists. It is often classified as an excessive dryness, which is not present at birth but 
develops during the first years of life. There is a marked seasonal variation and the 
dryness worsens in dry climate.  
In 2005-2006, Irwin McLean et al. and other experts on genetic skin disorders have 
discovered that ADIV is caused by mutations in the filaggrin (FLG) gene located on 
chromosome 1. The FLG gene encodes profilaggrin, a protein that is needed for the 
formation of the stratum corneum.9 During epidermal differentiation profilaggrin is 
cleaved into multiple filaggrin peptides that aggregate keratin filaments. ADIV is semi-
dominant meaning that heterozygous mutations in the FLG gene result in either no 
discernible phenotype or a very mild form of ADIV whilst homozygous mutations result 
in moderate to severe ADIV. An additional major discovery by the same experts was 
that mutations in the FLG gene are also held responsible for the development of atopic 
dermatitis (AD) and asthma.10 Thus, patients with ADIV are predisposed to develop AD 
(or eczema) later in life, which is of a greater concern that the ADIV itself.10,11 
The other ichthyosis subtypes, of which only a few will be described in more detail, are 
far rarer and far more severe than ADIV and can be considered orphan diseases. There-
fore patients are often referred to specialized academic centres for diagnosis and treat-
ment. The only effective drugs available today for the treatment of severe ichthyosis are 
retinoic acid (RA) and its synthetic analogues.  
X-linked recessive ichthyosis (XRI) 
XRI is caused by a defect in the STS gene (steroid sulfatase) which leads to an accumu-
lation of cholesterol-3-sulfate in the epidermis.12,13 The result is a defect in desquama-
tion. The skin is covered with small, dark, firmly adherent scales accentuated on sides 
of the neck and on the trunk. Face, palms and soles are generally spared. As it is an X-
linked recessive trait, the disorder is only manifested in males and has an incidence of 
1/6000. It may be present at birth but is often not noticed for months or years. The 
overall severity does not change with time but distinctively worsens in dry weather. 
Autosomal recessive congenital ichthyosis: Lamellar ichthyosis (LI) 
LI is, with an incidence of 1/300,000-600,000, one of the most severe forms of ich-
thyosis. Inherited in an autosomal recessive trait, it is already apparent at birth and 
persists unremittingly throughout life. Many LI patients are born encased in a tight, 
shiny, translucent membrane with underlying erythroderma and are called ‘collodion 
babies’, because the membrane resembles collodion, which is a syrupy solution that was 
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once used to coat photographs.4,14 The “collodion membrane” is gradually replaced over 
the first weeks of life by generalized large, dark brown and plate-like scales with mini-
mal to no erythema. Increased susceptibility to bacterial and fungal skin infections, as 
well as heat intolerance, may be a common problem in this group. 
Mutations in the transglutaminase-1 gene, TGM-1, have been found in about 30% of 
patients with features of the ‘classical’ non-erythrodermic LI, in the past also referred to 
as non-erythrodermic lamellar ichthyosis or NELI.15-18 Transglutaminase-1 is a crucial 
epidermal enzyme expressed in the upper differentiated layers. It facilitates the forma-
tion of an insoluble protein envelope by cross-linking numerous structural proteins (e.g. 
loricrin, keratin intermediate filaments, and others) as well as the attachment.19,20 Only 
few patients carrying TGM-1 defects have mild to moderate erythroderma with white, 
gray or small scales.21-23 Today this group is classified as congenital ichthyosiform 
erythroderma. In the past they were assigned to the LI group and referred to as 
erythrodermic lamellar ichthyosis or ELI.4,24 
In other individuals with LI, misense mutations have been reported in a novel gene 
namely ABCA12, which belongs to the large super-family of ATP-binding casette 
transporter genes.25 ABCA12 is hypothesized to be involved in epidermal lipid traffick-
ing. Complete loss of ABCA12 function results in harlequin ichthyosis, the most severe 
form of congenital ichthyosis often lethal in the neonatal period.26,27 In 2006, Lefevre et 
al. reported mutations in a new cytochrome P450 gene (encoding for CYP4F2) in 
lamellar ichthyosis.28 
Autosomal recessive congenital ichthyosis: non-bullous congenital ichthyosi-
form erythroderma (n-CIE) 
The clinical features of n-CIE, a usually severe inflammatory ichthyosis occurring in 
about 1/200.00 individuals, are somewhat milder than in lamellar ichthyosis. In contrast 
to classical LI, the skin is always red and scales are usually white, fine and powdery. In 
some subtypes of n-CIE, the palms and soles are severely hyperkeratotic.6 Ninety 
percent of the patients are born as collodion babies. Shedding of the collodion mem-
brane within the first weeks of life reveals persistent, generalized scaly erythroderma. 
Pruritus is characteristic for n-CIE and in most patients sweating is compromised and 
markedly reduced from infancy onwards. Heat intolerance and increased susceptibility 
to infections of the skin is common.  
Although inherited as an autosomal recessive trait in the vast majority of families, 
autosomal dominant transmission has occasionally been reported. Several genes have 
been implicated it its pathogenesis, including TGM-1 as discussed above, the lipoxy-
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genase genes ALOXE3 and ALOX12B and the ichthyin gene which encodes a protein of 
unknown function localized in the plasma membrane with homologies to both transport-
ers and G-protein coupled receptors.29,30 Occasionally, the related Chanarin-Dorfman 
disease, caused by mutations in the ABHD5 gene, may be confused with n-CIE.31 
Autosomal dominant epidermolytic ichthyoses 
The epidermolytic ichthyoses (<1/100,000) i.e. congenital bullous ichthyosiform 
erythroderma of Brocq (CBIE) and ichthyosis bullosa of Siemens (IBS) are autosomal 
dominant disorders of keratinisation which are associated in younger patients with 
blistering.32,33At least half of the cases have no family history and thus are presumed to 
represent new mutations.34 Genetic defects in the keratin genes KRT1 and KRT10 have 
been described for CBIE and in KRT2e for IBS, which clinically appears as a mild 
variant of CBIE.35-37Apart from generalized erythroderma, the skin may appear normal 
immediately at birth. However, within a few hours of life, extensive blisters and peeling 
are apparent. 
Progressive hyperkeratosis, predominantly in the flexures, scalp, anterior neck, abdomi-
nal wall and infragluteal folds is obvious from early childhood. Yellow-brown waxy 
scales tend to form parallel rows of spines or ridges especially near large joints. The 
scaling remains a life long while the blistering improves significantly with age. Infec-
tion of blisters is common. Colonization with bacteria and yeast cause an embarrassing 
body odour. 
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Psoriasis 
Psoriasis is a chronic, multi-factorial and complex skin disorder affecting 1 to 3 % of 
the world’s population. There are several variations of psoriasis, but this thesis deals 
only with the most common form, psoriasis vulgaris or plaque-type psoriasis, which 
accounts for 90% of all cases. Because the manifestations of the disorder are visible and 
obvious, the disease has a profound psychosocial impact.38,39 A symmetrical distribution 
of skin lesions is the rule in plaque-type psoriasis. Any part of the body skin may be 
involved, but the face is frequently spared. The most commonly involved areas are the 
elbows, knees, scalp, sacrum, umbilicus, intergluteal cleft, and genitalia. A typical fully 
developed lesion is a sharply demarcated, red-violet, round or oval plaque of 1 cm or 
larger in diameter surmounted by white silvery scales. In darkly pigmented patients, 
lesions are hyperpigmented with various shades of brown or black. About 70% of 
patients complain of pruritus, skin pain, or burning, especially when the scalp is in-
volved. The course is chronic, with exacerbations and remissions. 
Histological examination of psoriatic lesions reveals the following abnormalities: 
epidermal hyperproliferation, premature keratinisation resulting in a depleted number of 
granular cells and infiltration of immune cells and polymorphonuclear leukocytes.40-42 
The cause of psoriasis is unknown. Manifesting itself as a skin disorder, it was consid-
ered until the 1980’s to be a disease resulting from abnormal regulation of keratinocytes 
growth and differentiation. Mueller et al. had provided the first evidence of T-cell 
involvement.43 Over time, more evidence is gathered that impaired or defective cell 
mediated immunity (T-cell driven) plays a critical role in the pathogenesis.44-48 The 
same counts for the involvement of a genetic component. Supporting evidence includes 
the fact that psoriasis runs in some families; secondly, the increased incidence of psoria-
sis in children when one of both parents has psoriasis; thirdly, analysis of concordance 
rates amongst monozygotic and dizygotic twins; and fourthly, a higher than expected 
frequency of certain white cell antigens (Class I human leucocyte antigens or HLAs) on 
T-cells in patients with early-onset psoriasis and their close relatives. 
The mode of inheritance is still uncertain. Based upon analyses of family pedigrees, 
polygenic inheritance probably provides the best model for the complex genetics of 
psoriasis. Genome-wide linkage scans have demonstrated several genetic loci that are 
associated with susceptibility for psoriasis; these studies have recently been reviewed by 
Rahman and Elder.49 A number of HLA class I and II antigens were found to be associ-
ated with psoriasis, such as HLA-B13, -B17, -B37 and -Cw6.50 Further studies revealed 
that these latter associations were secondary to an association with HLA-Cw6. The 
locus that includes the HLA-C gene, now known as PSORS1, is the major susceptibility 
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locus for psoriasis.51-53PSORS1, mapped to chromosome 6p21.3 by independent groups, 
was found to be involved in about 50% of psoriatic patients. PSORS1 is situated within 
the major histocompatibility complex (MHC) region of chromosome 6, which contains 
human lymphocyte antigen genes and various interleukin genes.54-56 At present, 8 
different psoriasis susceptibility loci have been suggested on different chromosomes57 
like 6p58, 17q59 and 20p60. The alpha-antitrypsin gene locus and a polymorphism of the 
IL-1 receptor antagonist gene have also been associated with psoriasis.61,62 The prob-
ability that genes found to be associated with psoriasis may or may not cause the disease 
in an individual, depends on the activity of the genes in relation to one another, which is 
determined by the inheritance pattern. 
Also, other factors such as injury, infection or stress are involved in triggering the onset 
of the disease which leads us to the latest hypothesis reported by Boss et al. that psoria-
sis is probably a genetically determined triggered state of otherwise dormant innate 
immunity.47 
Psoriasis has several morphological expressions.39 The form that psoriasis takes in a 
patient depends on a combination of genetics, environmental factors, associated diseases 
and concomitant medications. Psoriasis cannot be cured nor prevented. Symptomatic 
treatment is the only treatment currently available. 
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Acne 
Acne vulgaris is a very common skin disease affecting most people at some point in 
their life between 11 and 30 years. Of the 15-30% that needs medical treatment due to 
the severity of the condition, 2-7% of the patients are left with post-acne scars.63 Al-
though the disease is not life-threatening, it can have serious adverse effects on a per-
son’s psychosocial development and the quality of life leading to emotional problems 
and even depression.64,65 
Limited to the sebaceous follicles of the head and upper trunk, acne vulgaris is a skin 
disorder with a very complex aetiology involving 4 major factors: increased sebum 
production, hyperkeratosis of the pilosebaceous duct, colonization with Propionibacte-
rium acnes and, finally, inflammation. The primary lesion in acne is the “microcomedo” 
that may evolve over time into a non-inflammatory one, i.e., an open comedone (black-
head) or a closed one (whitehead) and further to an inflammatory lesion (pustule, papule 
or nodulocystic lesion).66 Yet, the exact sequence and precise interdependence of the 
pathogenic factors in acne, and especially their point of origin have remained unclear. 
The conventional concepts have recently been critically reviewed and discussed by 
Zouboulis et al.63  
Oral isotretinoin, developed more than 20 years ago, is the only drug currently available 
that affects all four before mentioned pathogenic factors of acne.67-69 Although not 
directly affecting P. acnes, its inhibitory effect on sebum production leads to alteration 
of the follicular microclimate and indirect fall of P. acnes counts reducing its ability to 
induce inflammation. 
Acne can be graded according to Cunliffe into mild, moderate and severe based on the 
total number of comedones, inflamed lesions and a total lesion count.70,71 Correct 
grading of acne is important, ensuring patients are not under or over-treated. 
Acne may be triggered or worsened by external factors such as mechanical obstruction 
(i.e. helmets, shirts and collars), medications, occupational exposures, cosmetics and 
emollients. 
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Treatment of hyperkeratotic disorders 
General treatments 
The treatment of ichthyosis, psoriasis and acne is purely symptomatic. The choice of 
treatment depends on the severity of the disease and the response of the patient. Mild to 
moderate forms are usually treated with topical agents whereas the severe forms require 
oral treatment.4, 71-74 
 
In ichthyosis and psoriasis, emollients are usually tried first followed by keratolytic 
lotions containing salicylic acid or urea. However, these ointments are of limited value 
in ichthyosis as they are only effective in ADIV, whereas the more severe ichthyosis 
subtypes do not markedly improve.4 
Anti-inflammatory agents can be used when an immune or inflammatory component is 
involved. As a prototype of this class of drugs, topical corticosteroids are quite effective 
in the treatment of both acne and psoriasis.71-73 However, long-term use of topical 
corticosteroids can cause side effects, ranging from cutaneous atrophy to systemic 
adrenal suppression.73 
Topical and oral antimicrobials (e.g. azaleic acid, benzoyl peroxide, antibiotics) have 
been a mainstay of acne treatment for more than 30 years. For optimizing results, they 
are often used as a combination therapy in more inflammatory forms of acne. However, 
the potential for bacterial resistance limits their long-term use.71,75 
Hormonal therapy with oral anti-androgens is an excellent treatment option for women 
suffering from severe acne when oral contraception is desirable.76,77 
Cyclosporin A, a systemically active T-cell suppressor (calcineurin antagonist), is an 
efficient immunosuppressant but it is reserved for the more severe cases of psoriasis due 
to its toxicity profile (especially hypertension and renal impairment).43,78 
Recently, antibodies (“biologics”) that modify immune signalling have been introduced 
for the treatment of psoriasis. These agents must be administered intramuscularly or 
intravenously, are accompanied by various systemic adverse effects and have yet 
unknown long-term safety profiles.79 
Agents that block cell division are also helpful in psoriasis, but they have to be adminis-
tered systemically and are accompanied by significant toxicity, limiting their use to 
severe cases. Methotrexate is a good example of such a drug. While very effective, its 
use is limited by its hepatotoxicity and bone marrow toxicity.74,80 
Phototherapy, which comprises PUVA (psoralen plus UVA-irradiation), and small- and 
broad-spectrum UVB, is the treatment of choice for psoriasis when larger areas are 
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involved and topical treatments are insufficient.73 Short-term use of phototherapy is 
relatively safe but cumulative sessions increase the risk for skin cancer. Phototherapy is 
frequently combined with topical or systemic treatments in order to enhance the thera-
peutic effect whilst using reduced cumulative UVA/UVB doses (cfr. chapter 7).81-87 
Another attractive concept for the treatment of keratinization disorders is modulation of 
the keratinization process at the level of gene regulation. The vitamin A and D deriva-
tives all-trans-RA and 1α,25-dihydroxyvitamin D3, respectively are steroid hormones 
that modulate the expression of genes essential for keratinocyte growth and differentia-
tion. They exert most of their biological activities through binding to specific nuclear 
receptors (the VDR and the RARs/RXRs, belonging to the superfamily of nuclear 
receptors), which act as ligand–inducible transcriptional factors. Vitamin D3 analogues 
such as calcipotriol, calcitriol (1,25-dihydroxy vitamin D3), tacalcitol (1,24-dihydroxy 
vitamin D3) are only available as topical treatments for psoriasis because systemic 
administration is accompanied by significant disturbances in calcium homeostasis.73,88,89 
A 2-compound ointment of calcipotriol and betamethasone dipropionate, a potent 
corticosteroid, has recently been developed and proven to be efficacious in treating 
moderately severe forms of plaque psoriasis. A good clinical improvement of lamellar 
and epidermolytic ichthyosis with topical calcipotriol has been demonstrated. However, 
the limited maximum weekly amount of 100 g constitutes a restriction for its use, as in 
these patients, a substantial part of the total body surface is affected.90 
The retinoids, a group of natural and synthetic compounds that share structural and/or 
functional similarity with vitamin A, have been used widely for oral and topical treat-
ment of ichthyosis, psoriasis and acne.71,73,74,91,92 Their long history and mechanism of 
action will be discussed in greater detail below. Topical retinoids are often used in the 
treatment of mild to moderate forms, despite being associated sometimes with signifi-
cant irritation.72,73,93,94 Systemic retinoids are reserved for patients with more severe and 
recalcitrant types because of their toxicity such as long lasting teratogenicity, hyper-
triglyceridemia, liver abnormalities and skeletal malformations. 69, 95-99 
 
In conclusion, there is ample room for alternative therapies that are at least as effective 
as the established ones but have a more favourable side-effect profile.100-102A new and 
promising approach is a pathway-based therapy, which increases the endogenous all-
trans-RA levels only in tissues that actively metabolize all-trans-RA by blocking 
retinoic acid metabolizing enzymes. Compounds that can do this are available and are 
called retinoic acid metabolism blocking agents, or RAMBAs. The RAMBA approach 
as a treatment to ichthyosis, psoriasis and acne is the subject of this thesis. 
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Retinoids 
History 
Retinoids are a group of natural and synthetic compounds that share structural and/or 
functional similarity with vitamin A (retinol, ROL). The importance of retinoids in the 
skin was first noted in 1925 by Wolbach and Howe, who showed that vitamin A (reti-
nol)-deficiency, or the absence of compounds with vitamin A activity, leads to kerati-
nizing metaplasia and hyperkeratosis.103 Numerous studies followed, focusing on the 
metabolism and pharmacological action of retinoids in the skin and the development of 
retinoid treatment for various skin diseases. The chemical structures of the natural 
occurring retinoids are presented in Figure 1.1. 
Vitamin A was initially investigated at non-physiological doses in acne and psoriasis. 
Megadoses of vitamin A (2-4 million IU) resulted only in a slight improvement of 
psoriasis, but the symptoms of a vitamin A intoxication, such as intracranial hyperten-
sion with nervous disturbances, dryness of the mucous membranes and skin peeling 
were unacceptable to patients.104 Thousands of analogues have since been synthesized, 
out of which 3 successive generations have been established for topical and systemic 
treatment of hyperkeratotic disorders. 
The first generation comprises the non-aromatic retinoids: β-carotene (pro-vitamin A), 
all-trans-RA (tretinoin) and 13-cis-RA (isotretinoin). All-trans-RA as well as isotreti-
noin proved to be of use for the topical treatment of acne but their use was hampered by 
their irritating potential.72,105 Besides, they had no anti-psoriatic potential following 
topical application. Systemic treatment with all-trans-RA and isotretinoin requires high 
doses in order to be effective which produces unacceptable side effect restricting their 
use. For more than 20 years, isotretinoin is the only oral retinoid effective in the treat-
ment of acne but it is reserved for the more severe forms due to its toxicity profile 
(increased liver enzymes, hypertriglyceridaemia, teratogen city, cutaneous side ef-
fects,…).106 Today, it is a first line treatment in severe nodular acne and is commonly 
used for recalcitrant acne resistant to oral antibiotics.67,69 
Because the efficacy of orally administrated vitamin A and all-trans-RA was insuffi-
cient, the search for synthetic analogues with a better efficacy and safety profile went on 
and resulted in the synthesis of the mono-aromatic retinoid derivative etretinate and, 
later, of its free active carboxylic acid metabolite acitretin.107,108 Etretinate and acitretin 
are highly (and equally) effective systemic treatments for psoriasis with adverse events 
that appear to be similar in severity and incidence.109,110 Today acitretin is the preferred 
systemic retinoid for psoriasis because of its better pharmacokinetic profile.111 The 
i
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mean elimination half-life of acitretin is about two days, whereas the mean elimination 
half-life of etretinate, the ethyl ester of acitretin, is 120 days but can still be detected in 
the subcutis as long as 18 months after treatment.112-113 Acitretin was developed because 
it was thought to be cleared from the body more rapidly than etretinate. However, re-
esterification of acitretin to etretinate in the human body has found to be possible, 
especially if the patient has a substantial alcohol intake.114 Therefore, in view of the 
teratogenic effect, women of childbearing potential who have been treated with acitretin 
have to continue contraception for 2 years in Europe and for 3 years in the US after 
stopping the therapy which puts a real burden on its use.115 Next to its teratogenicity, the 
use of acitretin is also hampered by a serious toxicity profile which is discussed more 
into detail in chapter 7.102,116-118 
So the search for new analogues offering at least the same efficacy and a better 
risk/benefit ratio as the previous ones resulted in the development of a third generation: 
the polyaromatic retinoid derivatives or arotenoids: e.g. tazarotenic acid, adapalene and 
the specific RXR-ligands (rexinoids) like bexarotene. Topical adapalene is on the 
market for the treatment of acne whilst topical tazarotene has been approved for both 
the treatment of acne and psoriasis.119-126 Nevertheless, subjects treated with one of 
those compounds are not free from cutaneous irritation at the site of application. Oral 
tazarotene and bexarotene have been proven effective treatments in acne and/or psoria-
sis, respectively, but they are not without potentially serious side effects (see also 
chapter 7).127-129 Today, the search for more efficacious and less toxic retinoids contin-
ues.  
Retinoid sources and metabolism 
All-trans-RA sources 
All-trans-retinoic acid (all-trans-RA), the naturally occurring derivative of vitamin A 
(retinol; ROL) regulates the expression of genes involved in cell proliferation, differen-
tiation and apoptosis and is essential for normal embryonic development and general 
health in the adult.130 The chemical structures of the naturally occuring retinoids are 
presented in Figure 1.1. Ultimately, all retinoids in the body are derived from the diet, 
where they are ingested either as retinyl esters (RE) derived from animal fat or as 
carotenoids (β-carotene) derived from yellow and green vegetables; see Figure 1.2.131,132  
Ingested RE are converted to ROL in the intestinal lumen by enteral hydrolases, allow-
ing absorption of free ROL by the mucosa. β-carotene enters the enterocytes by passive 
diffusion where it is converted to 2 retinal (RAL) molecules through central cleavage by 
GENERAL INTRODUCTION 
 27
β-carotene-15,15’-dioxygenase.131, 133-135 In addition, an eccentric cleavage pathway was 
proposed, based on in vitro work, in which β-carotene is cleaved into RAL and apo-
carotenals with different chain lengths, but this has not been confirmed in vivo. 
RAL binds to cellular retinol binding protein II (CRBPII) and is reduced to ROL by a 
microsomal retinal reductase.136 The fact that CRBPII is highly expressed in the absorp-
tive cells of the small intestine and comprises up to 1% of the soluble proteins suggests 
that CRBPII has an essential role in the initial processing of ROL from food. In the 
enterocytes, also free ROL forms complexes with CRBPII.137 This ROL-CRBPII 
complex serves as a substrate for a lecithin:retinol acyltransferase (LRAT). LRAT is 
responsible for the re-esterification of ROL to RE which will be incorporated into 
chylomicrons (tri-acylglycerol-rich lipoproteins) together with phospholipids, choles-
terol and triglycerides during absorption of normal loads of vitamin A.138-140 However, 
when large amounts of ROL are rapidly absorbed into enterocytes (due to a vitamin A 
rich meal or high pharmacological doses) it will accumulate in the cell membranes as 
CRBPII and LRAT become saturated leading to an increased activity of another en-
zyme, the acyl-CoA:retinol-acyltransferase (ARAT). The excessive amount of free ROL 
will then be esterified by ARAT and temporarily stored in lipid droplets.141 
The chylomicrons containing the RE travel through the intestinal lymphatic system 
where they undergo lypolysis to give rise to chylomicron remnants, which are primarily 
cleared by the liver.142 Also, extra-hepatic chylomicron uptake has been shown in bone 
marrow and spleen and to a lesser extent in testes, lung, kidney, fat and skeletal mus-
cle.132,143 The uptake of the chylomicron remnants by the parenchymal cells in the liver 
(endocytosis) is mediated by the apolipoprotein E receptor.144-146 In the parenchymal 
cells, RE are hydrolyzed and free ROL is released into the blood together with retinol-
binding protein (RBP).147 In the blood, 95% of the ROL-RBP complex associates with 
transthyretin (TTR) which transports the complex to extra-hepatic tissue. TTR is a 
serum protein which has the ability to bind and transport simultaneously but independ-
ently both the ROL-RBP complex and the thyroid hormone.132 Excess ROL in the 
hepatocytes undergoes a paracrinic transfer to the stellate cells in the liver where it will 
form a complex with cellular binding protein I (CRBPI) who facilitates the esterification 
of ROL by LRAT to form RE for storage.148 Fifty to 80% of the total body ROL is thus 
stored as RE in the stellate cells of the liver, from which it can be released to maintain 
constant ROL concentrations in the plasma. Extra-hepatic tissues also play a role in 
storage and mobilization of ROL and contribute to vitamin A homeostasis.149 ROL is the 
most abundant retinoid in blood. Under normal dietary conditions, the plasma ROL 
concentrations are relatively high (2µmol/L), making ROL available throughout the 
body for potential conversion to all-trans-RA.
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Figure 1.1  Chemical structures of naturally occurring retinoids. 
 
Tissue uptake of ROL and intracellular metabolism 
The specific mechanism by which ROL is transferred from ROL-RBP or ROL-RBP-
TTR to the target cells is not yet fully understood. Several possible mechanism have 
been proposed, like a specific RBP receptor-mediated uptake, a non-specific spontane-
ous transfer of ROL (and all-trans-RA) and fluid-phase endocytosis.132,150,151 Based on 
the available evidence, a receptor-mediated uptake of ROL is believed to be the most 
important mechanism to deliver ROL to cells that require it. Beginning 2007, Kawagu-
chi R. and co-workers published the discovery of the long-sought membrane receptor 
for RBP which mediates cellular uptake of ROL.291 STRA6, a previously discovered but 
uncharacterized multitransmembrane domain protein, has now been identified in bovine 
retinal pigment epithelium cells as a specific membrane receptor for RBP. STRA6 binds 
to RBP with high affinity and has robust ROL uptake activity from the ROL-RBP 
complex. STRA6 is widely expressed in embryonic development and in adult organ 
systems where a RBP receptor would be expected such as RAL pigmented epithelium 
of the adult eye, placenta, brain, spleen, female genital tract, testis, lung and skin. The 
RBP receptor represents a major physiological mediator of cellular vitamin A uptake.  
 
Once inside the cell, ROL can associate with CRBPI and serve either as a substrate for 
esterification by LRAT (note: in the intestine substrate for LRAT is ROL-CRBPII) or it 
can be converted to all-trans-RA depending on the ratio freeCRBPI/boundCRBPI.152 It 
has been postulated that the quantity of free CRBPI present in the target cell also deter-
mines the amount of ROL that is taken up by the cell.153 
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The basic cellular pathway leading to the conversion of ROL to all-trans-RA consists of 
2 steps which are mediated by numerous dehydrogenases. The first step is a reversible 
oxidation/reduction of ROL-CRBPI to RAL-CRBPI, which can be catalysed by three 
different enzyme families: the alcohol dehydrogenases (ADH), the short-chain dehydro-
genases/reductases (SDR) and the cytochrome P450s.154 The second step is mediated by 
tissue specific retinal dehydrogenases (ALDH) and is an irreversible oxidation of RAL 
or RAL-CRBPI to all-trans-RA, which will form a complex with a cellular retinoic acid 
binding protein (CRABPI or II).152,155,156 Some all-trans-RA will bind to specific reti-
noic acid receptors for signaling, while the rest will be subjected to oxidative degrada-
tion to more polar metabolites by various CYP450 enzymes (including CYP26A1, 
CYP26B1, CYP26C1: see below). 
CRABPI and II 
Intracellularly, all-trans-RA is bound to either CRABPI or CRABPII with high affinity; 
CRABPI binds it with a higher affinity than does CRABPII.157 Natural metabolites of 
all-trans-RA, including 4-hydroxy-RA, 4-oxo-RA, 18-hydroxy-RA, 3,4-didehydro-RA 
can also bind to CRABPS. Binding of 9-cis-RA to CRABPs occurs with a lower affinity 
than all-trans-RA and there is only little, if any binding, of 13-cis-RA or 9,13-dicis-
RA.158-160 CRABPI is expressed almost ubiquitously whereas CRABPII is only ex-
pressed in certain tissues e.g. skin, liver, bone, uterus, ovary and choroid plexus. Al-
though both CRABPI and II are widely expressed in the embryo, they don’t coexist in 
the same cells. Both CRABP isoforms are present in the cytosol and the nuclei of cells. 
In general, expression of CRABPII has been associated with cells that synthesize large 
amounts of all-trans-RA.161-163 Neither the exact functions nor the distinct roles of the 2 
CRABP isoforms are completely understood at present.164 In general, retinoid binding 
proteins act to solubilize and stabilize their hydrophobic and labile ligands in aqueous 
solutions. Nowadays, a growing body of evidence indicates that each binding protein 
also has a distinct function in the transport, metabolism and action of the retinoid they 
associate with. However, CRABPI and CRABPII null mutant mice have a normal 
phenotype and so does the double knockout, which challenges the hypothesis that 
CRABPs would facilitate the catabolism of all-trans-RA.165-166 
In human skin, the intracellular levels of CRABPI protein are similar in the dermis and 
the epidermis, whereas CRABPII levels are much higher in the epidermis.167-169 
Melanocytes are the primary source for CRABPI, whereas keratinocytes and fibroblasts 
are sources of CRABPII.170 Differentiation of human epidermal keratinocytes in vitro is 
accompanied by increased cellular all-trans-RA concentration and increased expression 
of CRABPII.171 Moreover, newly synthesized retinoic acids are retained by CRABPII. It 
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should be mentioned here, that in psoriasis and other hyperproliferative skin diseases, 
retinoid binding proteins display atypical patterns which adds to the above suggestion 
that they are involved in the regulation of intracellular retinoid concentrations.172-173 
 
 
Figure 1.2 Generalized ans simplified scheme of RA uptake and metabolism. RE: Retinylester; ROL: Retinol; 
RAL: Retinal, RA: All-trans-Retinoic Acid; LRAT: Lecithin Retinol Acyl Transferase; ARAT: Acyl-CoA 
Retinol Transferase; CRBP: Cellular Retinol Binding Protein; CRABP: Cellular Retinoic Acid Binding 
Protein; ALDH: Retinal Dehydrogenase; CYP450 Cytochrome P450-dependent enzymes (e.g. CYP26). 
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Hydroxylation via CYP26: one route of all-trans-RA metabolism 
All-trans-RA homeostasis is maintained by regulation of its rate of synthesis (from 
ROL) and its rate of degradation. RA catabolism governs tissue sensitivity to RA. 
All-trans-RA is metabolized via hydroxylation at the C4 or C18 position of its cyclo-
hexenyl moiety, which gives rise to 4-OH-RA that further oxidizes to 4-oxo-RA and 
other polar metabolites, or to 18-OH-RA.174-175 That these reactions are cytochrome 
P450 dependent (CYP) was already hypothesized in 1979 by Roberts et al. 176-177, based 
on the observation that all-trans-RA metabolism occurred in microsomal fractions, 
required NADPH and oxygen and was inhibited by carbon monoxide and well-
established CYP inhibitors like ketoconazole, liarozole and clotrimazole.178-184 
 
The CYP superfamily of heme-binding mono-oxygenases catalyses lipid-soluble sub-
strates i.e. the non-specific oxidative conversion of a large number of endobiotics (fatty 
acids, sterols and steroids), a variety of xenobiotics and environmental toxins.185 The 
term P450 derives from the observation that this cytochrome has an unusual absorption 
spectrum with a peak at about 450 nm when the iron atom is reduced and the sixth 
coordination position is occupied by carbon monoxide.186 Although generally expressed 
in the liver, CYPs have also been found in extra-hepatic tissue like kidney, mucosa of 
the gut, lung, skin, placenta, reproductive organs, embryonic tissue and the brain. 
Several CYPs have been described to catalyze the 4-hydroxylation of all-trans-RA but 
their specificity is generally low.187-193 In the late nineties, a novel CYP was first cloned 
and characterized in zebrafish and later in mouse, human, chicken and frog ( enopus) 
displaying high specificity towards all-trans-RA.194-198 This enzyme, designated 
P450RA1 but known officially as CYP 26A1, is expressed in a number of adult tissues 
like liver, heart, hypophyse, adrenals, duodenum and colon and is inducible by all-trans-
RA both in vivo and in cell lines. This indicates that regulation of all-trans-RA catabo-
lism may include a positive feedback loop.199-201 CYP26A1 is also differentially ex-
pressed in mammalian embryos and inducible by all-trans-RA.202 Here too, this auto-
regulatory mechanism is believed to protect certain tissues for all-trans-RA overload 
(fluctuations in maternal RA which could result in teratogenesis) by oxidizing it to more 
polar metabolites.203 In the adult liver, the principal site of retinoid metabolism, 
CYP26A1 expression and all-trans-RA metabolism are not only acutely regulated by 
all-trans-RA administration (cfr. retinoid therapy) but also chronically depending upon 
the dietary intake of ROL.204 In cell cultures CYP 26A1 gene regulation and expression 
is highly dependent on the cell type. Four different situations have been reported in 
various human cell lines: 1) no CYP26 expression and no induction by all-trans-RA; 2) 
X
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no CYP 26 expression but inducible by all-trans-RA; 3) basal CYP 26 expression and 
induction by all-trans-RA is observed; and 4) CYP 26 is expressed in a constitutive way 
and is not inducible by all-trans-RA, thus forming a barrier for all all-trans-RA expo-
sure. 
 
Today four members of the CYP26 family have been cloned and characterized sharing 
sequence similarity but distinct catalytic activity. CYP26A1 and CYP26B1catabolize 
all-trans-RA both in the embryo and the adult but does not appreciably metabolize the 
9-cis and 13-cis isomers.205,206 CYP 26B1 is broadly expressed at very low levels in 
most human tissues and predominantly in a constitutive way in adult brain , the cerebel-
lum and pons, in particular.206-209 This is in contrast to CYP26A1 which did not show 
appreciable expression in any of the brain tissues, suggesting a unique role for 
CYP26B1 in brain development and functioning.202,206 During mouse embryogenesis, 
CYP26B1 was also specifically expressed in dermis surrounding the developing hair 
follicles. CYP26B1 appears to be inducible by all-trans-RA in several cell lines. The 
catalytic activity of CYP26C1, cloned by Taimi et al. in 2004, appears to be distinct 
from the other CYP26 members as it can metabolize also 9-cis-RA and it is much less 
sensitive (5 times) to the inhibitory effects of ketoconazole, a 4-hydroxylase inhibi-
tor.180,182,187 CYP26C1 is not widely expressed in the adult and has so far only be de-
tected in a small number of human cell lines. Comparison of the distribution of 
Cyp26C1 with that of Cyp26A1 and Cyp26B1 in the chick and mouse embryo shows 
that they generally occupy non-overlapping sites of expression suggesting individual 
roles for each of the CYP enzymes in the developing embryo.205,210,211 Only recently, a 
fourth CYP26 member involved in the metabolism of all-trans-RA has been cloned in 
zebrafish namely CYP26D1.212-213 
 
What about the skin? Vanden Bossche et al. have shown that skin epidermal micro-
somes from neonatal rats 4-hydroxylate all-trans-RA in a CYP-dependent way.180,187 
Isoenzymes of CYP families 1, 2, 3 and 4 were shown by other groups to be present in 
human epidermal foreskin keratinocytes.214-216 A 4.5 fold increase in metabolism of all-
trans-RA to 4-oxo-RA has been described in skin treated with all-trans-RA but the 
principal CYP enzyme responsible for this conversion in human skin has not been 
defined yet.217 
Smith et al. identified CYP2S1 in human skin and showed its capacity to metabolize all-
trans-RA into 4-hydroxy and 5,6-epoxy-RA; remarkably, no 4-oxo-RA was detected as 
a metabolite.218,219 They also showed an induction of CYP2S1 expression by all-trans-
RA, ultraviolet radiation, PUVA and coal tar. Furthermore, there was a higher cutane-
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ous CYP2S1 expression than CYP26 which suggests a functional role of CYP2S1 in the 
cutaneous catabolism of all-trans-RA. The fact that no 4-oxo-RA was formed adds to 
the suggestion that another CYP may be responsible for oxidization of 4-OH in skin. 
Of the CYP26 family, only CYP26A1 has been detected in human epidermis and 
keratinocytes.220,221 Very recent work by Heise et al. revealed no basal levels of 
CYP26A1 mRNA expression in monolayer cultures of normal human epidermal kerati-
nocytes (NHEK) and dermal fibroblasts. Only a weak CYP26A1 expression was de-
tected in NHEK and it could be enhanced by stimulation with all-trans-RA. However, 
in contrast to the cultured monolayers, a constitutive expression of CYP26A1 was found 
in vivo and in organotypic 3D skin models but it was restricted to basal epidermal 
keratinocytes as well as to eccrine sweat glands and sebaceous glands. To the best of my 
knowledge neither CYP26B1 nor CYP26C1 have been detected so far in human skin. 
Glucuronidation: a second route of all-trans-RA metabolism 
All-trans-RA has a short elimination half-life in vivo and in cultured cells (6-7 hours), 
except for B-lymphocytes.222-226 Glucuronidation and enterohepatic circulation serves as 
another route of elimination/recirculation in vivo.227-231 Human liver glucuronyl trans-
ferase UGT2B7 has been identified as responsible for the glucuronidation of all-trans-
RA, 4-oxo-RA, 5,6-epoxy-RA (via their carboxyl group) and of 4-OH-RA (via the 
hydroxyl group).232-233 
UGT2B7 that catalyzes retinoyl-β-glucuronide synthesis from all-trans-RA does not 
recognize all-trans-RA bound to CRABPI as a substrate which leads to the hypothesis 
that glucuronidation in vivo would preferentially occur in cells that do not express 
CRABPI like hepatocytes and small intestinal mucosal cells.234 Retinoyl-β-glucuronide 
is, unlike other all-trans-RA derivatives, water-soluble and is considered a product of 
detoxification. Retinoyl-β-glucuronide is biologically active but does not bind to cellu-
lar binding proteins or nuclear receptors.235-236 Glucuronide formation may provide a 
water-soluble pool of all-trans-RA in times of vitamin A need. 
Other all-trans-RA sources 
First, all-trans-RA can be generated in the cells following the uptake and metabolism of 
plasma ROL. Secondly all-trans-RA is present in the circulation, originating from 
eccentric cleavage of β-carotene from the diet or formed in the intestine.198 Unlike ROL 
and RAL, all-trans-RA and its isomers, 13-cis-RA and 9-cis-RA can not be stored so it 
circulates in plasma, bound to serum albumin, and as such contributes significantly to 
all-trans-RA pools in several tissues.237 The molecular mechanisms for cellular uptake 
are not clear. However, the processes used are tissue and cell type specific and also 
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responsive to the physiological state. Under normal physiological dietary conditions, 
both ROL and all-trans-RA are present in plasma but at different concentrations. In 
contrast to ROL (2µmol/l), the plasma concentration of all-trans-RA and 13-cis-RA is 
approximately 100-fold lower: 7-14 nmol/l (=1.2-4.2 ng/ml) and 3.7-6.3 nmol/l, respec-
tively.145, 238-240 9-cis-RA has also been shown to occur naturally in vivo, although the 
levels found were a lot lower.241 Importantly, although 13-cis- and all-trans-RA have an 
identical chemical structure their elimination half-lives are quite different due to a 
different molecular geometry: around 20 versus 0.9 hours respectively.242-244 The differ-
ence in elimation rate is believed to be responsible for the fact that 13-cis-RA (isotreti-
noin) is more active than all-trans-RA in treating acne. All-trans-RA can substitute for 
ROL in growth, morphogenesis and epithelial differentiation but not completely in 
reproductive function. Most important is that all-trans-RA can not replace RAL in the 
visual cycle.245 
The fact that all-trans-RA can be easily detected in many adult and embryonic tissues, 
whereas 9-cis-RA can not be detected in the same tissue, could mean that all-trans-RA 
is the only ligand needed physiologically for RA signaling.246 
Mechanism of Action 
Retinoids exert most of their biological activities through binding to specific retinoid 
receptors, belonging to the superfamily of nuclear receptors which also include the 
steroid, vitamin D (VDR), thyroid (TR), the peroxisome proliferator-activated (PPAR) 
and a number of orphan receptors. Nuclear receptors regulate transcription of genes by 
acting as ligand-inducible transcription factors. 
 
Two classes of retinoid receptors have been discovered: RAR and RXR, each contain-
ing three subtypes: α, β and γ.247-251 Each subtype is encoded by a different gene which 
is located on a different chromosomes being 17q21.1 (RAR- α), 3p24 (RAR- β), 12q13 
(RAR- γ), 9q34.3 (RAR- α), 6p21.3 (RXR- β) and 1q22-23 (RXR- γ). There are also 
multiple isoforms of these subtypes that are generated by alternative splicing and by 
differential use of promotors. All-trans-RA has been identified as a potent activator and 
high affinity ligand for the RARs, whilst its 9-cis isomer (9-cis-RA) appears to be the 
natural ligand for RXRs in vitro.252-254 9-cis-RA not only binds and activates all 3 RXR 
subtypes at physiological concentrations (Kd~15nM) but also the 3 RAR subtypes at 
lower Kd values (0.2-0.7 nM).255,256 However, since tissue concentrations of 9-cis-RA 
tested up to now, appear to be in the low nanomolar range [3-5 fold lower than all-
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trans-RA], the question on the availability of 9-cis-RA at high enough concentrations to 
stimulate RXRs in vivo has been raised and is still unanswered. 252 
 
RARs function as a heterodimer complex with RXRs, whereas the RXRs may act either 
as homodimers or as a heterodimer complex with a variety of other nuclear receptors 
that play an important role in cell function and physiology. This means that the biologi-
cal activities of specific RXR ligands could be broader than that of compounds that 
specifically activate RARs. The expression pattern of the retinoid receptors shows cell 
and tissue specificity and is dependent upon variable factors such as state of differentia-
tion, inflammation and diseases.257-258 The expression patterns of the various RAR and 
RXR isoforms indicate that most, if not all, tissues are potential targets of retinoid 
action, although different RXR homodimer and RAR-RXR heterodimer complexes will 
transduce the retinoid signal in different tissue.259 
 
In adult human skin, the predominant RAR protein expressed is RAR-γ whilst only 
minimal but detectable levels are found for RAR-α; RAR-β is undetectable.260 The 
concentration of RXRs is five times as high as the total concentration of RARs, with 
RXRα being the most abundantly expressed; RXR-β is minimally detectable and RXR-
γ undetectable.260 The mRNA levels of the receptors are compatible with the protein 
levels. The predominant receptor complexes in the human skin are RARγ-RXRα and 
the RXR-VDR, the latter one being of major importance in RXR-signaling.261 
 
Each retinoid receptor exists of 6 functional domains of which the 2 most important are 
the ligand binding domain (where the ligand binds to the receptor) and the DNA binding 
domain (where the receptor binds to the DNA of the target genes).262 Dimers of retinoid 
receptors are localized in the nucleus of the cell where they bind, even in the unliganded 
state, to specific DNA regulatory sequences termed retinoid response elements (RARE 
or RXRE) in the promotors of retinoid-responsive genes. As such they can regulate 
genes involved in processes as cell differentiation, cell proliferation, apoptosis, etc. A 
comparison of the in vitro DNA binding repertoires of RAR and RXR homodimers and 
of RXR/RAR heterodimers indicates that heterodimers bind more efficiently and more 
selectively than homodimers. RAR-RXR heterodimers are suggested to be the func-
tional units in vivo that transduce the retinoid signal.247 
Retinoid response elements are usually located within the 5’-regulatory region of 
retinoid regulated genes, sometimes they are found within introns. RAREs consist of a 
direct repeat (DR) of a core hexameric sequence, PuG(G/T)-TCA, separated by either 1, 
2 or 5 base-pairs (DR1, DR2 and DR5) depending of the genes.247 A large number of 
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genes contain 1 or more RARE and therefore are potentially responsive to RA. More 
than 500 genes with diverse functions are regulated by retinoic acid, and RAREs have 
been localized in many of these genes including RARβ, CRBPI, CRABPII and members 
of the Hox and HNF gene families.263 Because the RXR functions as a partner for 
several nuclear receptors other than RAR, it has the potential together with the ligands 
that bind to them, to influence an even wider variety of genes than are regulated by 
RARs.264 
 
According to a current model of transcriptional activation, the unliganded receptor 
dimers, when bound to DNA, recruit proteins with histone deacetylase activity (co-
repressors), which results in chromatin condensation and gene silencing.265 Ligand 
binding causes the receptors to undergo a conformational change that favours the 
dissociation of co-repressors and the recruitment of other proteins (co-activators) with 
histone acetylase activity, which opens up the chromatin, making it accessible to tran-
scriptional machinery to initiate transcription. This results in the induction of retinoid-
mediated expression.266-268 
Cellular effects 
The cellular effects of all-trans-RA also largely depend upon the presence of cellular 
retinoid-binding proteins and upon the activity of all-trans-RA metabolizing enzymes. 
The molecular mechanisms underlying the action of retinoids are still intensively 
investigated and not yet fully understood. On one hand, retinoids have been shown to 
act as an antiproliferative agent in hyperproliferative systems and on the other hand 
cause an induction of hyperproliferation in systems with a normal proliferation.269 
Retinoids have also been shown to contain immunomodulating properties like modula-
tion of T-cell responses270, inhibition of chemotactic responses, activation of polymor-
phonuclear leukocytes271 and immunostimulation of natural killer lymphocytes. Fur-
thermore retinoid treatment has been shown to induce an increase of the number of 
Langerhans cells in normal as well as in psoriatic skin. It has also been described that 
retinoid receptor activation inhibits the induction of migration inhibitory factor-related 
protein (MRP-8) a marker for hyperproliferation and abnormal keratinisation by inter-
feron γ (IFN- γ).272 
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Retinoic Acid Metabolism Blocking Agents: RAMBAs 
Mechanism of action 
Clinically, the RA-mediated induction of Cyp26A1, as discussed above, may be signifi-
cant when using retinoids as pharmacological agents. In APL (acute promyelocytic 
leukaemia), where all-trans-RA is often used as a treatment, a high proportion of 
patients start exhibiting all-trans-RA resistance after an initial remission.273 Cyp26A1 
induction may be responsible for this acquired retinoid resistance as Cyp26A1 mRNA 
has been shown inducible by all-trans-RA in APL cell lines.274 Cyp26A1 is also induc-
ible in skin where retinoids have been used extensively to treat conditions such as acne, 
psoriasis and ichthyosis.275 Prolonged treatment of skin with retinoids can induce 
Cyp26A1-mediated metabolism leading to reduced responsiveness, higher effective 
therapeutic doses and consequently unwanted side-effects. 
 
An alternative approach to administering retinoids has emerged i.e. modulating retinoic 
acid concentrations at the tissue level by using Retinoic Acid Metabolism Blocking 
Agents or RAMBAs sometimes referred to as retinoic acid 4-hydroxylase inhibitors. As 
discussed earlier, one of the pathways by which intracellular all-trans-RA is metabo-
lized occurs by 4-hydroxylation at the C4 position of the cyclohexenyl ring to form 4-
hydroxy-all-trans-RA which is converted by a reductase into 4-keto-all-trans-RA that is 
in turn further transformed into more polar metabolites. Both the 4-hydroxylation 
process of all-trans-RA and the further oxidation of 4-keto-all-trans-RA to more polar 
metabolites involve microsomal cytochrome P-450 (CYP) dependent enzymes.152,276 
RAMBAs are non-retinoid drugs that block the CYP dependent enzyme i.e. the RA-4-
hydroxylase (CYP26) responsible for the intracellular catabolism of all-trans-RA in 
specific target cells which results in an increase of the intracellular all-trans-RA concen-
tration (see Figure 7.2, Chapter 7).187,277 This selective and targeted modulation of all-
trans-RA concentration at the tissue level should hypothetically enhance the efficacy 
and limit toxicity compared to oral retinoids. 
Unlike existing therapies where high amounts of exogenous retinoids, natural or syn-
thetic, are administered to the body, a RAMBA modulates the body’s own production of 
all-trans-RA to achieve the same therapeutic effects. Once treatment is stopped, a 
RAMBA is quickly eliminated from the body returning the metabolism of retinoic acid 
back to normal and declining the elevated all-trans-RA tissue levels back to physiologi-
cal levels. The rapid clearance of the RAMBAs is important as it decreases the potential 
for side effects in contrast to the available synthetic retinoids, which may stay in some 
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organs for a long time, and which can cause retinoid related chronic toxicity and birth 
defects for months after discontinuation of therapy. 
History of RAMBAs 
The first azole shown to display RAMBA properties was the antifungal ketoconazole. 
Besides its antifungal activity, ketoconazole was shown to inhibit in an apparently 
competitive manner the CYP mediated metabolism of all-trans-RA by hamster liver 
microsomes.180,182 The search for more selective CYP inhibitors of all-trans-RA me-
tabolism led to the identification of liarozole.  
Liarozole is an imidazole derivative that is lacking anti-fungal activity but shares with 
ketoconazole its inhibitory effects on epidermal all-trans-RA metabolism (IC50=2μM) 
and on the CYP mediated 17-hydroxylase-17,20-lyase in testes microsomes. Like 
ketoconazole, administration of liarozole to rats enhances endogenous plasma concen-
trations of endogenous all-trans-RA and reduces the elimination rate of intravenously 
injected all-trans-RA from plasma.183,184 Liarozole also inhibits several other cyto-
chrome P450-dependent steroid biosynthesis reactions—mainly the conversion of 
androgens to estrogens (aromatase) and of 11-deoxycorticosterone to corticosterone 
(11-hydroxylase).278,279 
Developed in the 90’s as a non-hormonal agent in the treatment of prostate cancer and 
various other cancers, liarozole was considered to be of potential benefit in the treat-
ment of skin disorders like psoriasis and ichthyosis based on the fact that the reported 
adverse events in the cancer trials were mainly cutaneous reactions showing a striking 
similarity with vitamin A-related symptoms. A total of 6 clinical trials assessing the 
efficacy and safety of oral liarozole in psoriasis have been conducted.280-284 Currently, 
liarozole is in development as an orphan drug for ichthyosis.285-287 An overview of 
liarozole’s in vivo pharmacology related to dermatology will be presented in Chapter 4. 
Two clinical studies in ichthyosis, one with topical and one with oral liarozole are part 
of this work and are discussed in Chapters 5 and 6. 
Whereas the first RAMBAs where non-selective CYP inhibitors, a thorough screening 
of hundreds of molecules against different CYP-isozymes yielded a very selective and 
highly active retinoic acid 4-hydroxylase inhibitor namely R115866 (RambazoleTM), 
representing a third generation.288,289 R115866 is a substituted benzyl-1, 2, 4,- triazole 
derivative which is a stable, enantiomerically pure base. R115866 inhibits all-trans RA 
catabolism in the nanomolar range (IC50= 4 nM, human CYP26 transfected yeast 
microsomes) and is about three orders of magnitude more powerful than liarozole 
(IC50= 3µM). At concentrations needed to inhibit all-trans-RA catabolism, R115866 
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displays only trivial inhibitory effects (IC50= 1.2-2.6 µM) on the CYP-dependent bio-
synthesis of steroids (testosterone and oestradiol). Furthermore, consistent with its 
ability to enhance endogenous RA content in tissues and plasma, R115866 was found to 
generate retinoid-mimetic biological activities in various retinoid sensitive animal 
models of keratinisation.288-290 In these studies no major effects other than its primary 
pharmacodynamic effect were evidenced. 
By virtue of this property and the modulating effects of all-trans-RA on epithelial 
growth and differentiation, R115866 is currently under clinical investigation for both 
oral and topical treatment of psoriasis and acne. The results of the first exploratory 
studies with R115866 in these patient populations will be presented in this work. 
Aim and outline of the thesis 
It is well known by now that hyperkeratotic disorders like ichthyosis, psoriasis and acne 
are retinoid-sensitive diseases. These chronic conditions are rarely life-threatening but 
they may cause major physical, psychosocial and cosmetic disability, and require 
ongoing treatment. For decades, topical as well as oral retinoids have been widely used 
as treatments. Amongst the systemic treatments available today, only the vitamin A 
derivatives are efficacious for all these keratinization disorders. Psoriasis and acne 
respond to a broader variety of agents because of the principal inflammatory compo-
nent. However, considering the serious toxicity associated with existing systemic 
therapies and the limited choice within the topical armamentarium, there is need for safe 
systemic and alternative topical agents for the treatment of keratinization disorders. The 
capability of RAMBAs to enhance and sustain pharmacologically active skin tissue 
levels of endogenous RA by blocking its CYP-mediated metabolic inactivation would 
represent a new attractive therapeutic approach. The question whether this new class of 
compounds can have a potential in these difficult-to-treat skin disorders is addressed in 
this work. 
 
Chapter 1 describes the main hyperkeratotic diseases and the current treatment modali-
ties. 
The first part of the thesis deals with the pharmacology of the RAMBAs focusing on 
dermatology. The effect of 3 generations RAMBAs on cell proliferation and viability in 
3 major skin cell types i.e. keratinocytes, fibroblasts and endothelial cells is described in 
Chapter 2. In Chapter 3 the effect of topical R115866 on cell viability and skin perme-
ability is studied in vitro using human reconstituted epidermis as an alternative for 
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animal testing. Chapter 4 gives an overview of the in vivo pharmacology of liarozole, 
the first RAMBA that has ever been in clinical development for dermatology. 
The second part summarizes and discusses the therapeutic applications of liarozole in 
patients with ichthyosis (XRI, LI and CBIE) as interest in this molecule has received a 
boost because of its received orphan drug status for congenital ichthyosis by the Euro-
pean Commission and the U.S. Food and Drug Administration. Chapter 5 covers a 
short and long-term clinical study with topical liarozole. In Chapter 6 the efficacy, 
safety and tolerability of oral liarozole is compared to acitretin, the only oral retinoid 
and systemic treatment approved in some EU countries for the treatment of ichthyosis. 
The third part of this work is dedicated to psoriasis, starting with a review of the use of 
retinoids and RAMBAs in psoriasis; see Chapter 7. The results of an exploratory study 
with R115866, a new generation RAMBA in moderate to severe psoriasis is presented 
in Chapter 8. 
The fourth part of the thesis is about acne. Chapter 9, covers the results of an explora-
tory clinical study with oral R115866 in moderate to severe facial acne. 
Finally, in the last part i.e. Chapter 10, the implications of the major findings in this 
thesis are discussed and future perspectives are given. 
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Introduction 
All-trans-RA is a key regulator of epithelial homeostasis as it modulates the expression 
of genes which are essential for keratinocyte growth and differentiation.1 It exerts most 
of its biological activities through binding to specific nuclear receptors RARs and RXRs 
(belonging to the superfamily of steroid/thyroid nuclear receptors), which act as ligand–
inducible transcriptional factors.2 The cellular effects of all-trans-RA also largely 
depend upon the presence of cellular retinoid-binding proteins, which may be involved 
in all-trans-RA metabolism and the activity of all-trans-RA metabolizing enzymes.3 
All-trans-RA and retinoids in general have been proven efficacious in many keratinisa-
tion disorders.4 
Ketoconazole, liarozole and R115866 are azole derivatives representing 3 generations 
Retinoic Acid Metabolism Blocking Agents (RAMBAs), each with increasing potency 
and selectivity.5-8 R115866 is the most potent and selective RAMBA. RAMBAs inhibit 
the 4-hydroxylase, a cytochrome P450 (CYP)-dependent enzyme involved in the intra-
cellular metabolic inactivation pathway of endogenous all-trans retinoic acid (all-trans-
RA).9-11 Blocking the metabolism of all-trans-RA, results in a transient increase of all-
trans-RA levels within the cells. As such, RAMBAs could represent a novel alternative 
in the treatment of keratinization disorders.12-14 
Transglutaminase-1 (TG-1), a member of the transglutaminase family, is a crucial Ca2+-
dependent enzyme expressed in vivo in the upper differentiated layers of the epidermis 
where it facilitates the formation of the insoluble protein envelope by cross-linking 
numerous structural proteins (e.g. loricrin, keratin intermediate filaments, and others) as 
well as the attachment of the lipid envelope.15,16 This cross-bridging produces stable 
structures composed of polymerized proteins which are essential in a wide variety of 
biological processes to maintain cell and tissue integrity. The cell envelope is a highly 
insoluble structure; it retards water loss through the epidermis and protects the internal 
milieu of the body against external mechanical stimuli, chemical injury and biological 
invasion. Calcium (Ca2+) promotes the differentiation of epidermal keratinocytes both in 
vitro and in vivo.17,18 When normal human epidermal keratinocytes (NHEK) are cultured 
in vitro under high calcium conditions (1.8-2 mM) they differentiate and express the 
membrane-bound TG-1. All-trans-RA has been shown in vitro to modulate this Ca2+-
induced differentiation by downregulating the expression of TG-1.19 
The aim of the present study was two-fold. First to compare, in vitro, the effects of 
R115866 and its predecessors ketoconazole and liarozole with all-trans-RA on cell 
viability and cell proliferation of normal human keratinocytes (NHEK), human adult 
dermal fibroblasts (HDFa) and Human Microvascular Endothelial Cells (HuMVEC). 
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Secondly, to compare the effect of all-trans-RA alone and in combination with the 
different RAMBAs on Ca2+ induced differentiation in NHEK using TG-1 as a bio-
marker. 20 
Materials & Methods 
Materials 
All-trans-RA, gentamycin, Ca2+/Mg2+- free PBS and 3-[4,5-dimethyl-thiazol-2-yl]-2,5-
diphenyl tetrazolium bromide or MTT were purchased from Sigma. Ketoconazole, 
liarozole and R115866 are compounds from Barrier Therapeutics nv, their chemical 
structures are presented in Figure 2.1. All-trans-RA, ketoconazole, liarozole and 
R115866 were dissolved in 100% DMSO to a concentration of 10-2M and further 
diluted in culture medium. All dilutions were prepared separately for the different cell 
types in their corresponding culture medium. Final DMSO concentrations in working 
solutions were 0.1% or less. All culture manipulations or preparations of solutions 
containing all-trans-RA were performed under yellow light conditions. MTT was 
dissolved in Ca2+/Mg2+- free PBS to a concentration of 5mg/ml.  
Cell culture 
Normal human epidermal keratinocytes (NHEK) derived from foreskin of a 9 year-old 
donor were supplied by MAIA Scientific as cryopreserved third-passage cells. Cells 
were cultured in keratinocyte serum-free medium (KSFM, Gibco-Life Technologies) 
supplemented with epidermal growth factor (EGF), bovine pituitary extract (BPE) and 
gentamycin (Sigma) according to the supplier’s instructions. For all experiments 4th 
passage cells were used. 
 
Human Dermal Fibroblasts (adult) (HDFa) isolated from a 17 year old female donor 
were purchased from Cascade Biologics as well as the medium and supplements. Cells 
were grown in Medium 106 supplemented with Low Serum Growth Supplement 
(LSGS) and gentamycin according to the manufacturer’s instructions. LSGS contains 
fetal bovine serum, basic fibroblast growth factor, epidermal growth factor, heparin, and 
hydrocortisone. For all experiments 5th passage cells were used. 
 
Human Microvascular Endothelial Cells (HMVECad) deriving from the dermis of a 30 
year old female donor were purchased from Cascade Biologics as well as the medium 
and supplements. Cells were grown in Medium 131 supplemented with Microvascular 
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Growth Supplement (MVGS) and gentamycin according to the manufacturer’s instruc-
tions. MVGS contains fetal bovine serum, basic fibroblast growth factor, epidermal 
growth factor, heparin, hydrocortisone and dbcAMP. Culture surfaces were coated with 
Attachment Factor (containing gelatin) which was provided with the medium. For all 
experiments 5th passage cells were used.  
 
Ketoconazole 
 
Liarozole 
 
R115866 
 
Figure 2.1 Molecular structures of the RAMBAs: ketoconazole, liarozole and R115866. 
Growth inhibition and cell viability assay 
NHEK were seeded at 2000 cells/well, HDFa at 4000 cells/well and HMVECad at 4000 
cells/well in 96 well plates and grown in their respective medium at 37°C, 5% CO2 for 
24 hours. 
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Growth Inhibition Assay. Twenty-four hours after seeding, cells were exposed to inves-
tigational compounds ketoconazole, liarozole, R115866 and all-trans-RA using 10-fold 
dilution series (10-5-10-10 M) for the time needed to reach 100 % confluent monolayers 
in control solution (medium + 0.1% DMSO). After this incubation time, 25 µl MTT per 
well was added to the cultures and further incubated for 2.5 hours at 37°C. The medium 
was then aspirated and isopropanol was added to dissolve the formazan crystals. Optical 
densities (OD) were measured at 540-650 nm. 
 
Cell viability Assay. Cells were cultured until 100% confluence was reached and subse-
quently exposed to the investigational compounds (ketoconazole, liarozole, R115866) 
or to all-trans-RA using 10-fold dilution series (10-5-10-10 M) for 96 hours with replen-
ishment of the medium ± compound after 48 hours. After the incubation time, 25 µl 
MTT /well was added to the cultures which were then further incubated for another 2.5 
hours at 37°C. Thereafter the medium was aspirated and isopropanol was added to 
dissolve the formazan crystals. Optical densities were measured at 540-650 nm. 
TG-1 in situ ELISA for NHEK 
NHEK were cultured in KSFM under low Ca2+ conditions (0.088 mM) until they 
reached ± 60% confluence. The medium was then replaced by KSFM with high Ca2+ 
(1.8mM) and cells were treated with either a RAMBA (ketoconazole, liarozole, 
R115866, R116010 alone (at 10-6-10-8 M), all-trans-RA alone (at 10-8-10-12 M) or all-
trans-RA/RAMBA combinations for 5 more days. At day 5, after monitoring cell 
viability with MTT, cells were processed for TG-1 measurement using an in situ 
ELISA. 
 
Cell viability. MTT was added to the cultures and after incubation of 2.5 hours at 37°C, 
the reaction was stopped by removing the medium and freeze-thawing the monolayers 
twice. Formazan precipitates were dissolved in ethanol/aceton (60/40; v/v, -20°C) 
resulting at the same time in fixation of the monolayers. Cell viability was measured by 
reading the OD at 540-650 nm. 
 
In situ ELISA for TG-1. After measuring cell viability, the fixed monolayers were 
washed once with ethanol/aceton (60/40; v/v) to remove the formazan. Subsequently, 
they were dried, rehydrated and blocked with 1% bovine serum albumine (BSA). 
Immunostaining of TG-1 was performed with a mouse monoclonal antibody to TG-1 
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(clone B.C1) and a secondary peroxidase-labeled goat-anti-mouse antibody. After 
incubation with o-phenylenediamine, the OD was measured at 490 nm. 
Results and discussion 
Growth inhibition and cell viability 
Mitochondrial activity-based assays were set-up and implemented for the evaluation of 
the cell isolates and of the effects of compounds on cell growth and cell viability in the 
3 different cell types. 
The viability of the cells was determined by a colorimetric MTT assay. The test is based 
on the reduction of yellow MTT by mitochondrial dehydrogenases from living cells into 
blue/purple formazan crystals, which are insoluble in culture medium. The amount of 
formazan generated is proportional to the number of viable cells after exposure to the 
test agent and is expressed as the percentage (%) to the untreated control using the 
following formula: 
 
 
Growth inhibition and cell viability curves of the different compounds for the different 
cell types are shown in Figures 2.2-2.4. Estimated IC50 and TC50 values are tabulated in 
Table 2.1. 
The data point out that the different cells display a different sensitivity towards the 
compounds tested. In both assays, keratinocytes are more sensitive to the compounds 
tested than fibroblasts. No effects on cell growth or cell viability were seen in endothe-
lial cells at the concentration range of 10-10 to 10-5M for any of the tested compounds. 
When comparing the different RAMBAs, it is clear that liarozole does not affect cell 
growth or cell viability, in any of the cell types, not even at 10-5M, the highest concen-
tration tested. 
Like all-trans-RA, R115866 dose-dependently inhibits keratinocyte growth 
(IC50~2.2x10-6M) and affects cell viability (TC50 ranging between 3.3-10 x 10-6M) at 
micromolar concentrations. Ketoconazole, here only tested in keratinocytes, is even 
more potent than R115866 in inhibiting cell growth (IC50=10-6M). Effects on cell 
viability are seen at concentrations higher than 10-6M. 
In HDF, R115866 doesn’t seem to affect the cell growth up to concentrations of 10-6M 
but at only a 10-fold higher concentration growth is inhibited by almost 80%. Also the 
100
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dilution  test of  O.D. cells surviving of %
540nm
540nm ×=
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cell viability is affected at concentrations above 10-6M but the estimated TC50 
(2.5x10-5M) is higher than the estimated IC50 (7.5x10-6M). All-trans-RA displays a 
linear dose-dependent inhibitory effect on cell growth. Forty % growth inhibition is 
reached at the highest concentration tested. At physiological concentrations (from 10-10 
to 5x10-8M) no effect is observed on cell viability. A 20-30% inhibition of mitochon-
drial activity is observed at 10-5M, the highest concentration tested. 
 
Table 2.1 Overview of the effects on cell growth (estimated IC50) and cell viability (estimated TC50) by all-
trans-RA and RAMBAs measured in the different cell lines. 
Compound 
Cell growth 
IC50 (M)* 
Cell viability 
TC50 (M)* 
Concentration range 
(M) 
NHEK 
Ketoconazole 10-6 >10-5 10-10-10-5 
Liarozole > 10-5 >10-5 10-10-10-5 
R115866 5x10-6 5x10-6 10-10-10-5 
All-trans-RA 5x10-6 7.5x10-6 10-10-10-5 
HDFa 
Liarozole >10-5 >10-5 10-10-10-5 
R115866 7.5x10-6 2.5x10-5 10-10-10-5 
All-trans-RA >10-5 >10-5 10-10-10-5 
HMVECad 
Liarozole >10-5 >10-5 10-10-10-5 
R115866 >10-5 >10-5 10-10-10-5 
All-trans-RA >10-5 >10-5 10-10-10-5 
* italic: estimated value by linear interpolation 
Inhibition of Ca2+ induced TG-1 expression in NHEK 
An assay format for analysing the effect of all-trans-RA alone or in combination with 
RAMBAs on Ca2+-induced keratinocyte differentiation using TG-1 as a biomarker has 
been set up, optimized and validated. Two endpoints were sequentially measured in 
each well using a mitochondrial activity-based assay followed by an in situ ELISA. This 
assay not only combines the advantage of simultaneous monitoring of effects of com-
pounds on cell growth, viability and differentiation but is next to that also a more 
economic assay. 
Prior to analysing the (potentiating) effect of RAMBAs on the all-trans-RA-induced 
down-regulation of TG-1 expression in cultured keratinocytes, main efforts have been 
put on the characterization of diverse keratinocyte isolates. Primarily, the keratinocyte 
isolates were assessed on their capacity to respond to calcium-dependent differentiation 
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by using an in situ ELISA for TG-1. Secondly, concentration titration experiments for 
the inhibition of TG-1 expression by all-trans-RA were carried out, allowing the identi-
fication and selection of all-trans-RA-sensitive keratinocyte isolates. (Data not shown) 
Concentration-response curves for the inhibition of TG-1 expression by all-trans-RA or 
in combination with each of the RAMBAs in NHEK are displayed in Figure 2.5. Corre-
sponding estimated IC50 values by linear interpolation are represented in Table 2.2. The 
rate of potentiation of the retinoid-induced inhibition of TG-1 expression by the RAM-
BAs was assessed by calculating the ratio of the IC50 of all-trans-RA divided by the IC50 
of all-trans-RA+RAMBA and is presented in Table 2.2. 
 
Table 2.2 Inhibition of Ca2+-induced TG-1 expression by all-trans-RA alone and in combination with a 
RAMBA. 
 All-trans-RA + + + + 
 RAMBA − 10−8Μ 10−7Μ 10−6Μ 
IC 50 (nM) Ketoconazole 2-3 2 0.04 <0.001 
 Liarozole 3-4 2 0.2 0.001 
 R115866 4-5 0.03 0.02 <0.001 
Potentiation Ketoconazole − 1-1.5 50-75 >2000-3000 
 Liarozole − 1.5-2 15-20 3000-4000 
 R115866 − 133-160 200-250 >4000-5000 
 
As expected all-trans-RA dose-dependently down-regulated TG-1 expression with an 
IC50=2.10-9M to 5.10- 9M. When all-trans-RA was combined with each of the RAM-
BAs, dose-response curves shifted to the left. Minor differences in potency amongst the 
different RAMBAs were observed at a concentration of 10-6M; all 3 lowered the IC50 of 
all-trans-RA at least 2000-fold. The decrease in TG-1 expression by ketoconazole could 
partially be due to its effect on proliferation. At 10-7M, R115866 was 4 to 10 times more 
potent than ketoconazole and liarozole respectively and at 10-8M even a 100 times. 
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Figure 2.2 Dose-dependent growth inhibition and cell viability curves of all-trans-RA and the RAMBAs in 
NHEK. 
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Figure 2.3 Dose-dependent growth inhibition and cell viability curves of all-trans-RA and the RAMBAs in 
HDF. 
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Figure 2.4 Dose-dependent growth inhibition and cell viability curves of all-trans-RA and the RAMBAs in 
HuMVEC. 
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Figure 2.5 Inhibition of TG-1 expression by all-trans-RA (10-8 to 10-12M) alone and in combination with a 
RAMBA (10-6 to 10-8M) in NHEK. TG-1 was measured with an in situ ELISA (absorbance 490nm) and 
values were corrected for cell number as measured with MTT (absorbance 540nm). Values represent mean of 
intra-assay quadruplicates 
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In conclusion, in line with their proposed mechanism of action, the RAMBAs potenti-
ated the inhibitory effect of all-trans-RA on TG-1 expression in differentiating kerati-
nocytes with R115866 being superior to ketoconazole and liarozole. This is in concor-
dance with their intrinsic potency to inhibit CYP 26, a cytochrome P450 dependent 
hydroxylase. 
Although IC50 values for all-trans-RA were reproducible and the potentiating effects for 
RAMBAs, measured using the method published by Svendsen et al. (1997), were 
statistically significant, the TG-1 measurement by in situ ELISA was shown to have a 
rather high variability.21 This could be attributed to plate position effects and to the 
variable stages of keratinocyte differentiation, already visibly present in the pre-
confluent monolayers at the start of incubation. This variation results from the fact that 
as soon as keratinocytes experience a state of confluency in the centre of a growing 
colony, they are already primed to differentiate, even in low Ca2+ culture conditions. For 
this reason, the TG-1 assay design/ in situ ELISA can still be considered for further 
optimization. 
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Abstract 
R115866, a substituted benzyl-1, 2, 4,- triazole derivative, is a new generation of Reti-
noic Acid Metabolism Blocking Agent (RAMBA). R115866 was found to generate 
retinoid-mimetic biological activities in various retinoid sensitive animal models of 
keratinisation and is currently under clinical investigation for both oral and topical 
treatment of psoriasis and acne. In the light of its potential for topical treatment, the 
effect of R115866 on viability the human skin and modulation of the skin barrier per-
meability was investigated in vitro using Reconstituted Human Epidermis (RHE). Cell 
viability was assessed using the MTT assay and morphological evaluation.The modula-
tion of the skin barrier permeability was assessed by measuring the passage of tritiated 
water through the RHE at different incubation times. The results show that R115866 
(10-5 to 10-7M) is devoid of significant enhancing effects on the permeation of tritiated 
water through RHE and exhibits no cytotoxic effects on the tissues. Further work will 
be necessary to evaluate the effects of these molecules on other barrier characteristics 
like proteins and lipids. 
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Introduction 
R115866 (RambazoleTM) a substituted benzyl-1,2,4,- triazole derivative is a new genera-
tion of Retinoic Acid Metabolism Blocking Agent (RAMBA). The investigational drug 
is a stable, enantiomerically pure base which has been identified both in vitro and in 
vivo as a compound with highly specific and selective CYP inhibiting properties against 
hydroxylases involved in the catabolism of all-trans retinoic acid.1-3 Its potency lies in 
the nanomolar range (IC50=4nM) which is about three orders of magnitude more power-
ful than liarozole (IC50=3µM), a previous generation RAMBA. In comparison to its 
retinoid catabolism inhibiting activity, R115866 shows only trivial inhibitory effects on 
the CYP-dependent biosynthesis of steroids. R115866 was found to generate retinoid-
mimetic biological activities in various retinoid sensitive animal models of keratinisa-
tion and is currently under clinical investigation for both oral and topical treatment of 
psoriasis and acne.3-5 
In the light of its potential for topical treatment, the effect of R115866 on viability and 
modulation of the human skin barrier permeability was investigated using Reconstituted 
Human Epidermis (RHE) from SkinEthics as an in vitro model. Together with 
R115866, two chemically related azole derivatives R115865 (S-enantiomer of 
R115866) and R116010 were tested.6 
Culturing of normal human keratinocytes on inert filters has led to the production of 
functional human skin equivalents. These cultures raised at the air-liquid interface 
exhibit a well stratified and cornified epidermis with normal barrier function and meta-
bolic activity mimicking the in vivo situation.7 So far, they have been used for the 
assessment of cutaneous immunotoxicological responses, for studies of epidermal 
responses to irritants and sensitizers, for metabolic studies of pharmaceuticals and for 
the determination of absorption properties and are suggested a valid alternative for in 
vivo animal testing.8,9 
Modulation of the human skin barrier permeability by R115866 is assessed by measur-
ing the passage of tritiated water through the RHE.10 The principle of the assay is the 
following. The molecules to be tested are applied on the cornified side of RHE in 
association with tritiated water whilst culture medium is added to the basal chamber 
inserts. At different incubation times, the tritiated water permeated through the RHE is 
quantified by liquid scintillation counting (LSC). Consequently, if the tested products 
alter the stratum corneum permeability, the tritium permeation rate will be modified. At 
the end of the study period, a Methyl Thiazolyl Tetrazolium (MTT) assay is carried out 
to assess the possible effects of the compounds on viability of the cultured layers. In 
parallel, tissues are fixed with glutaraldehyde for histological examinations. 
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The aim of this study was two-fold: first to estimate the modulation of the human skin 
barrier permeability by R115866 and second, to investigate if any cytotoxic effects were 
induced. 
Materials and methods 
Compounds and Reagents 
Barrier Therapeutics’ compounds R115866, R115865 (S-enantiomer of R115866) and 
R116010 were supplied as 10-2 M stock solutions dissolved in 100% DMSO (Figure 
3.1). They were diluted aseptically in serum free culture medium and mixed with 
tritiated water (Amersham Biosciences, 500 µCi) in order to obtain final working 
solutions of 10-5, 10-6 and 10-7 M. The final specific activity of tritium was 45 kBq/50µl 
working solution. 
RHE model 
For histological and in vitro percutaneous absorption studies RHE were purchased from 
SkinEthic Laboratories (Nice, France). RHE consist of a multilayered epidermis that 
exhibits similar morphological and growth characteristics as human epidermis in vivo.7 
Briefly, they are obtained by culturing normal human keratinocytes in a biochemically 
defined medium on polycarbonate culture inserts lifted to the air-liquid interface for 16 
days. The keratinocytes form several layers following the stratification pattern of 
epidermis. The epidermal tissues (0.50 cm2) were shipped to the laboratory in 24 well 
plates on medium containing agarose gels. At their arrival, the inserts were removed and 
replaced onto 0.5 ml of SkinEthic maintenance medium (SkinEthic Laboratories), as 
recommended, and incubated overnight (37°C, 5% CO2) before testing. Under these 
conditions the RHE can be maintained viable for several days. 
In vitro percutaneous absorption assay 
For testing the percutaneous absorption, 0.5 ml of fresh medium was placed under each 
RHE insert and 50 µl of each solution containing 10-5 M, 10-6 M or 10-7 M of com-
pound/tritiated water (45 kBq) was applied directly on the cornified side of the corre-
sponding tissue. Each concentration was applied on 3 different tissues for LSC. One 
tissue was treated with only the compound -no tritiated water- for histology. The tissues 
were incubated at 37°C (5% CO2) for maximum 2 days. After 15’, 30’, 45’, 1h, 2h, 4h, 
6h, 8h, 24h and 48h of incubation, the culture medium (0.5 ml) was withdrawn from the 
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receiver chamber for analysis by LSC and replaced by fresh culture medium. The 0.5 ml 
aliquots were weighed out in scintillation vials. After adding 10 ml Ultima Gold, the 
vials were capped, hand-shaken for a few seconds and left for at least 2 hours prior to 
counting (10 minutes) on a Beta counter (Packard Tri Carb 2900 TR). 
As controls, 3 tissues were treated with 50 µl of culture medium containing 0.1% 
DMSO and 45 kBq of tritiated water and one tissue with only culture medium contain-
ing 0.1% DMSO for histology. Finally, 4 tissues were left untreated. 
Histology 
At the end of the experiment, punch biopsies (8 mm in diameter) were taken from the 
fourth tissue (non-radioactive) for histological examination. Biopsies were immediately 
fixed in 3% glutaraldehyde in 0.1M KH2PO4, buffered to a pH of 7.4 at room tempera-
ture for 30-60 minutes and stored at 4°C until histological preparation. After fixation the 
samples were washed using the same buffer to which 7.5% sucrose was added for 
osmolality reasons and post-fixed for 1 hour in 1% osmium tetroxide buffered to pH 7.4 
with veronal acetate 50mM. After a brief wash in the buffer, the samples were dehy-
drated in a graded series of ethanol and routinely embedded in epoxy resin (Epon). 
Light microscopic evaluation of morphological changes was performed on semi-thick 
Epon-embedded sections (2µm) stained with toluidine blue for 30 seconds. For electron 
microscopy, ultra-thin Epon-embedded sections (50nm) were counterstained with 
uranium acetate and lead citrate and examined in a Philips CM100 electron microscope. 
Cell viability measurement by MTT reduction 
The viability of the RHE was determined by a colorimetric 3-[4,5-dimethyl-thiazol-2-
yl]-2,5diphenyl tetrazolium bromide (MTT) assay. The test evaluates the transformation 
of MTT, yellow, by mitochondrial dehydrogenases into blue/purple formazan crystals, 
which are insoluble in culture medium. When the tissue is healthy, an intense purple 
color is observed while the culture remains white when necrosis occurred. 
Briefly, 0.5 ml of MTT solution (Sigma) at 0.5 mg/ml in culture medium is added to all 
test wells containing tissue. The plate is incubated for 60 minutes at 37 °C, 5% CO2. At 
the end of the incubation period, the MTT solution is discarded and replaced by isopro-
panol (Sigma). The extraction process in isopropanol is performed during 30 minutes at 
room temperature on a shaking platform. From each well, 200 µl aliquots of blue MTT 
extraction solution is transferred to a corresponding well of a 96-well plate and the 
optical density (O.D.) is measured using a microplate reader (SpectraMax 340) at 540 
nm. The amount of formazan generated is proportional to the number of viable cells 
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after exposure to the test agent and is expressed as the percentage (%) to the untreated 
control using the following formula: 
 
 
The measurement of the viability of the RHE was taken in triplicate. 
Data handling 
All calculations were carried out using Microsoft® Excel 2000 and Graphpad Prism® for 
Windows version 3.02 (GraphPad software, San Diego, CA, USA). The conversion of 
individual cpm data into mean Bq/ml values and the acceptance of each result according 
to the coefficient of variation obtained were computed automatically using an Excel 
spreadsheet. 
Steady-state fluxes (Jss) were determined from graphs in which the cumulative amount 
of penetrated 3H was plotted against time. Fluxes were calculated from the slope of the 
steady-state portion of the curves. The permeability coefficient was calculated using the 
equation: 
 
Kp is the permeability coefficient (cm/s), A is the surface area of the RHE, Cd and Cr 
are the concentrations in the donor and the receiver compartments, V is the volume of 
the receiver compartment (ml), and dCr/dt is the steady state slope of the concentration 
versus the time profile in the receiver compartment. 
 
Significance of differences between treatments was analysed using GraphPad PrismTM 
3.02 software. The results were analysed by comparison of slopes (cumulated 3H per-
meated versus square root of time). The comparisons were always performed versus 
control. A second data analysis was realized by using a test based on confidence interval 
procedure related to Wilcoxon Rank Sum/Mann-Whitney rank test. The values being 
out of range (75-133% of the control) and exhibiting a P value <0.05 (slope compari-
son) were considered as significantly different. 
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Figure 3.1 Chemical structures of the different molecules: R115865, R115866 and R116010. 
 
R
N
N
N
N
H
N
S
S
N
SN
N
N
H
N
S
S
N
N
N
N
H
N
S
CHAPTER 3 
 76
Results and discussion 
Permeation study 
The overall precision expressed as the overall mean of triplicates coefficient of variation 
(CV%) is 13±2% for the samples collected during the 0-8h time interval and 21±2% for 
the samples at 24-48h. Considering a target acceptance limit of 15%, the variability is 
satisfactory and can be considered as low compared to the data obtained with human 
skin samples (CV% in the range 30-45%). 
Time dependent variations of permeated amounts of 3H-water for the different com-
pounds are shown in Figure 3.2. Independently of compounds/concentrations applied, 
the permeation profiles exhibit 2 peaks at 0.75 and 4 hours respectively. Those results 
are in accordance with previous observations (data not shown). The RHE permeability 
in this experimental set-up is affected by two factors. In a first step, the presence of 
water affects the barrier function in the tissue by modulating the hydration rate in the 
stratum corneum and the epidermis. Water is a small molecule (diameter: 0.28 nm) 
which can penetrate through microscopic pores between lipid molecules. The oxygen 
atoms of phosphate and carbonyl groups of gangliosidic sialic acid residue are most 
likely the targets for water bonding. The phospholipid morphology of the membrane is 
affected by the presence of water in this particular residue. Therefore, a marked increase 
in tritiated water permeability is transiently observed in the first hour(s) of the experi-
ment. In a second step, the RHE permeability is probably affected by the presence of the 
tested molecules inducing conformational changes in the tissue (i.e. disruption of the 
ordered lipid bilayers) and/or improving the partitioning coefficient in the stratum 
corneum. These two parameters explain the profiles observed. 
Time-dependent cumulated amounts of 3H permeated across RHE in the presence or 
absence of the molecules are shown in Figure 3.3. The results show that it increases 
rapidly to reach a plateau after 4 hours. 
The total amount of radioactivity that passed into the receptor medium in 48 hours was 
33.4±1.3 MBq, which is on average 74.2% of the dose applied. Steady-state flux condi-
tions were reached after approximately 2 hours, independently of the dose/molecule 
applied. A mean steady-state flux value of 8850 Bq/cm2/h was found for the control, 
9906 Bq/cm2/h for R115865, 8996 Bq/cm2/h for R116010 and 9132 Bq/cm2/h for 
R115866. As is shown in Table 3.1, the steady flux rates of the compounds are not 
statistically different from the control. 
For the control tissues, we can consider that the Kp of the model is 1.64 x 10-4 cm/min 
(Table 3.2). This is in accordance with previous results obtained by others with the same 
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model (1.38 x 10-4 cm/min) as well as ex vivo in Swiss mouse epidermis (1.95 x 10-4 
cm/min).11-12 However, this is 4 to 5-fold higher what has been found ex vivo through 
human skin (0.416 x 10-4 cm/min) and hairless mouse skin (0.533 x 10-4 cm/min), by 
using a traditional diffusion protocol at 37°C.13-15 The biggest limitation of any com-
mercially available epidermal model is the weak barrier function compared to human 
skin. On the other hand the culture model appears to be more consistent in its perme-
ability and responsiveness than the highly variable human skin. 
Morphology 
Light Microscopy  Punch biopsies were taken from the non-radioactive tissues at the 
end of the experiment for histological examination. Light microscopical images re-
vealed no obvious morphological changes as is demonstrated in Figure 3.4. Total 
thickness and topography of the different layers were unchanged. 
Electron Microscopy 
At the ultrastructural level, treatment resulted in the structural preservation of subcellu-
lar organelles in all epidermal layers, as shown in Figure 3.5.  
Cell viability (MTT assay) 
The results of the MTT assay performed at the end of the assay period (48 hours) to 
evaluate the potential cytotoxic effects of the different products are reported in Table 
3.3. After 48 hours of contact, the mean % of surviving cells was close to 100% for all 
the treatments. This indicates that, in the conditions of the assay, the tested products as 
well as the presence of DMSO are devoid of cytotoxic effects on the tissues. Moreover, 
those results demonstrate the tissues integrity during the assay period.  
Conclusions 
The preliminary results show that the molecules R115865, R115866 and R116010 are 
devoid of significant penetrating enhancing effects of tritiated water through RHE at all 
doses tested. On the contrary, from 2 hours of incubation onwards, the cumulated 
amount of tritiated water seemed to decrease with 10-5M R116010 and R115865 com-
pared to the control (Figure 3.3.A). The permeation is probably affected by conforma-
tional changes caused by the presence of the molecules. All compounds were devoid of 
cytotoxic effects. Further work is necessary to evaluate the effects on other barrier 
characteristics of these molecules like proteins and lipids. 
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A  
B  
C  
Figure 3.2 Cumulative amount of tritiated water diffused through RHE in the presence of R115866 (A), 
R116010 (B) and R115865 (C): 10-5, 10-6 and 10-7 M. Each value represents the mean of 1 experiment 
performed in triplicate. 
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A  
B  
C  
Figure 3.3 Cumulated amount of tritiated water permeated through RHE after topical application of 10-5 (A), 
10-6 (B) and 10-7 M (C) of the different products: R115865, R116010 and R115866. Each data point represents 
the mean of 1 experiment performed in triplicate. 
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Table 3.1 In vitro tritiated water flux rate at steady state after application of 10-5, 10-6 and 10-7M of the 
different molecules. Each value represents the mean of 1 experiment performed in triplicate. 
  Flux rate (Bq/cm2/h) 
Concentration 10-5 M 10-6 M 10-7 M 
R115865 9708 9841 10170* 
P-value** 0.0140 0.0240 0.0120 
R116010 8563 9880 8545 
P-value** 0.0690 0.0100 0.2090 
R115866 9099 9115 9183 
P-value** 0.1249 0.3516 0.5476 
Control (0.1% DMSO) 8850 8850 8850 
* significant by comparison of slopes 
** Wilcoxon Rank Sum/Mann-Whitney rank test 
 
Table 3.2 In vitro Tritiated water coefficient of permeation obtained after application of R115865, R115866 
and R116010 at 10-5, 10-6 and 10-7 M. 
  Kp (cm/min) x10-4 
Concentration 10-5 M 10-6 M 10-7 M 
R115865 1.798 1.822 1.883 
R116010 1.586 1.830 1.582 
R115866 1.685 1.688 1.701 
Control (0.1% DMSO) 1.639 1.639 1.639 
 
Table 3.3 Percentage of surviving cells obtained after treatment of RHE in vitro with the molecules to be 
tested. Each value represents the mean of 1 experiment performed in triplicate. 
  
O.D. Individual % of surviving cells 
Mean % 
of 
surviving 
cells 
Control-Untreated 1.372 1.261 1.441  
Mean  1.358 
R115865 -10-5 1.360 1.266 1.323 100 93.2 97.4 96.9 
R115865-10-6 1.361 1.194 1.437 100 87.9 106 98.0 
R115865-10-7 1.484 1.297 1.273 109 95.5 93.7 99.5 
R116010-10-5 1.344 1.409 1.246 99.0 104 91.8 98.2 
R116010-10-6 1.424 1.322 1.334 105 97.3 98.2 100 
R116010-10-7 1.496 1.403 1.392 110 103 103 105 
R115866-10-5 1.389 1.144 1.273 102 84.2 93.7 93.4 
R115866-10-6 1.362 1.260 1.318 100 92.8 97.1 96.7 
R115866-10-7 1.317 1.103 1.257 97.0 81.2 92.6 90.3 
Control - 0.1% DMSO 1.195 1.252 1.107 88.0 92.2 81.5 87.2 
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Figure 3.4 Light microscopical images of RHE treated with (a) Control (b) R115866, 10-5M and (c) R116010, 
10-5 M. See page 229 for colour figure. 
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Figure 3.5 Electron microscopical images of RHE treated with (a) Control (b) R115866, 10-5M. 
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Abstract 
Liarozole, an imidazole derivative developed in the late eighties by the Janssen Re-
search Foundation in Belgium, represents a class of compounds coined Retinoic Acid 
Metabolism Blocking Agents. Other members of that class are ketoconazole and 
R115866 (RambazoleTM). 
Extensive in vitro and in vivo pharmacological testing identified liarozole as an inhibitor 
of several mammalian cytochrome P450 isozymes among which the ones involved in 
the oxidative metabolism of all-trans retinoic acid. In vivo, this pharmacological activity 
results in increased plasma and tissue levels of endogenous retinoic acid and conse-
quently offers a potential therapeutic benefit in skin disorders of keratinization like 
ichthyosis, psoriasis and acne. The objective of this paper is to provide an overview of 
the non-clinical and clinical in vivo pharmacology of liarozole related to dermatology. 
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Introduction 
All-trans retinoic acid (RA), a metabolic derivative of vitamin A, is one of the principal 
endogenous compounds that control growth and differentiation of epithelial tissues.1,2 
Retinoic acid (RA) exerts its activity through binding to specific nuclear retinoic acid 
receptors (RARs and RXRs), which act as ligand-inducible transcriptional factors. On 
interaction with RA, these RARs bind to specific DNA sequences and either repress or 
activate the transcription of adjacent target genes.3,4 Plasma and tissue levels of RA are 
kept under tight homeostatic control. One of the mechanisms contributing to this ho-
meostatic control is the metabolic inactivation of RA through oxidative metabolism, 
which is initiated by the 4-hydroxylation of RA to form 4-hydroxy-RA and 4-keto-RA 
(=4-oxo-RA).5 Both the 4-hydroxylation of RA and the further oxidation of 4-keto-RA 
to more polar metabolites are mediated by microsomal cytochrome P450 (CYP) 
isozymes. 
Ketoconazole, at first identified as an imidazole anti-fungal, was found to inhibit in 
vitro the catabolism of RA by established cell lines6,7 and microsomal preparations.8,9,10 
Accordingly, oral ketoconazole was shown in vivo to delay the metabolism of exoge-
nously administered RA11, to enhance plasma levels of endogenous RA11 and to prevent 
keratinization in the animal model of oestrogen-induced vaginal keratinization in 
ovariectomized rats (non published observations). These observations lead to the initia-
tion of an extended project on the synthesis and screening of Retinoic Acid Metabolism 
Blocking Agents (RAMBAs). As a result liarozole, a novel imidazole derivative, was 
identified as a valuable candidate. 
Liarozole, which refers chemically to (±)-5-[(3-chlorophenyl)(1H-imidazol-1-
yl)methyl]1H-benzimidazole, is chemically related to the anti-fungal imidazole, keto-
conazole. Originally developed as an inhibitor of testosterone biosynthesis, subsequent 
testing showed it to inhibit both androgen-dependent and -independent experimental 
tumors. Clinical studies also revealed anti-tumor activity and a surprising retinoid-like 
cutaneous secondary effect associated with elevated levels of plasma RA. The objective 
of this paper is to provide an overview of the non-clinical and clinical in vivo pharma-
cology of liarozole related to dermatology. 
CHAPTER 4 
 88
RA-related pharmacodynamic effects 
Non Clinical Pharmacology 
Liarozole was found to inhibit in vitro the metabolism of RA by established cell lines or 
by microsomal preparations. To assess the effects of liarozole on the in vivo RA me-
tabolism, the following approaches were taken. 
Effects of liarozole on plasma and tissue RA concentrations in rats 
In rats11, the effect of orally administered liarozole was examined on plasma elimination 
of exogenously administered RA and on plasma levels of this endogenous retinoid. It 
was shown that pretreatment (-1h) with 40 mg/kg liarozole decreased the plasma clear-
ance of i.v. injected RA (0.1mg/kg) from 35 ml/min/kg in vehicle-pretreated rats to 13 
ml/min/kg in liarozole-pretreated rats whilst there was no effect on the distribution 
volume of the retinoid. Residual plasma concentrations of RA, measured 2 hours after 
its i.v. injection, were increased from undetectable levels (<1 ng/ml) in vehicle-
pretreated animals to 5.2, 10.1, 17.6 and 22.7 ng/ml after pre-treatment with 5, 10, 20 
and 40 mg/kg liarozole, respectively. 
Moreover, it was shown that liarozole (40 mg/kg, -1 h) was also able to increase the 
biological half-life of exogenously injected 4-keto-RA (0.1 mg/kg) in rats.13 The drug 
nearly doubled the plasma half-life from 7 to 12 min while having no effect on its 
distribution volume. 
Oral administration of liarozole to rats, not only delayed the plasma elimination rate of 
intrajugulary injected RA or 4-keto-RA, but also enhanced plasma levels of endogenous 
RA confirming the in vivo suppressive activity of liarozole on the biodegradation of 
endogenous RA. After a single oral administration of liarozole (40 mg/kg, -2h) to rats, it 
was shown that the plasma concentrations of endogenous RA were enhanced. To 
determine the duration of action of this RA enhancement, liarozole (40 mg/kg) was 
administered to rats 1 to 6 hours prior to plasma recovery.11 The peak level of endoge-
nous RA in plasma occurred at 3 hours after drug treatment. To assess the potency with 
which liarozole affects the in vivo biodegradation of the retinoid, rats were treated orally 
with various doses of liarozole (0.3-1.25-5-20 mg/kg) or vehicle.12 The RA plasma 
concentration measured 3 hours after drug intake amounted to mean RA levels of 
1.9±0.1 and 1.4±0.1 ng/ml plasma for liarozole doses of 20 mg/kg and 5 mg/kg, respec-
tively. The lower doses tested (1.25 and 0.3 mg/kg) were inactive. 
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In addition, single and repeated oral dosing of liarozole to rats enhanced also endoge-
nous RA levels in various tissues (unpublished data). In a first study rats were treated 
with a single oral dose of liarozole (40 or 10 mg/kg) or vehicle. At various time inter-
vals after treatment (2, 4, 6 and 8 h), the RA content was assessed in plasma, skin, fat 
(epididymal and perinephric), kidney, lung, liver and testis. Liarozole (40 or 10 mg/kg) 
was shown to induce tissue- and dose-dependent transient increases of endogenous RA 
which were mostly pronounced and long-lasting in skin and testis. Eight hours after 
treatment, significantly elevated levels of endogenous RA compared to the respective 
vehicle value could still be detected in extracts from skin and testis. Of note, these two 
tissues also contain higher concentrations of cellular RA binding proteins (CRABPs).14 
Strikingly, no effect was seen on endogenous RA concentrations in the liver at any of 
the time intervals tested. 
The findings of a second study in rats bearing androgen independent PIF-1 Dunning 
R3327 prostate carcinomas and treated with a single oral dose of vehicle or liarozole (20 
mg/kg) corroborated previous observations. Two, 4, 8 and 12 hours after treatment, RA 
concentrations were determined in plasma, skin, testis and tumor. Liarozole elicited a 
sustained increase of RA levels in skin and testis. Mean levels of RA were significantly 
enhanced in plasma at 2 and 4 hours and in skin and tumor at 2, 4 and 8 hours after drug 
administration. In testis, administration of liarozole resulted in statistically significant 
higher RA levels compared to the vehicle until 12 hours following drug administration 
(Table 4.1). 
Finally, subchronic oral administration of liarozole (40 mg/kg) or vehicle to rats once 
daily for 5 consecutive days also resulted into a protracted activity in skin and testis as 
seen in the single dose studies. RA concentrations were determined in plasma, skin, 
perinephric fat and testis at 2, 4, 6 and 8 hours after the last drug administration. At the 
2 and the 4 hour time-point, significantly enhanced RA values were measured in every 
organ tested in the liarozole group when compared to the vehicle group. Significantly 
elevated levels of RA compared to vehicle still persisted in skin and testis at 6 and 8 
hours following the last drug administration. These data indicate that repeated liarozole 
treatment of rats does not jeopardize the drug’s ability to augment endogenous plasma 
and tissue levels of RA.  
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Table 4.1 Effect of single oral administration of vehicle or liarozole (20mg/kg) on endogenous RA levels in 
plasma, skin, testis and tumor. 
RA concentrationa 
[ng (S.E.) per ml plasma or g of tissue] 
Tissue Time after last 
treatment 
(hours) 
Vehicle 
(20%PEG 200 in water) 
Liarozole 
(20 mg/kg) 
2 0.6 (0.1) 1.9 (0.1) 
4 0.6 (0.0) 2.0 (0.1) 
8 0.7 (0.1) 0.6 (0.1) 
Plasma 
12 0.8 (0.1) 0.4 (0.0) 
2 1.7 (0.2) 6.2 (0.6) 
4 0.9 (0.2) 5.5 (0.4) 
8 2.0 (0.3) 4.3 (0.5) 
Skin 
12 1.7 (0.2) 1.9 (0.2) 
2 3.0 (0.1) 5.5 (0.2) 
4 3.0 (0.5) 6.8 (0.3) 
8 3.8 (0.1) 5.5 (0.1) 
Testis 
12 3.3 (0.1) 5.1 (0.2) 
2 7.1 (0.9) 23.2 (2.9) 
4 9.1 (0.8) 21.6 (2.5) 
8 8.3 (1.0) 18.0 (1.6) 
Tumor 
12 7.3 (0.6) 9.0 (0.7) 
a Results are given as mean ± SE (n = 8) 
Suppression of estrogen-induced vaginal keratinization in ovariectomized rats by 
liarozole 
RA was shown to suppress the keratinization process in the stratified squamous epithe-
lium of the rat vagina. The rat vaginal epithelium assay has been recommended as an in 
vivo screening test for evaluating the potential biological activity of natural and syn-
thetic retinoids.15 As aforementioned liarozole treatment in vivo resulted in higher and 
more sustained plasma and tissue levels of endogenous RA compared to placebo treat-
ment. Accordingly such compound should be capable of generating RA-mimetic bio-
logical effects. Liarozole and RA, therefore, were compared for their effects on vaginal 
keratinization.12 Like RA, liarozole dose-dependently reversed the vaginal keratiniza-
tion induced by estrogenic stimulation in ovariectomized rats. Both compounds admin-
istered orally, once daily for 3 consecutive days, expressed equipotent antikeratinizing 
activity; they significantly reversed vaginal keratinization at a same dose of 5 mg/kg 
(Table 4.2). 
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Table 4.2 Inhibitory activity of liarozole and RA on vaginal keratinization induced in ovariectomized rats by 
estrogen treatment. Each drug was administered p.o. for 3 days to oestradiol undecylate-treated ovariec-
tomized rats. Animals were sacrificed 1 day after the last drug administration. * The degree of vaginal 
keratinization was scored by light microscopy according to the following arbitrary scale: ++ = presence of 
keratinized squamae covering the entire vaginal epithelium; + = presence of keratinized squamae along part of 
the vaginal epithelium; 0 = absence of keratinized squamae above the vaginal epithelium. ** = p<0.05 vs. 
solvent. 
Treatment  Dose (mg/kg) # of Animals 
Tested 
# of Animals with Keratinization Score* 
 0 + ++ 
Vehicle - 15 0 0 15 
20 6 6 0 0** 
5 8 4 2 2** 
1.25 6 0 1 5 
Liarozole 
0.3 6 0 0 6 
20 6 6 0 0** 
5 8 4 3 1* 
1.25 6 0 3 3 
RA 
0.3 6 0 0 6 
 
Since cytokeratin expression is a prominent marker of epithelial differentiation, the 
effects of liarozole and RA treatment on the production of keratin proteins by the 
vaginal epithelium were also examined.12 Liarozole and RA similarly affected the 
production of cytokeratins: both compounds turned off the expression of high molecular 
weight (57-60 kDa) keratin proteins and turned on the expression of the 45 to 47 kDa 
keratin proteins. 
Furthermore, antikeratinizing doses of liarozole were shown to coincide with a doubling 
of the endogenous RA concentration in the vaginal epithelium, leaving open the possi-
bility of a causal relationship between the drug-induced morphologic changes and local 
enhancement of retinoid levels.  
Induction of pinnal epidermal hyperplasia in hairless mice by liarozole 
Induction of epidermal hyperplasia is one of the few characteristic cutaneous activities 
induced by retinoids in vivo.16 Liarozole, in comparison to RA, was tested for its ability 
to induce epidermal hyperplasia in hairless mice (unpublished results). 
Repeated oral dosing (once daily for 14 consecutive days) of liarozole (20 mg/kg) or 
RA (10 mg/kg) to hairless mice similarly affected growth and differentiation of ear 
epidermis. Liarozole shared with RA the ability to induce epidermal hyperplasia and to 
affect the expression of cytokeratins in pinnal epidermis (Figure 4.1). 
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Figure 4.1 Thickness of the pinnal epidermis from hairless mice chronically treated with vehicle (PEG 200), 
RA (10 mg/kg), or liarozole (20 mg/kg) as measured by computerized image analysis. Individual values are 
shown as closed circles, mean values as open columns. N= number of treated animals, *p≤ 0.0001 versus 
vehicle. 
 
In a follow-up dose-ranging study (5, 10, 20 and 40 mg/kg), liarozole elicited only a 
statistically significant hyperplastic response at 20 mg/kg, whilst a species specific 
lethality was observed at 40 mg/kg.17 
Conversion of aberrant keratinization in tail epidermis of hairless mice by liarozole 
Another striking cutaneous feature of retinoids in vivo is the formation of a granular 
layer and the transformation of the parakeratotic type of keratinization to the orthokera-
totic type in the scale regions of murine/rat tail epidermis.17 Results of a dose-ranging 
study (5, 10, 20 and 40 mg/kg) in hairless mice, however, were non-conclusive. At 5, 10 
and 20 mg/kg no effects were observed, whilst at 40 mg/kg the limited number of 
surviving animals (3 out of 8 animals) hampered the interpretation of the results (unpub-
lished results).  
Liarozole and irradiated skin 
Potential interactions between ionizing irradiation and liarozole treatment were evalu-
ated in non-tumor bearing hairless mice (unpublished results). Oral liarozole (20 and 40 
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mg/kg) protected the skin from the toxic effects (moist desquamation, edema, paw 
swelling) induced by ionizing irradiation (fractionated regimen; 33x3Gy).  
Inhibition of phorbol ester-induced ornithine decarboxylase and tumor promotion in 
mouse skin by liarozole 
The chemoprotective effects of RA in cancer have been extensively investigated in the 
two-stage, initiation-promotion model of carcinogenesis in mouse skin.18,19 Retinoids 
act to suppress the formation of skin papillomas in this model by interfering with the 
promotion phase of mouse skin carcinogenesis. The acute induction of the enzyme 
ornithine decarboxylase (ODC) in mouse skin by various phorbol esters is highly 
correlated with their tumor-promoting activity. 
When administered orally to mice, liarozole (10-80 mg/kg) produced a dose-related 
inhibition of ODC induction in dorsal skin by the tumor promoting phorbol ester 12-O-
tetradecanoyl-phorbol-13-acetate (TPA). The observed potency of oral liarozole com-
pared favorably to oral RA, which was active at 1 to 10 mg/kg. 
Similarly, oral pre-treatment of mice with 20 to 80 mg/kg liarozole produced a dose-
related reduction in tumor incidence and tumor burden (i.e. the number of papillomas 
per mouse.) as was seen after topical pre-treatment of mice with 5μg RA during 17 
weeks of tumor promotion.20 
Conclusion 
The in vivo models reveal that liarozole and RA elicit similar morphologic and bio-
chemical effects on the proliferation/ differentiation processes of diverse types of 
epithelial tissues. These data support the hypothesis that liarozole, an inhibitor of the 
CYP-dependent metabolism of RA, mimics the action of RA. 
Clinical Pharmacology 
Volunteers-Single Dose Studies 
During single dosing studies with oral liarozole in male volunteers, it was shown that 
the plasma RA curve after placebo intake shows daily fluctuations, suggesting the 
presence of a certain biological variation in the human plasma RA level. However, this 
pattern of daily fluctuation was not discerned in all subjects. Each individual curve was 
characterized by a plasma RA peak level 1 to 4 hours after placebo intake. 
In one study, it was shown that, after intake of escalating single doses of liarozole (37.5-
75-150-300 mg) or placebo, there was a dose-dependent increase in plasma RA levels, 
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indicating that liarozole slows down the catabolism of RA. All liarozole doses increased 
plasma RA concentrations for up to 8 hours after administration, with peak increases at 
4 to 6 hours after drug intake. The mean area under the curve (AUC) 0-8h statistically 
significantly increased from 15.7ng.8h/ml for placebo to 22.5 ng.h/ml for liarozole 150 
mg (p=0.03, n=6) and 23.0 ng.h/ml for liarozole 300 mg (p=0.04, n=6). The data show 
that while there was a naturally occurring increase in the mean level of RA of 39% in 
placebo-treated subjects after 4 hours, RA levels increased more than 100% for both 
liarozole 150 mg and 300 mg. 
In another study with liarozole, where the dose-proportionality of the pharmacokinetics 
of single oral doses of liarozole (75-150-300 mg) was evaluated together with the 
effects on RA, it was found that the systemic exposure to liarozole increased more than 
direct proportionality would predict. The median Tmax was 1.0 hour for all treatments 
and the Cmax was 0.83, 1.93 and 4.28 µg/ml for respectively 75, 150 and 300 mg of 
liarozole. The increase in RA plasma levels reached its maximum at four hours after 
administration with all liarozole doses, with mean peak increases of 71%, 66% and 
105% for the 75, 150 and 300 mg dose respectively. Liarozole increased the AUC0-12h of 
plasma RA by 23-33% at all doses in comparison to placebo, but a clear dose-dependent 
effect was not detected. 
A graphical display of the relationship between plasma concentrations of liarozole and 
changes in RA levels (=RA level after liarozole minus RA level after placebo) reveals a 
hysteresis loop when the time points are joined in time sequence (Figure 4.2). This 
indicates that the time to reach the maximal plasma concentration of liarozole is not 
equal to the time to reach the maximal RA level meaning that a time-delayed relation-
ship exists between plasma concentrations of liarozole and RA. 
Volunteers-Multiple Dose Studies 
In a multiple dose study with 12 healthy male volunteers treated orally with 150 mg 
liarozole b.i.d. for 10 days, a similar increase in mean RA levels versus baseline could 
be observed 3 hours after drug intake on day 10 as on day 1. No changes in RA were 
seen in the placebo treated group.  This provides evidence of the sustained effect of 
liarozole on the RA levels. Importantly, no changes were observed for retinol; thus no 
effect on vision should be expected. 
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Figure 4.2 Hysteresis loop for the mean change in retinoic acid level (=RA level after liarozole minus RA 
level after placebo) against the plasma concentrations of liarozole 
 
Volunteers-Effect of topical liarozole 
Kang et al. investigated the effects of topical liarozole (3%) on the RA 4-hydroxylase 
activity of human epidermis of normal healthy adults and its ability to modify in vivo 
human skin responses to RA (0.001%) and all-trans-retinol (ROL, 0.025%).21 In this 
study, evidence was provided that liarozole inhibits human skin RA 4-hydroxylase 
activity and that this inhibition is associated with increased epidermal RA levels in vivo. 
Moreover it was shown that although liarozole, RA and ROL, when applied separately 
on human skin at the above mentioned low doses, were not associated with significant 
erythema or epidermal hyperplasia, concomitant application of liarozole and RA or 
ROL amplified human skin responses to the retinoid (erythema and hyperplasia with 
RA; no erythema but hyperplasia with ROL) in a manner characteristic of the retinoid at 
a higher dose. 
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Non RA-related Pharmacodynamic Effects on Cytochrome P450-
dependent Steroid Metabolism 
Non clinical Pharmacology 
In mammals, CYP dependent enzymes catalyze numerous hydroxylations involving 
endogenous compounds, particularly in steroid biosynthesis. Therefore, the selectivity 
profile of liarozole for the CYP dependent enzymes involved in ovarian, testicular and 
adrenal functions, as well as those involved in vitamin D3 metabolism, was extensively 
evaluated in vitro as well as in vivo.  
Aromatase (CYP19), 17-hydroxylase/17, 20-lyase (CYP17A) and 11-hydroxylase 
(CYP11B) were found in vitro to be main target enzymes for liarozole. Animal studies 
in rats and dogs corroborated that liarozole inhibits both estrogen and testicular andro-
gen biosynthesis in vivo. Daily oral administration of liarozole (5 to 80 mg/kg/day) for 3 
months to female rats decreased serum estradiol levels, whereas serum progesterone, 
androstenedione and luteinizing hormone (LH) concentrations increased. Similar 
findings were observed in female dogs orally dosed for 3 months with liarozole (2.5 to 
5 mg/kg, b.i.d.). All levels returned to normal after a 2 month recovery period. Compar-
ing rats and dogs, the dog seems to be the most sensitive species to inhibition of andro-
gen biosynthesis (17-hydroxylase/17, 20-lyase complex) by liarozole, since sustained 
castration levels of plasma/serum testosterone were observed after single (2.5 mg/kg) 
and chronic (2.5 mg/kg, b.i.d., up to 6 months) administration of liarozole. In contrast, 
peripheral androgen levels in male rats were much less affected after a single oral 
administration of liarozole (1 to 20 mg/kg) and were not modified by chronic treatment 
(10 to 160 mg/kg/day, up to 6 months). The lack of change in gonadal steroids in 
chronically treated rats probably results from a pituitary compensation mechanism as 
evidenced by the rise in gonadotropin levels (follicle-stimulating hormone (FSH) and 
LH). Similar findings were observed in 3-month oral treatment studies of both rat and 
dog. Furthermore, hormone levels returned to normal after a 2-month recovery period. 
The partial inhibition by liarozole of the 11β-hydroxylase (CYP11B) was responsible 
for the blunting of corticosterone, cortisol and aldosterone response to adrenocortico-
tropic hormone (ACTH) challenge in rats and dogs and for the reduction of the serum 
levels of these steroids observed in the 6-month chronic oral toxicity studies of both 
species.22 
Liarozole affects in vitro the final step in the activation of vitamin D3 as well as the 
catabolism of vitamin D3 (unpublished data). However, the outcome and the physiologi-
cal significance of the in vitro interactions of liarozole on vitamin D metabolism are still 
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not well clarified. No symptoms of hypervitaminosis D have been observed thus far in 
toxicological and clinical studies. 
Clinical Pharmacology 
Effect on Androgens 
In a single dose study with male volunteers treated orally with 75, 150 and 300 mg 
liarozole, plasma testosterone concentrations were reduced compared to placebo in a 
dose-dependent manner for up to 12 hours after drug intake. Lowest testosterone levels 
were reached 4 to 6 hours after drug intake with mean peak reductions of 41%, 61% and 
82% for the 75, 150 and 300 mg doses, respectively. 
In a dose-escalating study, male volunteers took a single oral dose of 40, 80, 160, or 320 
mg of liarozole. Again, a dose-dependent decrease in testosterone levels was observed: 
4 and 8 hours after intake, the testosterone levels were reduced by 35-30, 58-55, 71-69 
and 81-85 % respectively. Concomitantly an expected rise of the precursors 17α-
hydroxyprogesterone and progesterone and also of LH was observed. 
When administering 300 mg liarozole b.i.d. for 3 days to healthy male volunteers, 
testosterone levels dropped significantly within 4-8 hours after each liarozole intake. 
The trough testosterone concentrations, ±12 hours after liarozole treatment, showed a 
progressive escape, demonstrated by rising testosterone levels. This escape was linked 
to a marked increase in LH levels. On the fourth day, 24 hours after the last intake, the 
plasma testosterone levels normalized and LH concentrations decreased. A similar 
pattern was observed during a 10 days administration of liarozole 150 mg b.i.d. to 12 
healthy male volunteers. 
Adrenal androgens (DHEA and androstenedione) were assayed in healthy male volun-
teers after single or multiple dose liarozole. No detectable changes in the adrenal andro-
gens were observed. 
Effect on Progesterone, Estrogens and Gonadotropins (LH and FSH) 
Due to the inhibition of the testicular 17-hydroxylase; 17,20-lyase complex, a rise of the 
precursors 17α-OH-progesterone (up to 140%) and progesterone (up to 540%) was 
observed after single dose administration of liarozole (300 mg) in healthy male volun-
teers. In an escalating single dose study (40, 80, 160 and 320 mg), progesterone produc-
tion was significantly increased in a dose-dependent way by liarozole: its concentration 
reaches a peak 4 hours after liarozole intake and decreased progressively to return to its 
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normal level within 32 hours. 17α-OH-progesterone production was less affected and 
maintained its normal rhythm after ACTH administration. 
In healthy volunteers, liarozole was shown to be a potent aromatase inhibitor, leading to 
significantly decreased serum estradiol. The reduction of estradiol levels reached its 
maximum at 8 hours after a single oral dose of 75, 150 and 300 mg liarozole, with mean 
peak reductions of 71, 82 and 79%, respectively. Concentrations of estradiol were 
decreased for up to 32 hours after drug administration. Similar observations were seen 
in a 10-day treatment with oral liarozole 150 mg b.i.d. in healthy male volunteers. 
Serum estradiol levels remained lowered by 40 to 50% from day 1 to day 10. Twenty-
four hours after the last drug administration, serum estradiol levels rebounded to levels 
above those measured in the placebo session of day 1. 
LH and FSH follow the naturally occurring positive pituitary feedback mechanism upon 
the decrease of testosterone and estradiol induced by liarozole as was shown in a 10-day 
treatment with oral liarozole 150 mg b.i.d. in healthy male volunteers. 
Effect on Adrenal Steroids and Mineralocorticoids 
No consistent changes in the basal serum levels of both cortisol and aldosterone were 
observed during therapy with liarozole, whilst the levels of 11-deoxycorticosterone 
(DOC) increased 5- to 15-fold. A partial non-significant blunting of cortisol response to 
exogenous ACTH stimulation was observed both in volunteers and in relapsed prostate 
cancer patients after single (300 mg) and long-term (300 mg b.i.d. for 2 weeks) liarozole 
treatment respectively, but none of these patients had clinical signs of hypocortisolism. 
Neither were any symptoms of hypocortisolism observed in prostate cancer patients 
treated with liarozole for up to 2 years. On the other hand, the aldosterone response to 
exogenous ACTH stimulation was clearly blunted with a concomitant rise in DOC. 
Because of minor changes in basal aldosterone and mineralocorticoid activity of the 
accumulated precursor DOC, these changes were not clinically significant, as evidenced 
by the absence of any clinically significant changes in blood pressure or electrolytes in 
volunteers or in cancer patients. 
Effects on Vitamin D and Thyroid Stimulating Hormone (TSH) 
Given the known interaction of vitamin D and RA receptors, vitamin D was assayed in 
12 volunteers. During a 10-day treatment with 150 mg liarozole b.i.d., no alterations of 
the serum levels of 1, 25-dihydroxyvitamin D3 and of 25-hydroxyvitamin D3 were 
detected. 
The lack of obvious effect on plasma TSH levels after 3 days of dosing liarozole 300 
mg b.i.d. in six male volunteers suggests that the thyroid alterations observed in rats 
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after long-term administration of high doses of liarozole are not relevant to the human 
situation. Moreover, no clinical signs of thyroid dysfunction were observed in the 
clinical trials in prostate cancer. 
Non RA-related Pharmacodynamic Effects on non-Cytochrome P450-
dependent Steroid Metabolism and steroid receptor-binding profile 
The effects of liarozole on androgen metabolism were evaluated in primary cultures of 
collagenase dispersed rat prostate cells incubated with 5.10-9M of [14C] testosterone. Up 
to a concentration of 10-5M, liarozole did not affect prostatic 5α-reductase, the enzyme 
which converts testosterone into its biologically more potent metabolite dihydrotestos-
terone, nor 17β-hydroxysteroid dehydrogenase, which converts estrone to estradiol. The 
conversion of estrone and DHEA sulphate, mediated by the sulphatase enzyme, was 
also unaffected by liarozole. 
Liarozole did not alter in vitro radioligand binding to estrogen-, progestin-, androgen- 
and glucocorticoid-receptors. 
General Pharmacology 
Interaction with Specific Neurotransmitters and Neuromodulators 
Apart from weak binding affinity for the transporter sites for dopamine (Ki: 2300 nM) 
and norepinephrine (Ki: 4300 nM), liarozole was devoid of any activity in a variety of in 
vitro receptor binding assays when tested up to a concentration of 10µM. Moreover, 
liarozole did not inhibit the uptake of [3H]GABA (γ-aminobutyric acid) in crude rat 
synaptosomes. Based on the results of in vivo interaction studies liarozole was devoid of 
interaction with a variety of neurotransmitters and neuromodulators and their specific 
receptors (acetylcholine, dopamine, histamine, norepinephrine, serotonin, and opiate) up 
to 40 mg/kg, s.c. and 160 mg/kg, p.o. in rodents and 40 mg/kg, s.c. and p.o. in dogs. 
Interaction with the Central Nervous System 
Up to 40 mg/kg, s.c. and 160 mg/kg, p.o. in rodents and 2.5 mg/kg i.v., 40 mg/kg, s.c. 
and p.o. in dogs, liarozole failed to show any consistent effects on general behavior, 
body functions (muscle tone, body temperature, respiration, pupil diameter, palpebral 
opening), or reflexes in general observation tests. 
At high oral doses in rats, liarozole showed a tendency to decrease motor activity (ED50: 
113 mg/kg, p.o.), conditioned food-intake (ED50: 149 mg/kg, p.o.) and, possibly as a 
CHAPTER 4 
 100
direct consequence, faecal excretion (ED50: 149 mg/kg, p.o.) without affecting urinary 
excretion (ED50: >160mg/kg, p.o.). In dogs, liarozole did not inhibit conditioned two-
way avoidance behavior. 
Liarozole did not affect the behavioral effects induced by Ro-4-1284 in mice or by 
tryptamine, apomorphine, amphetamine, xylazine, reserpine, pentylenetetrazole, oua-
bain, barium (II) chloride, nitrogen, potassium cyanide, anoxia or acetic acid in rats. 
Interaction with Cardiovascular and Pulmonary Systems 
Cardiovascular safety was evaluated in several in vitro and in vivo experimental set-ups. 
In vitro studies on isolated cardiac tissue suggest that the compound and its metabolites 
lack the intrinsic capacity to prolong the action potential or induce early after-
depolarizations or triggered activity in different conditions (normal rhythm, bradycar-
dia, hypokalaemia, etc.) in cardiac cells up to a concentration of 10 μM exceeding the 
peak concentration of unbound liarozole in plasma at twice the expected therapeutic 
doses in man (150 mg b.i.d) by a factor 20. Liarozole at a concentration of 50 μM 
slightly shortened the duration of the action potential in canine papillary muscles and 
moderately prolonged the duration of the action potential in guinea pig papillary mus-
cles. 
In vivo, after cumulative i.v. doses from 0.01 to 2.5 mg/kg in closed-chest anaesthetized 
mongrel dogs, liarozole displayed no relevant effects on the bronchial system or the 
ECG. In this in vivo preparation, liarozole did not induce relevant changes in heart rate, 
aortic blood pressure, cardiac contraction and relaxation, total systemic and pulmonary 
resistance as compared to solvent. 
In a 6-month chronic toxicity study in Beagle dogs, liarozole hydrochloride was admin-
istered orally at daily doses of 5, 7.5 and 10 mg/kg. No drug or dose related adverse 
effects on heart rate and ECG were noted. 
Interaction with Gastrointestinal and Urinary Systems 
Liarozole when tested up to 1 µM had no effect on spontaneous movements and con-
tractions of isolated guinea pig ileum induced by acetylcholine, histamine and barium 
chloride. At 10 µM, transiently reduced spontaneous movement, a decrease in basal 
tone and a slight depression in acetylcholine-induced contraction were observed. At 100 
µM reduced spontaneous movement, a decrease in basal tone, and a depression in 
acetylcholine-, histamine- and barium-induced contractions were observed. On the 
contrary, liarozole administered up to 80 mg/kg p.o. or 2.5 mg/kg i.v. to guinea pigs had 
no effect on the spontaneous movement of small intestine in situ. 
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In rats, high oral doses of liarozole had anti-diarrheal activity (ED50: 32 mg/kg), inhib-
ited gastric emptying (ED50: 80 mg/kg, p.o.), reduced gastrointestinal propulsion (ED50: 
80 mg/kg, p.o.), and seemed to reduce (ED50: 149 mg/kg, p.o.) fecal excretion. In dogs, 
liarozole did not accelerate MgSO4-induced diarrhea (ED50: >40 mg/kg, p.o.) or block 
apomorphine-induced emesis (ED50: >40 mg/kg, p.o. or s.c.). 
In rats, liarozole showed cytoprotective activity against stress-induced gastric ulcers 
(ED50: 11 mg/kg, s.c.; 22 mg/kg, p.o.). After oral administration, liarozole also in-
creased gastric pH (ED50: 49 mg/kg). 
In two general observation studies liarozole did not affect urinary excretion in rats 
(ED50: >40 mg/kg, s.c.; >160 mg/kg, p.o.). In a 3rd study in which liarozole was admin-
istered orally at 5 to 80 mg/kg to rats, only the highest dose caused an increase in urine 
volume, in the concentration of potassium, and in total excretion of potassium and 
chloride. 
Allergy, Pain and Inflammation 
Liarozole (administered as medicated diet in an approximate daily dose of 40 mg/kg 
over a period of 40 days) did not produce anti-inflammatory activity against Mycobacte-
rium butyricum arthritis in rats. Liarozole (40 mg/kg, s.c.) did not consistently affect 
skin reactions induced by passive cutaneous anaphylaxis or intradermal injections of 
histamine, serotonin or compound 48/80. Liarozole (160 mg/kg, p.o.) failed to protect 
from platelet-activating factor (PAF)-induced lethality in rats, to inhibit substance P-
induced salivation and plasma extravasation in rats and to block lipopolysaccha-
ride(LPS)-induced lethality or hypothermia in rats, suggesting absence of glucocorti-
coid-like or aspirin-like anti-inflammatory activity (cyclo-oxygenase inhibition). In rats 
and mice, liarozole (160 mg/kg p.o. and 40mg/kg s.c.) did not inhibit acetic acid-
induced writhing in rats or mice, confirming the absence of aspirin-like analgesic or 
anti-inflammatory activity. 
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Abstract 
Background: Liarozole, a retinoic acid metabolism blocking agent (RAMBA), inhibits 
the cytochrome P450 (CYP)-dependent 4-hydroxylation of all-trans-retinoic acid (RA). 
This results in increased plasma and predominantly tissue RA levels and consequently 
offers a potential therapeutic benefit in skin disorders of keratinization, like ichthyosis. 
Objective: The purpose of this study was to assess the short (12 weeks) and long-term 
(72 weeks) efficacy, safety and tolerability of a 5% liarozole cream in patients diag-
nosed with one of the following subtypes of ichthyosis: X-linked recessive ichthyosis, 
lamellar ichthyosis and congenital bullous ichthyosiform erythroderma. 
Methods: Twelve patients were selected for the initial short-term study. After a wash-
out period, patients were treated for 6 weeks with liarozole 5% cream or placebo using a 
bilaterally paired double-blind approach. This was followed by an open phase of 4 
weeks during which both sides of the body were treated with liarozole 5% cream. 
Subsequently, 8 out of 10 patients whom completed the short-term study were moti-
vated to participate immediately in the open maintenance study for 72 weeks. Efficacy, 
safety and tolerability were monitored over the course of the studies. Efficacy variables 
were: evaluation of the overall response to treatment and severity and extent of the skin 
lesions on arms, trunk and legs. 
Results: At the end of the double-blind treatment phase, a significant unilateral im-
provement in extent and severity of skin lesions was observed in favour of the liarozole-
treated side which further improved during the open phase. This was supported by the 
overall assessment of the treatment and patient’s self-assessment of efficacy which was 
scored ‘good/excellent’ for 7/8 patients at the end of the open maintenance study. 
Clinical side effects were only minimal and the treatment was well tolerated. No clini-
cally relevant changes were found in the haematological, biochemical, and urinary 
parameters. Plasma levels of liarozole could be detected throughout the study, the 
highest levels being observed in those patients with more inflammatory types of ich-
thyosis. 
Conclusion: Data from this study indicate that topical treatment of different forms of 
hereditary ichthyosis with 5% liarozole cream is effective and well-tolerated, and may 
present an alternative to the existing therapies. 
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Introduction 
Interest in retinoic acid metabolism blocking agents (RAMBA), in particular liarozole, 
has received a boost because of its received orphan drug status for congenital ichthyosis 
by the European Commission and the U.S. Food and Drug Administration. 
Ichthyosis is a general term used for a clinically and genetically heterogeneous group of 
disorders with a generalized scaling affecting the entire skin. Classification, according 
to Traupe is primarily based on the onset of scaling and the presence or absence of 
associated symptoms.1 Four major groups can be categorized: isolated vulgar, associ-
ated vulgar, isolated congenital and associated congenital ichthyoses. Within those 
groups, a further classification is possible based on genetic, clinical, histological and 
biochemical features. Autosomal dominant ichthyosis vulgaris (ADIV) and X-linked 
recessive ichthyosis (XRI) are isolated vulgar ichthyoses. The group of isolated con-
genital ichthyoses can be subdivided in the harlequin ichthyosis, the lamellar ichthyoses 
(LI) including non-erythrodermic lamellar ichthyosis (NELI), erythrodermic lamellar 
ichthyosis (ELI) and autosomal dominant lamellar ichthyosis and the epidermolytic 
ichthyoses including congenital bullous ichthyotic erythroderma (CBIE) and ichthyosis 
bullosa of Siemens (IBS). These genetically determined dermatoses are rarely life-
threatening but usually severely debilitating and require life-long treatment. All types of 
ichthyosis, except for the autosomal dominant ichthyosis vulgaris (ADIV), are rare 
diseases and can be considered for an orphan drug designation. The incidence of ADIV 
is 1/250, XRI occurs in 1/6000 males whereas LI, CBIE and IBS are even rarer 
(1/100.00-300.000). Therefore, the latter diseases are considered for an orphan drug 
designation. 
Except for ADIV, all these forms of ichthyosis exhibit severe scaling not sufficiently 
improving with moisturizing or keratolytic creams. Topical therapeutic modalities 
available in ichthyosis mainly consist of urea and lactic acid, aiming at rehydration 
(moist retention) and keratolysis of the cornified cell layer. However, these ointments 
are of limited value as they are only effective in ADIV, whereas the more severe ich-
thyosis subtypes do not markedly improve. A good clinical improvement of lamellar 
and epidermolytic ichthyosis with topical calcipotriol has been demonstrated.2 How-
ever, to prevent derangements in calcium metabolism, the maximum weekly amount has 
been limited to 100 g. This limitation constitutes a restriction for its use, as in these 
severe ichthyosis patients, a substantial part of the total body surface is affected. 
Retinoids are powerful substances available for modulating or controlling keratinocyte 
proliferation and differentiation.3,4 Today the systemic retinoid, acitretin, is considered 
the only effective treatment option for severe ichthyoses.5 However a number of sub-
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stantial side effects like teratogenicity, hepatotoxicity, etc. are limiting its chronic use.6 
Topical retinoids on the other hand may represent good alternatives to avoid the sys-
temic side-effects. Nevertheless, to date they have not been shown to be a successful 
alternative because of their propensity for skin irritation with the exception of 13-cis-
retinoic acid.7 Short-term topical application of tazarotene, a novel receptor-selective 
retinoid, has proven to be effective but, as with other retinoids, irritancy is a significant 
side-effect.8 Long-term treatment and treatment of more than 10% of the body surface 
were not investigated. 
Liarozole, an imidazole derivative developed in the late eighties by the Janssen Re-
search Foundation in Belgium, represents a new class of compounds coined RAMBA’s. 
Extensive in vitro9-11 and in vivo12-14 pharmacological testing identified liarozole as an 
inhibitor of several mammalian cytochrome P450 (CYP) isozymes among which the 
one involved in the oxidative metabolism of all-trans retinoic acid (RA), the RA-4-
hydroxylase. Oral liarozole has shown to be an effective treatment for psoriasis and is at 
least as effective as acitretin in the treatment of severe ichthyoses.15-18 To broaden the 
margin between efficacy and side effects, a topical liarozole formulation was developed. 
The aim of the present study is to assess the short- and long-term efficacy, safety and 
tolerability of topical liarozole in the treatment of different forms of severe ichthyosis. 
Patients and methods 
Patients 
Male or post-menopausal (>2yrs) females, aged 18 or more and diagnosed with one of 
the following subtypes of ichthyosis: XRI, LI and CBIE were eligible. At least one of 
the lesion severity parameters (see clinical efficacy parameters) at baseline had to have 
a score of at least 2 on a 4-point scale in which 0 =absent, 1=mild, 2=moderate, 
3=severe. The lesions had to be symmetrical on both sides of the body. Main exclusion 
criteria were concurrent inflammatory skin disease, topical or UV treatment within 2 
weeks and systemic treatment within 4 weeks prior to the start of the treatment phase, 
use of vitamin A supplements (>1000µg/day) and clinically relevant abnormal labora-
tory test values. The study was approved by the Institutional Medical Ethical Review 
Board of the University of Nijmegen. Written informed consent was obtained after the 
nature of the procedures had been fully explained. All clinical investigations were 
conducted according to the Declaration of Helsinki principles. 
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Treatment 
In a randomized, double-blind, placebo-controlled, left-right comparative study, 12 
patients with severe ichthyosis were treated with topical liarozole, 5% cream and 
placebo only. Minimum wash-out periods, in which only placebo treatment was al-
lowed, were 1 month for systemic agents and 2 weeks for topical treatment or photo-
therapy. After the wash-out patients treated the lesions for 6 weeks on a double-blind 
basis: one half of their body with liarozole cream 5% and the contra-lateral side with 
placebo only. Thereafter, both sides of the body were treated with liarozole 5% cream 
for 4 weeks (open phase). The creams were applied thinly and evenly, twice daily. XRI-
patients had a documented steroid-sulphatase deficiency; sun exposure had to be 
avoided. Patients were examined before treatment, at week 0, 2, 4, 6 of the double-blind 
treatment phase and at week 10, the end of the open treatment phase. 
Upon completion of the short-term study (10 weeks), patients were motivated to partici-
pate in an open maintenance study with 5% liarozole for 72 weeks to gather long-term 
efficacy, tolerability and safety data. Visits took place with 4-week intervals. 
Clinical efficacy evaluations 
Since no standardized efficacy-scoring methods are available for ichthyosis, we had to 
develop our own. Efficacy variables evaluated over the course of the studies included 
severity and extent of the skin lesions on trunk, arms and legs and the overall response 
to treatment. 
At each visit, the investigator made an evaluation of the severity of the skin lesions by 
rating scaling, roughness, erythema, bullae and hyperpigmentation on trunk, arms and 
legs separately using a 4-point scale in which 0=absent, 1=mild, 2=moderate, 3=severe. 
Scaling and roughness were recorded in all subgroups, hyperpigmentation only in XRI, 
erythema and bullae in CBIE. 
The extent of the lesions on the arms and legs was recorded for the left and right side 
separately and expressed in % of the surfaces of these body parts, ranging from 0 to 
100%. 
During treatment, both the investigator and the patient made an overall evaluation of the 
response to treatment (=compared to baseline) on arms and legs and rated it on a 5-point 
scale in which 0=deteriorated, 1=unchanged, 2=moderately improved, 3=markedly 
improved, 4= cleared. 
Photographs were taken under standardized conditions during the short-term study at 
baseline, at the end of the double-blind treatment phase (week 6) and at the end of the 
open treatment phase (week 10). 
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Safety and Tolerability 
Throughout the study patients were monitored for adverse events (AEs). Haematologi-
cal, biochemical, urinary examinations were performed at most visits. Endocrinological 
parameters (cortisol, testosterone, oestradiol and luteinizing hormone, aldosterone and 
progesterone) were assessed at regular intervals. Plasma samples for drug level analysis 
were taken at week 6 and 10 of the short-term study and at week 0, 24, 48 and 72 of the 
maintenance study. 
Tolerance to treatment was assessed by the patients at the beginning of each visit prior 
to the investigator’s clinical assessment by rating subjective symptoms i.e. burning 
sensation (redness), skin tension and dry skin on both arms and legs separately, on a 4-
point scale in which 0=absent, 1=mild, 2=moderate, 3=severe. 
Statistics 
For the short-term study, a total of 12 patients were judged to be sufficient. Analysis of 
efficacy was based on the intent-to-treat population which includes all randomized 
patients who used at least one study medication and had post-baseline efficacy data. The 
difference of the extent and severity of skin lesions between left and right arm or leg 
and it changes from baseline were evaluated using a two-sided Wilcoxon-signed rank 
test. Since the maintenance study was an open follow-up study, the statistical analysis 
was performed in a descriptive manner. All statistical tests were two-tailed and were 
interpreted at the 5% level and performed on all patients. Analysis of safety for both 
studies was based on the all-patient population which includes all patients who received 
at least one dose of drug. 
Results 
Patients 
Twelve patients, 11 males and 1 female were recruited for the short-term study: 6 were 
diagnosed with XRI, 4 with NELI and 2 with CBIE. All were Caucasian with a mean 
age of 39 years, a mean weight of 72 kg, and a mean height of 177 cm. Two patients 
stopped treatment prematurely because of an AE: one at the end of the double-blind 
phase (itchy papules) and another during the open phase (contact eczema) but still 
provided data at the last visit, week 10. 
Eight patients (7 males, 1 female) whom had completed the short-term study partici-
pated in the open maintenance treatment. The mean age was 33.8 years and the subtypes 
TOPICAL LIAROZOLE IN ICHTHYOSIS 
 109 
were XRI (n=3), NELI (n=4) and CBIE (n=1). All patients completed the study; One 
patient discontinued therapy for 10 days due to a serious adverse event (myocardial 
infarction; not drug-related). 
Clinical efficacy evaluations 
Extent and severity of skin involvement: Short-term study 
Extent and severity of skin involvement on arms and legs throughout the short-term 
study is summarized in Table 5.1 and Figures 5.1 and 5.2. 
 
Table 5.1 Overview of the extent and severity of the skin lesions on arms and legs durint the short-term study. 
Statistical testing on the difference in the change between treatment sides, compared to baseline values: * 
p≤0.05, ** p≤0.01, *** p≤0.001.  
 Liarozole side  Placebo side 
Extent of lesions on arms (%) 
week 0 
week 6 
week 10 
 
86 
   44** 
33 
 
86 
69 
    45** 
Extent of lesions on legs (%) 
week 0 
week 6 
week 10 
 
87 
57 
48 
 
87 
74 
    58** 
Severity of scaling on arms  
week 0 
week 6 
week 10 
 
2.50 
     1.08*** 
1.00 
 
2.50 
2.33 
    1.36** 
Severity of scaling on legs  
week 0 
week 6 
week 10 
 
2.67 
    1.50** 
1.45 
 
2.67 
2.33 
1.82 
 
 
At the start of the double blind treatment phase, the extent of the skin lesions on the 
arms was 86%. At the end of this phase, the extent was 44% at the liarozole-treated side 
(p=0.001) and 69% at the placebo-treated side (p<0.005). The difference in reduction 
between both sides was statistically significant in favour of the liarozole-treated side 
(p<0.005). Also the severity of scaling and roughness was statistically significant 
reduced at the liarozole-treated side (p=0.005) but not at the placebo-treated side. 
Analysis of the difference between both sides revealed that liarozole was superior to 
placebo for both scaling and roughness (p=0.0005). After 4 weeks of bilateral treatment 
with liarozole, a considerable reduction of the extent of skin lesions (-24%) was found 
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at the previously placebo-treated arms (p<0.01), whereas only a moderate continued 
reduction (-11%) was found at the contra-lateral side (p<0.1). Analysis of the difference 
in shifts between both sides, displayed an improvement in favour of the side previously 
treated with placebo (p<0.05). 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 Evaluation of the extent of the lesions as a function of time during the short-term study. In the 
double-blind treatment phase, reduction of skin lesions on the arms is considerable (86 to 44%) at the 
liarozole-treated side, whereas improvement is only modest at the placebo-treated side (86 to 69%). There 
is clear a catching-up effect on the previously placebo-treated side during the open treatment phase with 
liarozole. 
 
 
With regard to severity, the previously placebo-treated arms showed a reduction of 
scaling (p<0.005) and roughness (p<0.005) which was absent at the contra-lateral side. 
Comparing both sides, again revealed improvement in favour of the previously placebo-
treated side (scaling and roughness: p<0.005). As shown in Table 5.1, the development 
of extent and severity of lesions on the legs in both double-blind treatment and open 
follow-up phase, parallels the shifts described for the arms. 
20 
30 
40 
50 
60 
70 
80 
90 
100 
Wash-out phase 
Placebo 
Double-blind treatment phase 
5% Liarozole vs. Placebo Follow-up phase 5% Liarozole 
Extent of lesions on the arms (%) Placebo 
Liarozole 
Baseline 
10 -4 -2 0 2 4 6
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Figure 5.  Evaluation of the severity of scaling on the arm as a function of time during the short-term 
study. The severity was scored on a 4-point scale in which 0=absent and 3=severe. The severity of the 
scaling on the arms shows a definite improvement in favour of the liarozole-treated side during the double-
blind treatment phase. A catching-up effect is observed on the previously placebo-treated side during the 
open treatment phase with liarozole. 
 
 
Overall response to treatment Short term  
The overall response to treatment, assessed by the investigator, was significantly supe-
rior to placebo from week 4 onwards. After 6 weeks of treatment the liarozole-treated 
arm was markedly improved in 11 cases (92%) and the placebo-treated arm in only one 
case (8%). The liarozole-treated leg was markedly improved in 7 cases (58%) and the 
placebo-treated leg in only one case (8%). None of the patients had completely cleared 
arms and legs. An overview of the overall assessment by the patient at the end of the 
open phase is presented in Table 5.2. Figure 5.3 shows a patient at baseline, at the end 
of the double-blind (week 6) and at the end of the open phase (week 10). 
2
: -  study
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Assessment on arm Assessment on leg 
Liarozole Placebo Liarozole Placebo 
 
N % N % N % N % 
No change 0 0 0 0.0 1 8.3 1 8.3 
Slightly improved 3 25.0 6 50.0 6 50.0 9 75.0 
Markedly improved 8 66.7 5 41.7 5 41.7 2 16.7 
Cleared 1 8.3 1 8.3 0 0.0 0 0.0 
 
 
Figure 5.3 NELI patient: a) before treatment, exhibiting large brown scales covering a substantial part of the 
skin surface; b) at the end of the double-blind treatment, showing marked improvement at the liarozole treated 
side (left side of the person), whereas improvement at the cream-base treated side (right side of the person) is 
only small; c) after 6 weeks double-blind and 4 weeks open liarozole treatment, improvement is marked on both 
sides. At the previously cream-base treated right side, minimal scaling is still visible. See page 230 for colour 
figure. 
 
Long-term study 
During the 72 weeks open maintenance treatment, the extent and severity of the lesions 
were further reduced compared to the results obtained at the end of the previous short-
term study. This was supported by the overall assessment of the result of treatment 
(rated by both the investigator and patients), which was considered to be 
 
a b c 
Table 5.2 Survey of overall assessment (arm and legs) scored by the patient at week 10 (the end of the open 
phase of the short-term study) compared to baseline. 
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‘good/excellent’ for seven patients at the end of the study. One patient became eventu-
ally completely cleared.  
Safety and Tolerability 
Six out of 12 patients reported AEs during the short-term study (Table 5.3). In 5 out of 
6, the AEs were probably drug related since they were present only on the liarozole 
treated side. Two patients discontinued treatment due to AEs: one patient because of 
itch and papules, probably drug related (after 42 days), and another because of contact 
eczema (after 54 days), which he had already developed during the wash-out phase 
when he was treated with placebo cream only. No serious adverse events were reported. 
In the maintenance study, side-effects were minimal and temporary: 7 out of 8 patients 
reported 11 AEs, the most frequently reported was ‘sticky feeling on the skin”, reported 
by 4 patients. One serious adverse event, myocardial infarction, was reported to be not 
drug-related. No clinically relevant changes of hematological, biochemical and urinary 
parameters were found. Endocrinological examinations revealed a reduction in the 
plasma oestradiol concentration, whereas no relevant changes were found in all other 
hormones tested. 
 
Table 5.3 Survey of adverse events of the short-term study: (A) dose reduction, (B) temporary stop, treatment 
continuation, permanent stop, (C) temporary stop, (D) dose reduction, (E) permanent stop. Per study phase, 
the side of the body (liarozole-treated or placebo-treated) of the adverse events is mentioned. 
Patient  Adverse events Wash- out 
phase 
Double-blind 
phase 
Open 
phase 
1 Itch on trunk  liarozole (A) liarozole 
2 Dry lips   liarozole 
3 - itch 
- erythematous papules on arms 
- itching erythematous papules on legs 
 liarozole (B)  
4 Bilateral contact eczema on nates, upper legs and 
abdomen 
placebo 
(C) 
placebo + 
liarozole (D) 
liarozole 
(E) 
5 Itch on trunk  liarozole  
9 Paresthesia after application of cream   liarozole  
 
Liarozole cream was well tolerated. In the short-term study, the tolerance ratings were 
not statistically significantly different between the liarozole-treated and placebo-treated 
side at the end of the double-blind treatment phase. The dryness of the arms and legs 
was reduced significantly on both treatment sides. Also at the end of the open phase, 
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tolerance ratings were the same for both sides. In the long-term maintenance study, 
burning sensation (redness), skin tension and dryness of the arms and legs were only 
reported the first 4 weeks and at week 48. Mild to moderate burning sensation of the 
trunk occurred more often and was reported until week 48. Mild skin tension and 
dryness on trunk were only reported during the first four weeks. 
Pharmacokinetics 
The plasma concentration of liarozole varied strongly between the different subtypes: 
XRI: <2.5-24 ng/ml; CBIE: 15-217 ng/ml and NELI: 25-428 ng/ml (Figure 5.4). The 
plasma concentration seemed to be related to the type of ichthyosis: the highest concen-
trations were found in patients with NELI and the lowest in patients with XRI. 
The female NELI patient was an exception to that as she had very low liarozole plasma 
levels varying between 25-60.5 ng/ml which is not even close to the amounts reached by 
the male NELI patients: 153-402 ng/ml. The amount of liarozole used in these groups 
was not different.  
 
Figure 5.4 Scatter diagram of the plasma concentrations of liarozole in the various forms of ichthyosis 
after 6, 10 weeks of the short-term treatment (NELI, n=4; CBIE, n=2; XRI, n=6) and after 24, 48 and 72 
weeks of the maintenance treatment (NELI, n=4; CBIE, n=1; XRI, n=3) with topical liarozole 5%, in a 
graph with a logarithmical vertical axis. The horizontal axis indicates the detection limit of the method 
used (2.5ng /ml). The liarozole plasma concentrations appear rather high in NELI, moderate in CBIE and 
low in XRI 
Week 6 Week 10 Week 24 Week 48 Week 72
10
100
1000
NELI
XRI
Plasma Concentration of liarozole (ng mL-1)
10
100
1000
CBIE
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Discussion 
Data from the reported study indicate that topical liarozole 5% cream is effective in 
various forms of ichthyosis (XRI, NELI, and CBIE). After 4 and 6 weeks of double-
blind treatment, the extent of the lesions and the severity of scaling were significantly 
more reduced at the liarozole-treated side than at the placebo-treated side. The effec-
tiveness of liarozole was also evident in the open phase, where the largest improvement 
was found at the previously placebo-treated side. The reduction of the extent and sever-
ity of the lesions further improved during the 72 weeks maintenance study. This was 
supported by the overall assessment of the result of treatment. 
Overall, long-term treatment with topical liarozole was well tolerated. Side effects were 
minimal and temporary. The most frequently reported AE was ‘sticky feeling on the 
skin” which was reported by 4 patients during the whole treatment period. The spectrum 
of side effects of topical liarozole is similar or milder to that of calcipotriol or topical 
retinoids. 
The studies indicate that administration of topical liarozole 5% cream can result in 
somewhat elevated liarozole plasma concentrations in patients with NELI or CBIE, but 
less in patient with XRI suggesting systemic absorption. As no significant differences 
were found between these groups in the amount of liarozole used, differences in plasma 
concentrations might be related to differences in the skin barrier function, resulting in 
differences in absorption. This will need further investigation in a larger population. 
However, except for one NELI patient, plasma levels were not elevated enough to 
contribute to the therapeutic effect of the drug, as only the side treated with liarozole 
cream, responded well to the treatment during the double-blind phase. This NELI 
patient had levels comparable to the peak plasma levels found in healthy volunteers 
after a single oral dose administration of 37.5 mg (unpublished data), considered a sub-
therapeutic dose in the oral dose-finding studies in psoriasis16. Clinical improvement is 
probably achieved by a local inhibition of the endogenous breakdown of retinoic acid, 
resulting in elevated retinoic acid levels specifically in the target epidermal cells, 
thereby minimizing the risk of systemic effects as illustrated by the good tolerance in 
this study. 
Plasma liarozole levels might exert hormonal effects, as the oestradiol levels were 
decreased in some patients. Since oestradiol levels tend to show quite some fluctuation 
during the day and over the course of a month in women, the absence of a correlation 
between liarozole and oestradiol levels makes conclusions particularly difficult. 
In conclusion, the end result of this topical RAMBA pharmacological approach is that 
the patient has the benefit of a retinoid activity without being exposed to the high levels 
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of RA or synthetic retinoids usually responsible for the safety issues with those latter 
drugs. These benefits, rationally derived from the pharmacological profile of a 
RAMBA, are supported by the clinical findings with topical liarozole in the treatment of 
severe ichthyosis and justify consideration of liarozole cream as front-line treatment for 
this rare and difficult to manage dermatological disease.  
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Abstract 
Background: Liarozole, a retinoic acid metabolism blocking agent, has been granted 
orphan drug status for congenital ichthyosis by the European Commission and the U.S. 
Food and Drug Administration. 
Objective: The purpose of this trial was to investigate the efficacy, tolerability and 
safety of oral liarozole vs. acitretin in patients with ichthyosis. 
Methods: In this double-blind comparative trial of liarozole vs. acitretin, 32 patients 
with ichthyosis were randomized to be treated with either oral liarozole 75 mg in the 
morning and 75 mg in the evening or with acitretin 10 mg in the morning and 25 mg in 
the evening for 12 weeks. Clinical efficacy, tolerability and safety were monitored. 
Results: Between-group comparisons for efficacy and tolerability revealed no statisti-
cally significant differences except for scaling on the trunk at baseline which was 
significantly worse in the liarozole group (p=0.024) and showed a more pronounced 
improvement in this group than in the acitretin-treated patients (p=0.047). Based on the 
overall evaluation of the response to treatment at endpoint, 10 out of 15 patients in the 
liarozole group and 13 out of 16 patients in the acitretin group were considered by the 
investigator to be at least markedly improved. The expected retinoic acid-related ad-
verse events were mostly mild to moderate and tended to occur less frequently in the 
liarozole group. No serious adverse events related to the drugs occurred. 
Conclusion: The present study indicates that liarozole at a daily dose of 150 mg is 
equally effective as a treatment for ichthyosis as acitretin but shows a trend towards a 
more favourable tolerability profile. The results of this trial warrant further clinical trials 
to confirm efficacy and safety of liarozole as an orphan drug in ichthyosis. 
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Introduction 
Ichthyosis is a general term used to describe a large and heterogeneous group of cornifi-
cation disorders that are genetic in nature and are characterized clinically by the forma-
tion of visible scales all over the body surface and an excessively dry skin.1 Most types 
of ichthyosis, except for autosomal dominant ichthyosis vulgaris (ADIV, prevalence: 
1/250), are rare diseases, e.g. X-linked recessive ichthyosis (XRI, 1/6000 males), 
lamellar ichthyosis (LI, 1/200,000), bullous congenital ichthyosiform erythroderma 
(CBIE, 1/300,000) exhibiting severe scaling not sufficiently improving with moisturiz-
ing or keratolytic creams. The quality of life of these patients may be severely affected.2 
Treatment of these debilitating diseases is by definition lifelong, but the options for 
treatment are limited. 
As disorders of keratinization, several forms of ichthyosis can be treated with all-trans-
retinoic acid (all-trans-RA), a physiological derivative of vitamin A and one of the 
principal endogenous compounds that controls growth and differentiation of epithelial 
tissue.3 However, the pharmacological activity of all-trans-RA is restricted by its rapid 
rate of metabolism via cytochrome P-450 (CYP) enzymes and the use of systemic 
retinoids is limited by side effects and long-lasting teratogenicity.4,5 Alternatives are 
urgently needed. 
Liarozole is an imidazole derivative developed in the late eighties by the Janssen Re-
search Foundation in Belgium. It inhibits the CYP-dependent hydroxylation of all-
trans-RA and represents a new class of drugs called retinoic acid metabolism blocking 
agents (RAMBAs). Liarozole has been granted orphan drug status for congenital ich-
thyosis by the European Commission and the U.S. Food and Drug Administration. 
Liarozole was identified through extensive in vitro6-8 and in vivo9-11 testing as an inhibi-
tor of several mammalian CYP isoenzymes among which the one involved in the 
oxidative catabolism of all-trans-RA, the retinoic acid 4-hydroxylase. By inhibiting the 
intracellular breakdown of endogenous all-trans-RA, its levels in plasma and predomi-
nantly in the skin increase to slightly above normal. Unlike synthetic retinoids, which 
add massive amounts of exogenous retinoid-like substances to the body, liarozole uses 
the body’s own production of retinoic acid to achieve therapeutic effects. Besides 
inhibiting the 4-hydroxylation of all-trans-RA, liarozole also inhibits cytochrome P450-
dependent steps in the biosynthetic pathways of testicular, ovarian and adrenal steroids, 
mainly the conversion of androgens to estrogens (aromatase), progestin to androgens 
(17-hydroxylase; 17,20-lyase) and of 11-deoxycorticosterone to corticosterone (11-
hydroxylase).12 However, the effect on testicular and adrenal steroid biosynthesis may 
not be clinical relevant, as upon chronic administration of oral liarozole in human 
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volunteers, recovery of plasma testosterone and cortisol levels was achieved by pituitary 
compensation (unpublished data). In accordance, psoriasis patients receiving oral 
liarozole treatment for 3 months did not develop abnormalities in cortisol and testoster-
one levels.13 
Based on its mechanism of action and its pharmacokinetic profile, liarozole may offer 
an effective treatment in keratinisation disorders such as ichthyosis with a possibly more 
favourable tolerability profile compared to the current treatments. Liarozole has been 
extensively tested in prostate cancer and psoriasis.13-15 As far as ichthyosis is concerned, 
oral treatment with liarozole has been evaluated in an open exploratory trial where it 
was shown to cause substantial clinical improvement in all patients at a daily dose of up 
to 300 mg.16 Side effects were limited to mucocutaneous symptoms. Topical liarozole, 
as a 5% cream, has also been proven to be very effective in ichthyosis.17 
The current article describes the results of a double-blind, multi-centre, comparative 
trial assessing the efficacy and safety of oral liarozole vs. the standard treatment of 
acitretin in patients diagnosed with different types of ichthyosis. 
Patients and methods 
Patients 
To participate in this trial, men and women, aged 16 or more, had to be diagnosed with 
one of the following subtypes of ichthyosis: XRI, LI or CBIE. At least one of the 
severity parameters according to the investigator’s assessment at baseline had to have a 
score of at least 2 on a 4-point scale (0=absent, 1=mild, 2=moderate, 3=severe). In 
addition, women had to be at least 2 years postmenopausal or to have had a hysterec-
tomy. Patients had to be, except for their ichthyosis, in good health according to their 
history and physical examination.  
Main exclusion criteria were concurrent inflammatory skin disease, topical or ultraviolet 
treatment within 2 weeks and systemic treatment within 4 weeks prior to the start of the 
treatment phase, use of vitamin A supplements (>1000µg daily) and clinically relevant 
abnormal laboratory test values. Patients were enrolled at 2 study centres: the Depart-
ment of Dermatology of the University Medical Centre Nijmegen (The Netherlands) 
and the Department of Dermatology, Hôpital St.Louis in Paris (France). The trial 
protocol was reviewed and approved by each study centre’s independent ethics commit-
tee and all patients provided written informed consent prior to enrollment. All clinical 
investigations were conducted according to the Declaration of Helsinki principles. 
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Treatment 
The trial was a phase II/III, multicentre, double-blind, randomized comparative study to 
investigate the efficacy, tolerability and safety of oral liarozole 150 mg daily, vs. the 
standard treatment of acitretin 35 mg daily in patients with ichthyosis. Duration of the 
treatment was 12 weeks. Minimum wash-out periods prior to starting medication were 1 
month for systemic agents and two weeks for topical treatment or phototherapy. During 
the wash-out period, patients were only allowed to use bland emollients given by the 
investigator. 
Both liarozole and acitretin were supplied as capsules identical in appearance, taste and 
smell and packaged in morning and evening boxes. Patients were instructed to take one 
capsule orally in the morning with food (liarozole 75mg, acitretin 10 mg) and one 
capsule in the evening with a meal (liarozole 75 mg, acitretin 25 mg) with 12 hours 
between the two intakes. At the end of week 4 or week 8 of the treatment phase, the 
daily dosage could be increased as a function of tolerance and efficacy to liarozole 225 
mg or acitretin 45 mg. If the patient did not tolerate the increased dosage, it could be 
lowered again. 
Randomization and blinding procedures 
Patients admitted to the trial were randomly allocated to one of the two treatment groups 
according to a randomization code generated by the Janssen Research Foundation. 
Balancing ensured that equal numbers of subjects were entered in each treatment group 
as required. In each center, subject numbers were assigned consecutively, starting with 
the lowest number available. The investigator was provided with a sealed envelope for 
each subject, containing coded details of the treatment in de double-blind phase. This 
code was to be broken only in case of emergency where the further treatment of the 
subject was dependent on the trial medication he or she had been receiving. If the code 
was broken the subject had to be withdrawn from the trial and followed up if appropri-
ate. All sealed envelopes were collected at the end of the trial. 
Clinical evaluations 
At the pretrial visit, the investigator assessed whether the patient met the inclusion 
criteria, a complete and current medical history was recorded and a physical examina-
tion including vital signs and body weight was carried out. Fasting blood samples were 
taken for haematology and blood biochemistry. A urine sample was collected for 
urinalysis. 
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Clinical efficacy measures 
Clinical evaluation of the skin took place at weeks 0 (baseline), 4, 8 and 12 of the 
treatment phase. As no standardized efficacy-scoring methods are available for ich-
thyosis, we had to develop our own methods. Clinical efficacy was evaluated in terms of 
an overall evaluation of response to treatment (compared to baseline) rated by both the 
investigator and the patient using a 5-point scale: 0=deteriorated, 1=unchanged, 
2=moderately improved, 3=markedly improved, 4=cleared. Other variables over the 
course of the study were severity of skin lesions assessed as individual symptoms 
(scales, erythema and bullae) scored for each location (trunk, upper limbs, and lower 
limbs) on a 4-point scale: 0=absent, 1=mild, 2=moderate, 3=severe. For each symptom, 
the sums of the scores over the different body sites were calculated and referred to as 
overall score for the specific symptom. In addition, for each location the sum was made 
for all symptoms and referred to as total symptom score for the specific location. An 
overall symptom score was calculated by summation over all symptoms and locations. 
Furthermore, photographs were taken under standardized conditions at baseline and, if 
possible, at all other visits. 
Tolerability and safety measures 
The tolerance to treatment was assessed by the subject by rating subjective symptoms of 
itching, redness, dry skin, dry lips and conjunctivitis on a 4-point scale: 0=absent, 
1=mild, 2=moderate, 3=severe. Blood and urine samples were collected for haematol-
ogy, biochemistry and urinalysis. Throughout the trial the patients were monitored for 
adverse events that were rated according to their severity (mild, moderate or severe) and 
relationship to the study medication (not, possibly or definitely related). 
Statistical analysis 
Sample size was determined empirically. As only a small number of patients with 
ichthyosis are available, a recruitment of 40 patients was considered realistic in the 
available time period. Results of hypothesis testing are reported as two-sided p-values. 
Two-sided p-values less than or equal to 0.05 were considered to indicate statistical 
significance. 
In the analysis of the trial, two patient populations were defined: i) the all-patient 
population which includes patients who received at least one dose of drug and ii) the 
intent-to-treat population, which includes all randomized patients, who used at least one 
trial medication, and had post-baseline efficacy data. 
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Analysis of efficacy was based on the intent-to-treat population. The primary efficacy 
variable was ‘overall response to treatment at endpoint’, defined as both the investiga-
tor’s and patient’s overall evaluation of response to treatment as at least markedly 
improved. Endpoint is defined as the last available observation of each patient. The 
number of responders for the primary efficacy variable was compared between the 
treatment groups using a two-sided Fisher exact probability test. In addition, 95% 
confidence intervals were constructed around the difference in response rate between 
the two treatment groups. Possible investigator effects were examined by summarizing 
the response rates within each centre by descriptive statistics and confidence intervals. 
For each visit, descriptive statistics were calculated for the additional efficacy variables. 
Absolute values of the investigator’s and patient’s evaluation of response-to-treatment 
and of the individual severity symptom scores were analyzed for differences between 
treatment groups at each timepoint by means of the Cochran-Mantel-Haenszel row 
mean-scores test. Severity of skin lesions and its changes from baseline were evaluated 
for within-group difference using the Wilcoxon signed-rank test and for between group 
differences using the Wilcoxon-Mann-Whitney rank-sum test. 
Tolerability was assessed in the intent-to-treat population both as individual symptoms 
and their sum as composite score for total tolerability. Absolute values of the individual 
tolerability symptoms were analyzed for differences between treatment groups at each 
time point by means of the Cochran-Mantel-Haenszel row mean-scores test. Changes 
from baseline of the individual tolerability symptoms and total tolerability score were 
evaluated for within-group difference using the Wilcoxon signed-rank test and for 
between group differences using the Wilcoxon-Mann-Whitney rank-sum test. 
Analysis of safety was based on the all-patient population. Type and incidence of all 
adverse events were tabulated per treatment group and phase. For the clinical laboratory 
data, descriptive statistics and pre- vs. post-treatment cross tabulations (with classes for 
below, within and above normal ranges) were generated for all tests done. Important 
abnormalities, as determined by the occurrence of pathological values, were tabulated 
per treatment group and phase.  
Results 
Patients 
Overall, 41 patients with ichthyosis were screened and 32 randomized, (all male, 30 of 
32 white skinned) 15 to liarozole and 17 to acitretin. Baseline demographics were 
comparable between the two treatment groups and are summarized in Table 6.1. 
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Table 6.1 Patient demographics at baseline. * expressed as median value. XRI=X-linked Recessive Ich-
thyosis; LI=Lamellar Ichthyosis; CBIE= Bullous Congenital Ichthyosiform Erythroderma 
Variable Liarozole (n=15) Acitretin (n=17) 
Ichthyosis subtypes:    
XRI 11 10 
LI 3 5 
CBIE 1 2 
Age (years, range)* 41 (17-74) 34 (16-52) 
Height (cm, range)* 179 (165-197) 176 (161-193) 
Weight (kg, range)* 69 (59-91) 68 (52-112) 
Heart rate (beats/min, range)* 68 (52-112) 64 (52-88) 
 
In the liarozole group, 6 patients had their daily dose increased up to 225 mg. One 
patient (CBIE) had to decrease the dose after 22 days because of an adverse event 
(bullous eruption) and switched to 75 mg daily on alternating days. In the acitretin 
group 3 patients had their daily dose increased to 45 mg and one to 60 mg. One patient 
(XRI) had to decrease the daily dose to 25 mg after 57 days because of an adverse event 
(skin disorder). 
Before trial completion, 3 patients in the liarozole group discontinued treatment due to 
adverse events and 2 discontinued in the acitretin group: one because of non-compliance 
and one due to adverse events (Figure 6.1). Two patients in the liarozole group had a 
second skin condition other than ichthyosis: one had a lipoma on the back, and another 
had multiple seborrhoeic keratoses. 
For analysis on an intention-to-treat basis, 15 patients were suitable in the liarozole 
group and 16 in the acitretin group. 
At baseline, there was no significant between-group difference for any of the individual 
symptom scores (scaling, erythema, bullae), on any of the body parts (trunk, upper and 
lower limbs) apart from the scaling on the trunk. The severity of scaling on the trunk at 
baseline was rated as severe in 10 of 15 patients of the liarozole group and only in 4 of 
16 patients of the acitretin group (p=0.024). There was also a significant between-group 
difference for the total symptom score on the trunk (p=0.031) at baseline, with the 
liarozole patients having more severe symptoms than the acitretin patients. The toler-
ance scores between groups at baseline were not significantly different. For haematol-
ogy, one patient in the liarozole group presented at baseline with a leucocytosis which 
normalized towards the end of the treatment. 
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Figure 6.1 Participant Flow. ITT, intent-to-treat. 
 
Clinical efficacy evaluation 
Except for one patient in the acitretin group, the intention-to-treat population was 
identical to the all-patient population. 
In the liarozole group, the investigators considered the overall response to treatment at 
endpoint as at least markedly improved in 10 of 15 patients, whereas 9 of 15 patients 
rated themselves as at least markedly improved. In the acitretin group, the investigators 
scored 13 of 16 patients as at least markedly improved at endpoint and 12 of 16 patients 
scored themselves as markedly improved. For both the investigator’s and patient’s 
overall evaluation of response to treatment, no statistically significant between-group 
difference was observed at any time point. Response to treatment at endpoint yielded 
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9/15 responders in the liarozole group, while there were 12/16 responders in the 
acitretin group. No statistically significant difference between treatment groups was 
observed (p=0.458). The 95% confidence interval of the difference in response rates 
(acitretin-liarozole) was -18% to 48%. 
The parameters assessed for the severity of the skin lesions were scaling, erythema and 
formation of bullae on trunk, upper and lower limbs. An overview on the individual 
overall scores (for scaling, erythema and bullae) and the overall total symptom scores 
per treatment group at baseline vs. endpoint is presented in Table 6.2. 
Apart from the scaling on the trunk at baseline (p=0.024), between-group comparisons 
showed no significant difference for any of the individual symptom scores (scaling, 
erythema, bullae) at any time point, on any of the body parts (trunk, upper and lower 
limbs). No statistically significant between-group differences were observed for the 
change in severity from baseline, at any time point, except for the scaling on the trunk at 
week 12 (p=0.024) and at endpoint (p=0.047). 
Overall scaling (sum of scaling at all locations) at each time point had improved signifi-
cantly from baseline (p≤0.001) within both treatment groups. Figure 6.2 shows the 
evaluation of the overall scaling, changes from baseline as a function of time. For 
overall erythema and overall bullae no significant changes from baseline were observed 
in any of the treatment groups. 
The overall total symptom score, in both treatment groups, had significantly improved 
from baseline, reaching p<0.001 for liarozole and p=0.008 for acitretin at endpoint. No 
statistically significant between-group difference at any time point could be observed 
for the overall total symptom score and for the change from baseline. Figure 6.3 repre-
sents the overall total symptom score (= sum of all symptoms at all sites), changes from 
baseline for both treatment groups as a function of time. Examples of clinical photo-
graphs are presented in figures 6.4 and 6.5. 
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 Table 6.2 Overview of the individual overall scores (scales, erythema, bullae) and the overall symptom score 
at baseline (B) versus endpoint (E) for both treatment groups. Maximum possible overall score for scaling, 
erythema and bullae is 9 each; maximum possible overall total symptom score is 27. XRI=X-linked recessive 
ichthyosis; LI=lamellar ichthyosis; CBIE= bullous congenital ichthyosiform erythroderma; ITT=intent-to-
treat. 
 Overall score: 
scales (B/E) 
Overall score: 
erythema (B/E) 
Overall score: 
bullae (B/E) 
Overall total 
symptom score: (B/E) 
Liarozole (ITT, n=15) 
1 XRI 9/2 0/0 0/0 9/2 
2 XRI 9/1 0/2 0/0 9/3 
3 XRI 4/0 0/0 0/0 4/0 
4 XRI 9/2 0/0 0/0 9/2 
5 XRI 9/6 0/0 0/0 9/6 
6 XRI 9/1 0/3 0/0 9/4 
7 XRI 9/1 0/0 0/0 9/1 
8 XRI 9/2 9/3 0/0 18/5 
9 XRI 7/3 0/0 0/0 7/3 
10 XRI 3/4 1/1 0/0 4/5 
11 XRI 6/2 3/0 0/0 9/2 
12 LI 9/0 4/6 0/0 13/6 
13 LI 6/1 3/9 0/0 9/10 
14 LI 9/3 3/0 0/0 12/3 
15 CBIE 9/6 6/6 2/1 17/13 
Acitretin (ITT, n=16) 
1 XRI 9/9 0/0 0/0 9/9 
2 XRI 9/1 0/2 0/0 9/3 
3 XRI 6/0 0/3 0/0 6/3 
4 XRI 7/0 0/0 0/0 7/0 
5 XRI 5/0 0/0 0/0 5/0 
6 XRI 8/2 0/0 0/0 8/2 
7 XRI 5/6 0/3 0/0 5/9 
8 XRI 6/1 0/0 0/0 6/1 
9 XRI 7/1 0/0 0/0 7/1 
10 XRI 5/0 3/0 0/0 8/0 
11 LI 9/3 6/3 0/0 15/6 
12 LI 6/3 0/0 0/0 6/3 
13 LI 7/3 0/3 0/0 7/6 
14 LI 6/3 6/3 0/0 12/6 
15 CBIE 9/6 0/6 0/4 9/16 
16 CBIE 8/3 6/3 0/0 14/6 
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Figure 6.2 Evaluation of the overall symptom score: changes in scaling from baseline as a function of time. 
Filled circles (z) represent liarozole and empty circles ({) represent acitretin median values. 
 
Figure 6.3 Evaluation of the overall total symptom score changes from baseline as a function of time. Filled 
circles (z) represent liarozole and empty circles ({) represent acitretin median values 
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 Figure 6.4 A patient with lamellar ichthyosis with the typical phenotype consisting of large brown scales 
covering the arm: (a) before treatment and (b) after 2 weeks of treatment with 75 mg liarozole twice daily. See 
page 231 for colour figure. 
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Figure 6.5 Typical hyperkeratosis in the neck of a patient with X-linked recessive ichthyosis which is giving 
the so-called ‘dirty look’ present before treatment with liarozole (a). Scaling is almost completely absent after 
treatment with liarozole (b). See page 232 for colour figure. 
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Tolerability and safety evaluation 
The evaluation of the tolerance to treatment (itching, redness, dry skin, dry lips, and 
conjunctivitis) by the patients showed no statistically significant between-group differ-
ences at any time point. An overview of the tolerance score per treatment group is given 
in Table 6.3. Within both groups, significant changes from baseline were observed at 
endpoint for dry skin which had improved (liarozole p=0.020, acitretin p<0.001) and 
dry lips which had worsened (liarozole p=0.003, acitretin p<0.001). Itching, being 
absent to mild at baseline in the majority of patients, improved in both treatment groups 
during treatment except for week 4 where it had worsened in the acitretin group.  At 
endpoint, itching was absent in 11 of 15 and mild in 4 of 15 patients in the liarozole 
group versus 10 of 17 and 6 of 17 in the acitretin group. One patient in the acitretin 
group still had severe itching. 
 
Table 6.3 Overview of tolerance scores of both treatment groups. No statistically significant between-group 
differences were observed. Significant changes from baseline were observed in both groups for dry skin 
(improvement) and dry lips (worsening).  
Scores: Absent/mild/moderate/severe, n 
Liarozole (n=15) Acitretin (n=17) 
Symptoms: Baseline Endpoint  Baseline Endpoint
  
Itching 6/8/0/1 11/4/0/0 6/9/1/1 10/6/0/1 
Redness 8/3/3/1 7/5/2/1 12/1/4/0 8/7/2/0 
Dry skin 4/0/3/8 5/5/4/1 1/0/10/6 5/8/1/3 
Dry lips 12/2/1/0 1/10/3/1 13/4/0/0 1/10/4/2 
Conjunctivitis 15/0/0/0 14/1/0/0 17/0/0/0 16/1/0/0 
 
 
As shown in Table 6.4, the investigators reported 10 adverse events in 46% (n=7) of the 
patients in the liarozole group and 25 adverse events in 71% (n=12) of the patients in 
the acitretin group. Most reported adverse events were mild to moderate. The most 
frequently reported adverse events occurring in ≥10% of the patients in the liarozole 
group were dry mouth and skin disorder (sticky skin) and in the acitretin group dry 
mouth, skin exfoliation, skin disorder (sticky skin and irritated skin), eczema and 
epistaxis. 
Before trial completion, 3 patients dropped out in the liarozole group due to adverse 
events: diarrhoea (moderate, not drug-related), fatigue (mild, possibly drug-related) and 
erythematous rash on face and hands (moderate, definitely drug-related). In the acitretin 
group, one drop-out was due to adverse events of epistaxis (severe), periungual granu-
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lomatous tissue (moderate) and skin exfoliation (moderate), all considered definitely 
drug-related. Apart from epistaxis, no other adverse events were reported as severe. No 
deaths or serious adverse events were reported throughout the study. 
 
Table 6.4 Overview of adverse events profile of both treatment groups.  
 Liarozole  
(n=15) 
Acitretin  
(n=17) 
Number of patients with 1 or more adverse events during treatment 7 12 
Adverse events reported in ≥ 10% of patients in any treatment group, n 
Dry mouth 2 3 
Skin exfoliation 0 4 
Skin disorder 1 3 
Eczema 0 2 
Epistaxis 0 2 
Serious adverse events  0 0 
Discontinuations  3a 2b 
Deaths 0 0 
a due to adverse events 
b one due to adverse events and one due to non-compliance 
 
 
Blood biochemistry in the liarozole group showed three abnormal values. One patient 
had a slight increase in chlorine (113 mmol/l, upper limit 111) at week 4 and also a 
slight increase in alanine aminotransferase (78 U/l, upper limit 60). Another patient had 
an increase in triglycerides at week 12 (3.22 mmol/l, upper limit 2.5). In the acitretin 
group, 5 abnormal values were seen in the blood biochemistry: one patient had a limited 
increase of urea on week 8 (9.7 mmol/l, upper limit 8.3), which almost normalized to 
8.9 mmol/l at week 12 and 4 patients had elevated triglycerides (Table 6.5). Most 
biochemical factors tested did not show significant changes. None of the changes 
mentioned was considered of major clinical relevance. 
 
Table 6.5 Overview of values from patients with elevated triglycerides (mmol/l) during the treatment period. 
Upper limit for triglycerides is 2.5 mmol/l. ND, not determined. 
Treatment group Baseline Week 4 Week 8 Week 12 
Liarozole 1.21 2.26 1.54 3.22 
Acitretin 2.24 2.72 4.52 2.75 
Acitretin 2.27 2.50 2.54 3.19 
Acitretin 2.02 1.65 ND 2.93 
Acitretin 1.65 3.06 2.50 2.81 
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Discussion 
Retinoids have been shown to normalize deregulated proliferative activity and exert 
some anti-inflammatory action.18 Although the underlying genetic defect within the 
ichthyosis population is heterogeneous, retinoids have been employed with good or 
excellent results in many types of ichthyosis except in ADIV.1 However, systemic 
administration of retinoids is frequently associated with mucocutaneous side-effects, 
liver toxicity and abnormalities of serum lipid profiles.19,20 Today, although not ap-
proved in certain countries, e.g. the USA, acitretin is the most effective systemic treat-
ment for most types of severe ichthyosis. The major issues with acitretin, from a clinical 
point of view, are hyperlipidaemia and its long-term teratogenicity. Pre-menopausal 
women are advised not to become pregnant for at least 2 (Europe) to 3 (USA) years 
following treatment. During acitretin treatment in psoriasis at a daily dose of 30-60 mg, 
a 35% increase in serum triglycerides was observed.21 Topical retinoids may represent 
good alternatives to avoid the systemic side-effects, although to date they have not been 
shown to be successful because of their propensity for skin irritation with the possible 
exception of 13-cis-retinoic acid.22 Short-term topical application of tazarotene, a novel 
receptor selective retinoid, has proven to be effective but, as with other retinoids, 
irritancy is a significant side-effect.23 So far, no specific treatment modalities are avail-
able for the heterogeneous group of ichthyosis. Considering the toxicity associated with 
existing oral therapies, there is need for safer and more effective agents. Compounds 
enhancing intracellular all-trans-RA levels, RAMBAs, represent a new therapeutic 
concept. 
RAMBAs are distinctively different from synthetic retinoids. RAMBAs are ‘non-
retinoid’ drugs that block the intracellular breakdown of the body’s own retinoic acid. In 
doing so, the intracellular all-trans-RA concentration increases to therapeutic levels but 
only in those tissues where all-trans-RA is metabolized by the 4-hydroxylase, including 
the skin. Animal and human studies have shown that the pharmacological effects of 
liarozole are mediated by enhanced levels of endogenous retinoic acid in the body. Oral 
administration of liarozole to rats delayed the plasma elimination rate of intrajugularly 
injected all-trans-RA and enhanced the plasma levels of endogenous all-trans-RA 
confirming the in vivo suppressive activity of liarozole on the biodegradation of en-
dogenous RA.9-10 In addition, endogenous all-trans-RA levels in various tissues were 
enhanced (unpublished data) and kinetic studies both in humans and animals revealed a 
rapid clearance of liarozole from the plasma and a normalization of all-trans-RA levels 
(within 24 hrs) once treatment was stopped.24 Following a twice-daily dose of 150 mg 
liarozole in healthy male volunteers, steady-state was attained within 2 days of dosing 
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with mean liarozole plasma concentrations fluctuating between 0.36 and 2.57 μg/ml. 
Plasma concentrations of liarozole hardly accumulated, the mean accumulation ratio 
was about 1.3 and the terminal half-life after the last 150-mg dose averaged 8.7 hours. 
In contrast to synthetic retinoids which are delivered to the body in large amounts and 
tend to stay in tissues and fat for months or even years, RAMBAs do not expose tissues 
to these high all-trans-RA concentrations responsible for retinoid-related chronic 
toxicity and teratogenicity for months to years after discontinuation of therapy. 
Liarozole is effective in different types of ichthyosis at a daily dosage of 150 mg. This 
finding is in agreement with the results from a previous trial in which liarozole was 
administered up to 300 mg daily to ichthyosis patients for 12 weeks.16 Compared with 
acitretin, no significant differences were observed for any of the efficacy parameters 
except for the improvement of the scaling on the trunk at week 12 (p=0.024) and at 
endpoint (p=0.047). This observation might be explained by assuming that liarozole is 
more effective at clearing severe scaling than is acitretin. Alternatively, as scaling on 
the trunk at baseline was more severe in the liarozole group, improvement of scaling 
may have been more obvious to the observers, resulting in relatively higher scores in 
symptom improvement. However, we consider it unlikely that all observers had the 
same bias. Hence we favour the former explanation. Most patients from both treatment 
groups had XRI and only a few presented with LI or CBIE. The main reason for this is 
probably the lower incidence (1/200,000-1/300,000) of the latter subtypes compared to 
XRI (1/6,000 males). Also the fact that women were excluded unless they were at least 
2 years postmenopausal or had had a hysterectomy made inclusion of patients with LI 
and CBIE even harder. 
The expected retinoic acid related adverse events were mostly mild to moderate in both 
groups but tended to occur less frequently in the liarozole group. The incidence of 
hypertriglyceridaemia in this trial was also lower in the liarozole group (n=1) than in the 
acitretin group (n=4). Importantly, the main advantage of liarozole over acitretin lies in 
the inherent property that liarozole has towards long-term teratogenicity, a major draw-
back for the use of oral retinoids in women. Its efficacy and its particular pharmacoki-
netics make the use of liarozole an attractive candidate for the treatment of ichthyosis. 
In conclusion, the efficacy and safety results obtained in this study warrant further 
development of liarozole as an orphan drug in ichthyosis. Considering the diversity of 
the ichthyosis types and the small number of patients within this study, a larger study 
will be needed to confirm these results. An international multicentre phase II/III study in 
patients with LI is ongoing. 
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Introduction 
It is well known that psoriasis is a retinoid-sensitive disease. For decades, topical as 
well as oral retinoids have been widely used as anti-psoriatic treatments. In general, 
topical treatment remains the most frequently used therapy for patients with mild to 
moderate psoriasis, whereas systemic retinoids contribute to the therapeutic manage-
ment of patients with more severe and recalcitrant types of psoriasis. 
The aim of this chapter is to give a brief overview of the history of retinoids in psoriasis 
and to focus on the clinically relevant data of topical tazarotene and oral acitretin, two 
retinoids that are largely contributing to the therapeutic management of patients with 
psoriasis. Oral tazarotene will be discussed briefly. Finally, the characteristics and 
future perspectives of the rexinoids (bexarotene) and the retinoic acid metabolism 
blocking agents (RAMBAs) in psoriasis will be highlighted. 
History and disease characteristics 
Psoriasis is a chronic, multi-factorial and complex skin disorder affecting 1 to 3 % of 
the world’s population. It is characterized by well-defined red patches covered by 
silvery, flaky scales ranging from a few spots on the extensor surfaces and the scalp to 
large areas all over the body. The disease can evolve with periodic flare-ups. There are 
several variations of psoriasis but the most common type is chronic plaque psoriasis. 
The cause of psoriasis is unknown and although psoriasis manifests itself as a skin 
disorder, it is not excluded that the disease is caused by impaired or defective cell 
mediated immunity (T-cell driven). It has been known for quite a long time that psoria-
sis runs in some families. Analysis of concordance rates amongst monozygotic and 
dizygotic twins is another source of evidence that genetic factors are importance for 
psoriasis. Psoriasis is associated with HLA-B13, HLA-B17, HLA-B37 and HLA-Cw6. 
Further studies revealed that these latter associations were secondary to an association 
with HLA-Cw6. 
Based upon analyses of family pedigrees, a polygenic inheritance provides the best 
model for the complex genetics of psoriasis. Genome-wide linkage scans have demon-
strated several genetic loci for psoriasis; these studies have recently been reviewed by 
Rahman and Elder1. 
Table 7.1 summarizes gene loci linked to psoriasis. PSORS1 has been mapped to chro-
mosome 6p21.3 by independent groups and is considered to be a major gene involved in 
psoriasis. It was found that about 50% of psoriatic patients had involvement of PSORS1. 
In fact, the critical region appears to be a 300 kb interval around the centromere end of 
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class I MHC. Although HLA-Cw6 is clearly associated with psoriasis, it is unlikely that 
HLA-C itself is the susceptibility gene. 
 
Table 7.1 Overview of gene loci involved in the pathogenesis of psoriasis 
Gene Locus Position on chromosome 
PSORS1 6p21.3 
PSORS2  17q25 
PSORS3  4q32-35 
PSORS4  1q21 
PSORS5  3q21 
PSORS6  19p13-q13 
PSORS7  1p35-34 
PSORS8  16q12-13 
PSORS9  4q31-34 
PSORASI  16q12 
 
 
Histological examination of the psoriatic lesions reveals the following abnormalities: 
epidermal hyperproliferation, premature keratinisation and immune cell infiltration2. Up 
to now no preventive therapy exists for psoriasis, symptomatic therapy is the only 
therapy available. 
The history of the development of retinoids in dermatology goes back decades and 
comprises several generations which have been extensively described in the first chapter 
of this book. 3,4 Briefly, already in the beginning of the last century, it was known that 
Vitamin A (retinol) plays a major role in the proliferation and differentiation of epithe-
lial structures. Vitamin A deficiency in man results in dry skin with follicular hyperk-
eratosis. At that time, an essential role of vitamin A was also attributed in diseases like 
Darier’s disease and ichthyosis. 
Vitamin A was investigated at non-physiological doses in acne and psoriasis. 
Megadoses of vitamin A (2-4 million IU) resulted only in a slight improvement of 
psoriasis, but the symptoms of a vitamin A intoxication such as intracranial hyperten-
sion with nervous disturbances, dryness of the mucous membranes and skin, peeling of 
the skin were unacceptable.5 Hundreds of derivatives of vitamin A were investigated 
and tretinoin (all-trans-retinoic acid) as well as isotretinoin (13-cis-retinoic acid) proved 
to be therapeutic substances in the topical treatment of acne.6 However tretinoin and 
isotretinoin had no anti-psoriatic potential following topical application. We had to wait 
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until 1997 before tazarotene, the first topical retinoid to be active in psoriasis, became 
available. 
Because the efficacy of orally administrated vitamin A and all-trans-retinoic acid (all-
trans-RA) was insufficient, the search for synthetic analogues with a better efficacy and 
safety profile resulted in the synthesis of the mono-aromatic retinoids like etretinate and 
later of its free active carboxylic acid metabolite acitretin. Etretinate and acitretin are 
highly and equally effective systemic treatments for psoriasis and adverse events appear 
to be similar in severity and incidence. Today acitretin is the preferred systemic retinoid 
for the treatment of psoriasis because of its better pharmacokinetic profile. A major 
problem with systemic retinoids is their teratogenicity and a separation of this phe-
nomenon from their therapeutic effects has still not been achieved. The search for new 
ligands offering at least the same efficacy and a better risk/benefit ratio than the existing 
retinoids has resulted in the development of specific RXR ligands or rexinoids like 
bexarotene which are effective but still not devoid of serious side effects. 
Another new approach is to increase the endogenous retinoic acid levels in the skin by 
blocking the catabolism of intracellular all-trans-RA with a RAMBA. RAMBAs such as 
liarozole and its successor R115866 have been proven efficacious in the treatment of 
keratinisation disorders like psoriasis, ichthyosis and acne. Currently R115866 is 
intensively investigated for the treatment of psoriasis (Phase 2b). 
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Topical retinoids: Tazarotene 
Tazarotene is the first topical retinoid being approved for the treatment of psoriasis, 
despite the fact that several topical retinoids have been available for decades for retinoid 
sensitive diseases. 
Mechanism of action 
Tazarotene is a synthetic acetylenic retinoid. It is in fact an ethyl ester prodrug that is 
rapidly hydrolyzed to tazarotenic acid, its active and more water-soluble form. Having a 
more selective affinity for the retinoic acid receptors (RAR) than tretinoin, tazarotenic 
acid shows transactivation through RAR-γ and RAR-β and less through RAR-α.7,8 
It does not bind RXR. The mechanism of action of tazarotene in psoriasis is not defined 
but the drug has been shown to have both antiproliferative and anti-inflammatory 
activities.9-11 
Pharmacokinetics 
Percutaneous penetration of topical tazarotene is limited.12 The systemic absorption 
after a single application in psoriatic patients is less than 1% of the applied dose and 
2.6% and 5.3% after once daily applications during 2 weeks of tazarotene 0.05% and 
0.1% gel respectively. After 12 weeks treatment with 0.05% and 0.1% tazarotene the 
systemic absorption was 1.8% and 3.9%, respectively.13 In phase III trials with either 
the gel or the cream, low tazarotene plasma concentrations (≤ 0.15ng/ml) were observed 
in 1-3% of the psoriatics after 12 weeks of treatment.12-15 Low but detectable 
(>0.05 ng/ml) plasma levels of tazarotenic acid were observed in 47-69% of these 
patients. 
The mean half-life (t½) of topical tazarotenic acid is similar in normal and psoriatic 
patients and is approximately 18 hours. Tazarotenic acid has a high affinity for plasma 
proteins (>99%) and has a relatively small volume of distribution (1.97 l/kg). Tazaro-
tene is mainly eliminated via urinary and faecal routes as sulfoxides and sulfones. 
CYP2C8 and flavine-containing mono oxygenases mediate oxidation of tazarotenic acid 
to its sulfoxide, which is the primary metabolite in urine.13 
Indications and contra-indications 
Topical tazarotene has been approved for the treatment of chronic plaque psoriasis in 
several countries and is available as a 0.05% and 0.1% cream or gel formulation.16-19 In 
the US, tazarotene cream is indicated for plaque psoriasis and the gel for stable plaque 
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psoriasis with up to 20% body surface involvement. In Europe, tazarotene gel is indi-
cated for mild-to-moderate plaque psoriasis involving up to 10% body surface area. 
Tazarotene is applied once daily in the evening and it is recommended to start with the 
0.05% formulations and to increase the concentration if necessary and tolerated. 
In view of its teratogenic potential, tazarotene is contra-indicated in pregnant women 
and in women who are not taking adequate birth control. Tazarotene is also contra-
indicated in patients being exposed to substantial sunlight and not using adequate sun 
protection and in patients using photosensitizers or having photodermatitis. 
Efficacy 
Tazarotene as monotherapy 
Tazarotene gel (0.05% and 0.1%) applied once daily for 12 weeks has been shown to be 
efficacious as monotherapy for mild to moderate plaque psoriasis in two large vehicle-
controlled clinical trials.14 With 0.1% tazarotene, already at week 1, a statistically 
significant improvement compared to the vehicle could be observed whereas for the 
0.05% formulation 4 weeks of treatment were needed. 
Also the cream formulation proved beneficial in the treatment of psoriasis in two 
vehicle-controlled studies.15 Both the 0.05 and 0.1% cream formulations applied once 
daily for 12 weeks followed by a 12 weeks treatment free follow-up were significantly 
more effective than the vehicle cream. The 0.1% tazarotene cream was generally more 
effective than the 0.05% cream, although slightly less well tolerated. During the 12 
weeks post treatment phase, both concentrations of tazarotene cream were significantly 
better than vehicle in maintaining therapeutic effect. 
In one study 0.1% and 0.05% tazarotene gel formulations applied once daily for 12 
weeks followed by a 12 week treatment free follow-up were compared to a potent 
corticosteroid, fluocinonide 0.05% cream twice daily.20 At the end of the 12 weeks 
treatment course both tazarotene gel formulations had a similar efficacy as the potent 
corticosteroid fluocinonide 0.05% cream but the corticosteroid showed an earlier onset 
of efficacy. Compared to tazarotene 0.05%, fluocinonide cream was significantly better 
from week 2-8 and compared to tazarotene 0.1% at week 4. Fluocinonide 0.05% cream 
should be the preferred treatment when a fast clearing is mandatory. On the other hand, 
tazarotene treatment has a slower relapse as compared to fluocinonide. 
Comparative studies between tazarotene 0.1% gel once daily and calcipotriol 0.005% 
ointment twice daily revealed a superior efficacy of calcipotriol during the first 8 weeks 
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but an equal efficacy after 12 weeks of treatment.21 Local irritation was noted only in the 
tazarotene treated lesions. 
Combination therapy with corticosteroids 
Whilst tazarotene is effective on its own, it is frequently used in the clinic in combina-
tion with corticosteroids or phototherapy in order to avoid retinoid dermatitis, which 
develops in a significant proportion of patients treated with tazarotene as a monother-
apy. 
The combination of tazarotene with various topical corticosteroids has been compared 
to tazarotene monotherapy,22-24 corticosteroid monotherapy25 and calcipotriol.26 In all 
trials, topical corticosteroid and tazarotene 0.1% gel were applied once daily, except in 
one study, where they were applied on alternate days. 24 
Table 7.2 summarizes the response rates obtained in two large scale studies comparing a 
12 week treatment of plaque type psoriasis with tazarotene 0.1% gel monotherapy 
versus the combination with a corticosteroid.22,23 The combinations of 0.1% tazarotene 
gel with mid-to high potency corticosteroids show a higher efficacy than tazarotene 
monotherapy after 12 weeks treatment.23 The results from the low potency corticoster-
oid group did not statistically differ from the vehicle group. 
It has also been shown that the median time to initial treatment success was substan-
tially improved by combining tazarotene 0.1% gel with a corticosteroid.23 It took at least 
4 weeks for tazarotene monotherapy + placebo to reach 50% improvement of PASI 
versus 3 weeks for the combination of tazarotene with fluocinolone acetonide 0.01% 
cream (high potency) and only 2 weeks for the combination with mometasone furoate 
0.1% cream (mid-potency). The best performing steroid was betamethasone dipropion-
ate 0.05% cream but the best strategy based on efficacy and tolerability in both studies 
was the concomitant use of tazarotene 0.1% gel with mometasone furoate 0.1% cream. 
Mometasone furoate 0.1% cream causes less local and systemic side effects than be-
tamethasone dipropionate 0.05% cream. 
The efficacy of the combination of tazarotene 0.1% gel once daily + calcipotriol 0.005% 
ointment twice daily compared to a clobetasol ointment treatment twice daily, in a 2-
week open label, left-right comparison study was not statistically significant different.27 
There seems to be no chemical incompatibility between calcipotriol ointment and 
tazarotene gel. 
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Table 7.2 Response rates to tazarotene 0.1% gel in combination with topical corticosteroids. Responses 
evaluated after 12 weeks of treatment. 
Reference Treatment 
Potency 
of 
corticosteroid 
% of patients 
reaching at least 
50% overall 
improvement vs. 
baseline 
21 Tazarotene N.A. 35 
21 Tazarotene 
+ fluocinonide 0.05% ointment. 
High  48 
21 Tazarotene 
+ mometasone furoate 0.1% ointment 
High 66 
21 Tazarotene 
+ diflorasone diacetate 0.05% ointment 
High 55 
21 Tazarotene 
+ diflorasone diacetate 0.05% cream 
Mid-high 44 
21 Tazarotene 
+ betamethasone dipropionate 0.05% cream 
Mid-high 78 
21 Tazarotene 
+ fluticasone propionate 0.005% ointment 
Mid-high 57 
22 Tazarotene 
+ placebo cream 
N.A. 80 
22 Tazarotene 
+ fluocinolone acetonide 0.01% cream 
Low 79 
22 Tazarotene 
+ mometasone furoate 0.1% cream 
Mid 91 
22 Tazarotene 
+ fluocinonide 0.05% cream 
High 95 
 
Combination with phototherapy 
Combination therapy of tazarotene and ultraviolet B therapy (UVB) proved to be rather 
effective although we have to be aware of the enhancement of phototoxicity of tazaro-
tene by simultaneous treatment. 
Several studies have indicated that tazarotene in combination with phototherapy is well 
tolerated and superior to monotherapy in terms of anti-psoriatic efficacy as well as in 
onset of action.28-31 In a clinical broad band UVB study, the combination of tazarotene 
gel 0.1% with UVB clearly shortened the time to reach 50% improvement (25 days 
versus 53) and lowered the median cumulative UVB dose needed from 1394.5 mJ/cm2 
to 390 mJ/cm2 compared to UVB monotherapy.31 
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In another study topical tazarotene plus narrow-band UVB (311nm) resulted in a 64% 
reduction of PASI assessed after 4 weeks as compared to a 48% reduction by UVB 
monotherapy.30 
One study comparing the effect of narrow-band UVB irradiation in combination with 
topical tazarotene versus the combination with calcipotriol and a second study compar-
ing PUVA in combination with tazarotene or tacalcitol ointment both failed to reveal 
significant differences between the respective regimens.32,33 
Side effects 
Local irritation is the most common side effect of topical retinoids. The most common 
side effects associated with topical tazarotene as a monotherapy are desquamation, 
burning/stinging, dry skin, erythema and pruritus.14,15,20 The incidence of side effects 
was higher in patients using the 0.1% formulations as compared to the 0.05% formula-
tions. When compared to calcipotriol monotherapy, the frequency of the above men-
tioned adverse events was higher using the tazarotene gel whilst the efficacy is the 
same. No significant phototoxicity was associated with the combination of topical 
tazarotene and UVB.30,31 
Treatment strategies 
In general, topical treatment remains to be the most frequently used approach in treating 
patients with mild to moderate psoriasis. Topical tazarotene and topical vitamin D3 
analogues have become a first line treatment the last decade. Dithranol and tar treatment 
are prescribed for patients not responding to other topicals and UVB treatment and for 
those patients who are not or not yet eligible for a systemic treatment. High potency 
topical corticosteroids as a monotherapy are used in those patients having strong irrita-
tion to vitamin D3 analogues or tazarotene. Combining topical tazarotene with a topical 
corticosteroid reduces both the irritancy to tazarotene monotherapy as well as the well-
known side effects of corticosteroids such as tachyphylaxis, striae, skin atrophy and 
adrenal gland suppression. The combination also increases the rate of improvement and 
the ultimate treatment efficacy as compared to tazarotene monotherapy. As compared to 
corticosteroid monotherapy the combination lengthens the remission. 
Reduction of the application time to a few minutes by washing-off a topical treatment 
has been shown to enhance efficacy and reduce irritancy. Short contact application has 
become a popular approach in dithranol treatment. It also has been shown for topical 
tazarotene that reduction of the application to a few minutes reduces irritancy substan-
tially without compromising efficacy too much.34 
CHAPTER 7 
 148
Systemic retinoids: Acitretin 
Today, acitretin, a second-generation systemic retinoid, is the preferred systemic reti-
noid in the treatment of psoriasis for more than 10 years.35,36 Acitretin can be used as a 
monotherapy but is frequently used in combination with other anti-psoriatic drugs.  
Mechanism of action 
Acitretin, which is the pharmacologically active metabolite of etretinate, has been 
shown to activate all three RARs, without evidence that it actually binds to these recep-
tors.37 Acitretin has been shown to reduce scaling and to interfere with various aspects 
of cutaneous inflammation, without evidence for immune suppression. 
Pharmacokinetics 
The absorption of acitretin is very variable amongst individuals and is optimal when 
ingested with food. The mean elimination half-life of acitretin is about two days38,39, 
whereas the mean elimination half-life of etretinate, the ethyl ester of acitretin, is 120 
days but can still be detected in the subcutis as long as 18 months after treatment.40 
Acitretin was developed because it was thought to be cleared from the body more 
rapidly than etretinate. However, re-esterification of acitretin to etretinate in the human 
body has found to be possible, especially if the patient has a substantial alcohol in-
take.41,42 Therefore, in view of the teratogenic effect, women of childbearing potential 
who have been treated with acitretin have to continue contraception for 2 years in 
Europe and for 3 years in the US after stopping the therapy. 
Drug interactions with acitretin may be relevant, in particular with drugs interfering 
with cytochrome P450 metabolism such as cyclosporine and with drugs competing for 
plasma protein binding such as phenytoin. 
Indications and contra-indications 
Table 7.3 summarizes the indications and contra-indications of the use of acitretin in 
psoriasis. The recommended initial and ongoing evaluations are outlined in Tables 7.4 
and 7.5, respectively. 
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Table 7.3 Indications and contraindications for acitretin in the treatment of psoriasis 
Indications: 
Severe psoriasis, which cannot be managed by topical treatments or phototherapy, including day-care and 
in-patient dithranol treatment 
Erythrodermic or pustular psoriasis 
Contraindications for acitretin in the treatment of psoriasis: 
Moderate to severe liver dysfunction 
Severe kidney dysfunction  
Pregnancy and lactation 
Women of childbearing potential who cannot guarantee adequate contraception during and up to 3 years 
following discontinuation of acitretin 
Hyperlipidaemia, especially hypertriglyceridaemia, which can not be controlled 
Concomitant medications which interfere with retinoids  
Concomitant hepatotoxic drugs 
Diabetes mellitus which cannot be controlled 
Alcohol abuse 
 
Table 7.4 Pre-acitretin treatment screening parameters. 
Pre-Acitretin Screening 
History to exclude contraindications 
Liver function tests (AST, ALT, γGT, alkaline phosphatase, bilirubin) 
Serum triglycerides and cholesterol 
Glucose 
Serum creatinine 
Pregnancy test 
Spinal X-ray (initially performed during the first 3 months of therapy if long-term treatment is anticipated) 
 
Table 7.5 List of clinical evaluations during acitretin treatment. 
Evaluation during acitretin treatment 
Monitor mucocutaneous side effects 
Serum cholesterol/triglycerides and liver enzymes (every 2 weeks for the first 6 weeks, then every 6–12 
weeks) 
Serum creatinine (elderly patients or patients with mild to moderate renal dysfunction) 
Monitor for development of hyperostoses by history and by X-ray of spine (once every two years) 
Pregnancy test (before treatment commences) 
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Efficacy 
Acitretin as monotherapy 
For palmo-plantar and generalized pustular psoriasis (von Zumbusch) and for 
erythrodermic psoriasis retinoids can be considered to be first-line therapies. Lesions 
respond more rapidly in monotherapy than with most other therapies. Initial dosages of 
1 mg/kg/day for pustular psoriasis, 0.5 mg/kg/day for chronic plaque psoriasis, and 0.25 
mg/kg/day for erythrodermic psoriasis are recommended. Since correct dosing is the 
determinant for optimal efficacy of acitretin, the dosage sometimes needs to be adjusted. 
In general, mild cheilitis is indicative for a sufficient bioavailability of acitretin. 
In generalised pustular psoriasis acitretin has been shown to be effective in 84% of the 
patients (Figure 7.1).43 The lack of immune suppression of acitretin makes this therapy 
also suitable for psoriasis associated with human immunodeficiency virus infection.44 
The plaque-type psoriasis responds variably and the use of acitretin as a monotherapy 
should be limited to severe forms not manageable by topical treatments or phototherapy, 
including day care and in-patient dithranol treatment. The clinical response is dose-
b a
Figure 7.1 Clinical response to acitretin (1mg/kg/day) in a patient with generalised pustular psoriasis 
(a) before and (b) after 4 weeks of treatment. See page 233 for colour figure. 
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dependent; different dosages of 10 to 75 mg/day have been evaluated.45-52 Starting with 
high doses of acitretin (0.5-1 mg/kg/day) may result in an initial worsening and the 
sudden appearance of side-effects on the skin (cheilitis, dry skin, pruritus) jeopardizing  
the compliance of the patient. Starting with a low dosage (10 mg/day) and a progressive 
increase of the dosage seems to be more acceptable for the patient and can avoid the 
worsening of the existing lesions. 
In a comparative study versus etretinate, at least 75% improvement in the PASI was 
observed in 23.1% of the patients treated with 50 mg acitretin after 8 weeks of treatment 
and at least 50% improvement of PASI was reached by 54% of the patients.53 In a 
second study, the mean PASI improvement after 12 weeks was between 70-75%.54 
Acitretin has been shown to be an effective maintenance therapy in patients with 
chronic plaque psoriasis. Of all patients 75% and 88% reached PASI-50 after 6 months 
and 12 months treatment respectively.45,55,56 
Treatment with acitretin during several months might improve nail psoriasis considera-
bly.57 Although present in 80-90% of all psoriasis patients58 and negatively affecting 
their quality of life59, no specific placebo-controlled studies are currently available in 
nail psoriasis. 
It is generally agreed that acitretin is not effective in psoriatic arthritis. 
Studies with acitretin between 25 to 60 mg daily have been shown to considerably 
reduce the risk of developing new cutaneous malignancies in patients who have re-
ceived high dose PUVA treatment in the past or have been treated with cyc-
losporine.60-63 
Combination with phototherapy 
A consensus conference on the treatment of acitretin in combination with UVB or 
PUVA revealed that the combination enhances efficacy and limits the treatment fre-
quency, duration and the cumulative doses compared to the UVB or PUVA monother-
apy. The combination also permits lower acitretin doses which imply an increased 
safety and compliance.64,65 
Broadband UVB in combination with acitretin has been shown to be highly effective as 
compared to monotherapies.66-69 A study comparing UVB treatment combined with 
placebo to UVB treatment combined with acitretin (50mg/day) resulted in a 74% 
improvement in PASI in patients treated with UVB plus acitretin 50 mg/day versus 35% 
with UVB and placebo and 42% with acitretin monotherapy.67 
The preferred schedule when using the combination is pre-treatment during 2 weeks 
with low-dose acitretin followed by the combination. In case of insufficient response to 
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UVB monotherapy, acitretin 25 mg may be added which requires a 50% reduction of 
UVB dose. 
The combination of 25 mg acitretin daily with narrowband UVB three times a week has 
been shown to be highly effective in patients with difficult-to-treat psoriasis70. An 
improvement of at least 75% of the severity score was reached in 72.5% of the patients, 
only 12.5% had less than 50% improvement. 
Also the combination of acitretin and PUVA71-73 or Bath PUVA74 has been shown to be 
more effective than the monotherapies. In general, 14 days prior to PUVA treatment 
patients have to take acitretin 25 mg/day. As with UVB, adding acitretin to PUVA 
monotherapy requires a reduction of the initial UVA dose by 50%. 
Combination therapy with topical vitamin D analogues 
Compared to each of the monotherapies, an improved efficacy has been observed for the 
combination of acitretin with topical calcipotriol (50 μg/g).75 
Combination therapy with biologicals 
Today no studies have been performed comparing the efficacy of the combination of 
acitretin and a biological with both monotherapies. The combination of acitretin 25 
mg/day with etanercept 25 mg twice weekly has been shown to be safe and effective in 
difficult-to-treat psoriasis.76 Also, several case studies have been reported showing that 
the combination of acitretin with a biological may be rather effective.77-79  A case of 
Acrodermatitis Continua Hallopeau responding successfully to the combination of 
etanercept and acitretin has been reported as well as a beneficial long-term improvement 
in a patient who had unsuccessfully treated with acitretin for 43 months but who im-
proved substantially by a 12 week combination course of alefacept and acitretin. 80,81 
Contraindicated combinations and combinations for restrictive use 
Cyclosporine inactivation by the cytochrome P-450 system can be inhibited by acitretin 
meaning that the combination of acitretin and cyclosporine carries the risk of accumula-
tion of cyclosporine. The effect of etretinate on the cytochrome P-450-mediated me-
tabolism of cyclosporine has been studied in vitro and indicates that there is no meta-
bolic interaction; it is likely that the two drugs are metabolized by different P-450 
isoenzymes.82 The combination of methotrexate and acitretin has been used in those 
patients in whom all treatments have failed.83 Although this combination can be very 
effective, due to severe hepatotoxicity this combination is not longer advisable.84 
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Strategies of combination treatment 
Psoriasis patients deserve long-term control of their disease with optimal benefit/risk 
ratio. The existing therapies, although providing excellent short-term control, may 
produce acute or chronic toxicities limiting their long-term use. Combination therapy 
can offer a solution. Cather and Menter85 defined three objectives for a combination 
therapy: the first objective would be to achieve a similar efficacy and a lower toxicity 
with a lower dose; the combinations calcipotriol plus acitretin and UVB/PUVA plus 
acitretin are well established approaches to reach this goal. A second objective is to 
achieve fast clearing and subsequently maintain the improvement by sequential therapy. 
Powerful clearing therapies such as cyclosporine, methotrexate, photo(chemo)therapy, 
infliximab or the traditional topical treatment with dithranol may be followed by 
acitretin maintenance resulting in a long-term safe control of the disease. In particular in 
patients with previous exposure to potentially carcinogenic treatments this approach is 
useful. The third objective is to avoid cumulative toxicity by rotational treatment. 
Patients with difficult-to-treat psoriasis whom require a continuous treatment should use 
rotate treatments in order to reduce toxicity and still maintaining improvement of their 
psoriasis. 
Side effects 
Mucocutaneous side effects of acitretin comprise cheilitis, dryness of the eyes, nasal and 
oral mucosa, epistaxis, xerosis, brittle nails, hair loss and burning or sticky skin. In fact, 
some degree of cheilitis is an indication for sufficient bioavailability and, therefore is, to 
some extent, a parameter to individualize the optimal dosage. Another side effect 
frequently seen during the first 4 weeks of treatment is the initial aggravation of psoria-
sis with an increase of the body surface area involved. A more seldom mucocutaneous 
side effect is “retinoid dermatitis”, which may mimic “unstable psoriasis”. Periungual 
pyogenic granulomas may occur during long-term use of acitretin.45,86 
In 25-50% of patients treated with acitretin hyperlipidaemia has been reported and it is, 
in most patients, reversible when reducing the dosage or when treatment is stopped.87 
Highly increased levels of triglycerides imply increased risk for pancreatitis and chronic 
increases may increase the risk for cardiovascular comorbidities. In patients treated with 
acitretin, one should be aware that diabetes mellitus, obesity, increased alcohol intake 
are risk factors for development of hyperlipidaemia. In patients with moderate to severe 
psoriasis increases in serum lipids and dislipidemias have been reported without retinoid 
treatment.88-91 Therefore, figures on occurrence of hyperlipidaemia in psoriasis should 
be corrected for the overall predisposition under psoriatics to develop hyperlipidaemia. 
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Lifestyles changes to prevent hyperlipidaemia should be stimulated in psoriatics and in 
particular those who are treated with retinoids. Elevation of transaminases are seen in 
13-16% of acitretin treated patients.86 A liver biopsy study did not reveal a significant 
risk for liver toxicity.92 Severe increases of liver test functions are rare, but may indicate 
toxic hepatitis induced by acitretin.93 
Strict contraception in women of childbearing potential is required during and 2 to 3 
years following acitretin treatment. Teratogenic complications following acitretin 
treatment is discussed elsewhere in this book.94-96 
Less frequently, patients receiving acitretin may experience arthralgia, myalgia or 
paraesthesia as well as possible worsening of pre-existing bone disorders during long 
term therapy. 97-99 Pseudotumor-like symptoms and signs have been recorded sporadi-
cally. The combination of retinoids with tetracyclins may increase the risk of this side 
effect. Symptoms and signs of intracranial hypertension are severe headache, nausea 
and vomiting, visual disturbances and papilloedema.95 Although the relationship to 
acitretin has not been convincingly shown, depression and suicide have been suggested 
to occur during acitretin treatment.95 Decreased colour vision and impaired night vision 
might occur during acitretin treatment. 
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Systemic retinoids: Tazarotene 
Oral tazarotene (4.5 mg/day) has been shown to be efficacious in moderate to severe 
psoriasis in two double-blind placebo-controlled trials and in a long-term open label 
trial.100 
Results of the phase III trials, reported at the Winter American Academy of Dermatol-
ogy in 2003, demonstrated effectiveness of oral tazarotene versus placebo. 
Additional data of the open label study, reported at the 62nd annual meeting of the 
American Academy of Dermatology 2004, also showed efficacy of oral tazarotene in 
long-term treatment of psoriasis (52 weeks, once daily). A moderate to complete clear-
ing (at least 50% global improvement) was achieved by 56% of the patients by week 16 
and 68% by week 24. A marked improvement (at least 75% global improvement) was 
achieved by 44% of patients by week 36. During long-term treatment, oral tazarotene 
was associated with adverse events such as alopecia, hypertriglyceridaemia, hepatotox-
icity, ocular dryness, desquamation and pruritus. 
Pharmacokinetic data of oral tazarotene indicate that the drug poses little risk for deep 
tissue storage and accumulation in humans suggesting a shorter post-treatment waiting 
period for women who wish to conceive after discontinuation of oral tazarotene treat-
ment. 
However, although efficacious in psoriasis, oral tazarotene has not yet been approved by 
the U.S. Food and Drug Administration (FDA) due to lack of safety data.100 
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Systemic Rexinoids: Bexarotene 
Innovations in retinoid treatment in psoriasis are to be expected from RXR-selective 
ligands or rexinoids. Bexarotene (Targretin®, LGD1069) a novel synthetic specific 
RXR-ligand has been developed for the treatment of cutaneous T-cell lymphoma 
(CTCL) where it was shown to inhibit T-cell accumulation which is also an important 
feature of psoriasis.101,102,111 Thus, as it might provide a new approach in the treatment 
of psoriasis, bexarotene is currently under investigation for this indication. 
Mechanism of action 
Bexarotene selectively binds and activates RXR receptors: RXRα, RXRβ and RXRγ.103 
and not to RARs. RXR receptors function as heterodimers with other nuclear receptors 
(e.g. retinoic acid receptor (RAR), vitamin D receptor (VDR), thyroid receptor (TR) and 
peroxisome proliferator activator receptor (PPAR)) who play an important role in cell 
function and physiology, meaning that the biological activities of bexarotene could be 
broader than that of compounds that activate RARs. 
Bexarotene has been shown to inhibit the growth of tumour cell lines of haematopoietic 
and squamous cell origin and to induce apoptosis.104-109 In vivo bexarotene induces 
tumor regression in some animals104, while in other models tumor induction is pre-
vented.106 As such, bexarotene has been developed for the treatment of CTCL.101 
In clinical studies bexarotene (300 mg/m2/day) proved to have an activity in patients 
with CTCL, even in patients in a late stage of the disease and who were not responsive 
to other systemic therapy, resulting in a regression or even temporary complete clinical 
response. The exact mechanism of action of bexarotene in the treatment of CTCL is 
unknown. 
Pharmacokinetics 
Oral bexarotene is absorbed with a Tmax of about two hours and its T½ is about seven 
hours. Studies in patients with advanced malignancies show approximate single dose 
linearity within the therapeutic range and low accumulation with multiple doses. 
Bexarotene is highly bound (>99%) to plasma proteins. In vitro studies suggest that 
cytochrome P450 3A4 is the major cytochrome P450 responsible for formation of the 
oxidative metabolites which may be glucuronidated. The oxidative metabolites are 
active in in vitro assays of retinoid receptor activation. Neither bexarotene nor its 
metabolites are excreted in urine in appreciable amounts. Bexarotene is thought to be 
eliminated primarily through the hepatobiliary system.110,111 
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Efficacy 
Benign hyperproliferative and retinoid sensitive disorders, such as psoriasis are good 
candidates for studies with bexarotene. In a first study by Smit et al. (2004) it was 
shown that systemic treatment with bexarotene up to 3.0 mg/kg/day, decreases epider-
mal proliferative and inflammation parameters. 112 In a phase II dose finding study (0.5, 
1, 2 and 3 mg/kg/day for 12 weeks), no significant dose-dependent difference between 
the 4 doses groups for mPASI (modified PASI), PEL (plaque elevation) and physician’s 
global assessment (PGA) was demonstrated.113 There was a statistical improvement of 
psoriasis (≥ 50%) with mean response rates of 22% for in mPASI, 52% for PEL and 
36% for PGA. Based on these data, doses higher than 3.0 mg/kg/day and lower than 0.5 
mg/kg/day should be investigated in a placebo-controlled design. If higher doses are 
needed, side effects known from the treatment of patients with CTCL may be a limiting 
factor for bexarotene in the treatment of psoriasis or the drug could also be evaluated in 
combination with other anti-psoriatic therapy. 
Side effects 
The U.S. FDA approved oral bexarotene for the treatment of cutaneous manifestations 
of CTCL in patients refractory to at least one prior systemic therapy. In the high doses 
used to treat CTCL nearly all patients suffer adverse effects, which can include hyper-
lipidaemia (risk of pancreatitis), hypothyroidism, and haematological reactions (leuko-
penia, anemia).114 Many side effects limit the use of bexarotene as a monotherapy for 
CTCL. 
Adverse events in the psoriasis trial were comparable to the CTCL trial with a lower 
frequency and severity.112 No serious adverse events related to the drug occurred. 
However, hyperlipidaemia (56%) and a decrease in free T4 serum levels (54%) were 
most frequently reported adverse events related to the drug. Typical retinoid-related 
adverse events were pruritus, in only 14% of the patients and cheilitis in 10%. 
Although the clinical data suggest an anti-psoriatic effect of bexarotene, the side effects, 
especially hypertriglyceridaemia and hypothyroidism, may require intervention and may 
restrict the use of higher doses in psoriasis patients. Further studies are needed to 
ascertain the relevance of bexarotene to the treatment of psoriasis.114 
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Retinoic Acid Metabolism Blocking Agents: RAMBAs 
A new class of molecules named Retinoic Acid Metabolism Blocking Agents (RAM-
BAs) sometimes referred to as retinoic acid 4-hydroxylase inhibitors have proven to be 
of therapeutic benefit in keratinisation disorders like psoriasis, ichthyosis and acne. In 
this section the mechanism of action of RAMBAs and their history will be presented 
followed by an illustration of the proof of principle in psoriasis with liarozole, the first 
RAMBA ever been in clinical development for indications like psoriasis and ichthyosis. 
Today, R115866 (RambazoleTM), representing a new generation of highly potent and 
selective RAMBAs, is in clinical development for the treatment of psoriasis. Specific 
information on its pharmacology and pharmacokinetics will be provided. Furthermore 
results of a phase 2a study in psoriasis will be highlighted, suggesting that R115866 has 
a promising profile for treating psoriasis. 
Mechanism of action 
All-trans-RA, a minor metabolite of retinol and β-carotene, is believed to be the most 
active naturally occurring retinoid. It’s significantly more active (100-1000 fold) than 
retinol in experimental systems. One of the pathways of all-trans-RA inactivation 
occurs by hydroxylation at the C4 position of the cyclohexenyl ring to form 4-hydroxy- 
all-trans-RA which is converted by a reductase into 4-keto-all-trans-RA that is in turn 
further transformed into more polar metabolites. Both the 4-hydroxylation process of 
all-trans-RA and the further oxidation of 4-keto-all-trans-RA to more polar metabolites 
involve microsomal cytochrome P-450 (CYP) dependent enzymes.115,116 RAMBAs are 
non-retinoid drugs that block the CYP dependent 4-hydroxylation which results in an 
increase of the intracellular all-trans-RA concentration.117,118 (see Figure 7.2) 
Unlike existing therapies where massive amounts of exogenous retinoids, natural or 
synthetic, are administered to the body, a RAMBA modulates the body’s own produc-
tion of all-trans-RA to achieve the same therapeutic effects. By inhibiting its intracellu-
lar catabolism, endogenous all-trans-RA accumulates in the skin to therapeutic levels. 
Once treatment is stopped, a RAMBA is quickly eliminated from the body returning the 
metabolism of retinoic acid back to normal and declining the elevated all-trans-RA 
levels back to physiological levels. The rapid clearance of the RAMBAs is important as 
it decreases the potential for side effects in contrast to the available synthetic retinoids, 
which may stay in some organs for a long time, and which can cause retinoid related 
chronic toxicity and birth defects for months after discontinuation of therapy. 
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Figure 7.2 Mechanism of action of RAMBAs 
 
History of RAMBAs 
The first azole shown to display RAMBA properties was the antifungal ketoconazole. 
Besides its antifungal activity, ketoconazole was shown to inhibit in an apparently 
competitive manner the CYP mediated metabolism of all-trans-RA by hamster liver 
microsomes.119 The search for more selective CYP inhibitors of all-trans-RA metabo-
lism led to the identification of liarozole. Liarozole is an imidazole derivative that is 
lacking anti-fungal activity but shares with ketoconazole its inhibitory effects on epi-
dermal all-trans-RA metabolism (IC50=2μM) and on the CYP mediated 17-hydroxylase-
17,20-lyase in testes microsomes. Like ketoconazole, administration of liarozole to rats 
enhances endogenous plasma concentrations of endogenous RA and reduces the elimi-
nation rate of intravenously injected RA from plasma.120,121 Liarozole also inhibits 
several other cytochrome P450-dependent steroid biosynthesis reactions - mainly the 
conversion of androgens to estrogens (aromatase) and of 11-deoxycorticosterone to 
corticosterone (11-hydroxylase).122,123 
Developed in the 90’s as a non-hormonal agent in the treatment of prostate cancer and 
various other cancers, liarozole was considered to be of potential benefit in the treat-
ment of skin disorders like psoriasis and ichthyosis. This was based on the fact that the 
reported adverse events in the cancer trials were mainly cutaneous reactions showing a 
striking similarity with vitamin A related symptoms. Currently, liarozole is in develop-
 
RAMBA 
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ment as an orphan drug for ichthyosis (excluding autosomal dominant ichthyosis vul-
garis).124-126 In this chapter, only its effects in psoriasis will be reviewed. Whereas the 
first RAMBAs where non-selective CYP inhibitors, a thorough screening of hundreds of 
molecules against different CYP-isozymes yielded a very selective and highly active 
retinoic acid 4-hydroxylase inhibitor namely R115866. 
Liarozole: proof of principle in psoriasis 
A total of 6 clinical trials assessing the efficacy and safety of oral liarozole in psoriasis 
have been conducted.127-131 All trials were double-blind, placebo-controlled, random-
ized, parallel group trials, except for one open pilot trial and one active-controlled trial 
with acitretin at daily doses of 25 mg. All trials initially consisted of a treatment period 
of 12 weeks and a follow-up of 8 to 12 weeks, except for the open study in which no 
follow-up period was foreseen. Liarozole was administered in daily doses ranging from 
50 to 300 mg 
A pooled analysis of the efficacy data of the 6 trials included in total 828 subjects of 
which 501 had been randomized to liarozole treatment.127. Significant mean decreases in 
PASI score compared to baseline and improvement in disease conditions were observed 
for all groups receiving liarozole. Nevertheless, large differences in response and 
improvement percentages between the groups receiving a liarozole dose lower than 150 
mg and higher than 150 mg were observed. Both PASI score evaluations and global 
clinical evaluations pointed out that relative increases in response were largest when 
increasing the liarozole dose from 75 to 150 mg. Upon further increasing the liarozole 
dose, no further significant changes in percentage of responders were noticed. All doses 
of liarozole were found to be well tolerated, although the occurrence of the most recur-
rent adverse events (e.g. skin disorders, pruritus, dry mouth) was notably higher in 
subjects receiving a liarozole dose higher than 150 mg. However, the incidence of such 
adverse events in the 150 mg liarozole group did not surpass that of the acitretin group. 
A liarozole dose of 150 mg was therefore found to be optimal for the treatment of 
psoriasis.  
R115866: a new generation ramba 
R115866 (RambazoleTM), a substituted benzyl-1, 2, 4,- triazole derivative, has been 
identified as a third generation of RAMBAs with improved potency and selectivity.132 
The investigational drug is a stable, enantiomerically pure base which has been identi-
fied both in vitro and in vivo as a compound with highly specific and selective CYP 
inhibiting properties against hydroxylases involved in the catabolism of all-trans-RA. 
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Regarding its potency, R115866 is an inhibitor of all-trans-RA catabolism in the nano-
molar range (IC50=4nM, human CYP26 transfected yeast microsomes) and is about 
three orders of magnitude more powerful than liarozole (IC50=3µM). As for its selectiv-
ity R115866 shows, in comparison to its retinoid catabolism inhibiting activity, only 
trivial inhibitory effects (IC50=1.2-2.6µM) on the CYP-dependent biosynthesis of 
steroids (testosterone and oestradiol). Furthermore, consistent with its ability to enhance 
endogenous RA content in tissues and plasma, R115866 was found to generate retinoid-
mimetic biological activities in various retinoid sensitive animal models of keratinisa-
tion.132 In these studies no major effects other than its primary pharmacodynamic effect 
were evidenced. By virtue of this property and the modulating effects of RA on epithe-
lial growth and differentiation, R115866 is currently in clinical investigation for both 
oral and topical treatment of psoriasis and acne. 
Pharmacokinetics 
In vitro studies using isolated hepatocytes and subcellular liver fractions from mouse, 
rat, dog and human indicated that R115866 was metabolized by all of the species. The 
potential of R115866 to interact with specific cytochrome CYP substrates was studied 
in human liver microsomes. The lowest IC50 values were observed for two substrates 
metabolized via CYP3A4; being 1.3 μM and 2.6 μM. These concentrations, however, 
are considerably higher than those observed following administration of R115866 to 
humans.133 
The pharmacokinetics of R115866 after single and repeated oral dosing was studied in 
healthy male subjects. The oral absorption after a single dose (0.6-20 mg) was fast with 
peak plasma concentrations reached within 1 h after dosing. R115866 was eliminated 
with a mean dominant half-life of 1-2 h and a mean terminal half-life of 6-7 h. The 
single-dose pharmacokinetics of R115866 appeared to be dose-proportional. After 
repeated b.i.d. dosing for 8 days (0.5-2-4 mg), steady-state was attained after one day. 
At the end of treatment on day 8, mean dominant and terminal half-lives were in the 
order of 2 h and 15 h, respectively. Steady-state plasma concentrations increased pro-
portionally with the dose between 0.5 mg and 2 mg b.i.d., and more than dose-
proportionally between 2 mg and 4 mg b.i.d. A dose-related increase in plasma RA was 
observed. On day 8 of the b.i.d. dosing of R115866, the exposure of RA in terms of 
Cmax was lower than on day 1, whereas in terms of AUC0-12h the exposure remained 
fairly similar.133 
Tissue distribution data are not available from humans but were collected following 
single oral administration of R115866 at 2.5 mg/kg to male rats. R115866 was exten-
sively distributed throughout the body with a volume of distribution at steady-state of 
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5.2 l/kg. As in plasma, maximum concentrations of R115866 were observed at 1 hour 
(the first sampling time) post-dose in all tissues investigated except for the skin (3 hours 
post-dose). Maximum tissue concentrations of R115866 in the skin (43.1ng/g) were 
similar to those in plasma (40.1ng/ml). Concentrations of R115866 in tissues declined at 
a rate similar to those in plasma, except in adrenals where the rate of decline was 
slightly slower.133 
Indications and contra-indications 
Today, no clinical data are available on drug-interactions and contra-indications with 
R115866. Even though R115866 belongs to the class of azole derivatives, the drug’s 
main mode of action in skin is based on the inhibition of the CYP-mediated metabolic 
inactivation of the body’s own retinoic acid. Hence drug interactions and other forms of 
interactions as well as contra-indications and precautions related with retinoids should 
be taken into consideration (e.g. prevention of pregnancy, monitoring of lipid levels, 
avoiding co- medication inhibiting or inducing CYP 3A4).133 
Efficacy 
The efficacy and safety of oral R115866 in moderate to severe plaque-type psoriasis 
was assessed in an open label, phase 2a trial where 19 subjects were treated once daily 
with 1 mg R115866 for 8 weeks.134 Efficacy analysis performed at the end of the treat-
ment phase and after a 2-week treatment free follow-up period showed a time-
dependent improvement of PASI. At end of treatment, 5/19 patients ( %) showed an 
improvement in PASI of at least 50% compared to 8/17 (47%) at follow-up meaning 
that the optimal clinical efficacy has not yet been reached with an 8 week treatment 
schedule. In all treated 
RA increased 0.5-1.5 ng/ml, 2 to 4.5 hours after intake of 1 mg R115866 and returned to 
approximately baseline levels within 24 hours. Figure 7.3 shows the elbow of a patient 
(a) at baseline and (b) at the end of the 2-week follow-up. 
Side effects 
Adverse experiences reported in association with the use of R115866 are expected to be 
fewer and less severe than those reported for retinoids. The most common observed 
symptoms in the clinical studies performed until now are those associated with in-
creased levels of RA, i.e. pruritis, xerosis and cheilitis. Additionally, epistaxis and cases 
of increased blood triglycerides have been reported.133,134 
 
patients, throughout the whole treatment period, plasma levels of 
26
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Conclusions 
Several retinoids have been developed and used successfully over the years for the 
treatment of psoriasis. However, today, acitretin (Neotigason®, Soriatane®) is the only 
oral, and tazarotene (Zorac®, Tazorac®) the only topical retinoid, approved for psoriasis 
in most European countries and in the U.S. Oral tazarotene has completed Phase III 
studies but at the time of writing its manufacturer has received a non-approvable letter 
from the FDA. Despite the fact that many new therapies, like the biologicals, have been 
developed, retinoids as monotherapy or in combination with other treatment modalities 
remain a useful therapy for the treatment of psoriasis. The search goes on and synthetic 
retinoids continue to evolve and improve in terms of specificity and decreased toxicity. 
Rexinoids and new approaches like RAMBAs are currently intensively investigated 
with promising results. 
Figure 7.3 Clinical response to R115866 (1mg/ day) in a patient with moderate to severe plaque type 
psoriasis (a) before treatment and (b) after 10 weeks i.e. 8 week treatment + 2 weeks treatment free 
follow-up. See page 234 for colour figure. 
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Abstract 
Background: R115866 (RambazoleTM) is a new generation all-trans Retinoic Acid 
Metabolism Blocking Agent (RAMBA), highly specific against the retinoic acid 4-
hydroxylase. The drug alleviates hyperproliferation and normalizes differentiation of the 
epidermis in animal models of psoriasis. 
Objective: To explore the efficacy, safety and tolerability of systemic R115866 in 
patients with moderate to severe plaque type psoriasis. 
Patients and methods: In this open label, single-arm trial, patients were treated with 
R115866, 1mg/day for 8 weeks, followed by a 2-week treatment free follow-up period. 
Patients were monitored for efficacy and safety. 
Results: Nineteen patients (ITT-population) were treated and 14 completed the entire 
study. Two patients discontinued due to lack of efficacy and 3 due to adverse events. At 
the end of the treatment, 26% of the patients showed at least 50% reduction in Psoriasis 
Area Severity Index (PASI) compared to baseline. Further improvement was observed 
at the end of the 2-week follow-up period where 47% of the patients showed a 50% or 
greater reduction in PASI. Kinetic data showed no evidence of accumulation of either 
R115866 or retinoic acid in plasma. The most common adverse events were pruritus, 
xerosis, cheilitis and an increase in blood triglycerides. The majority of adverse events 
were mild to moderate. No deaths or serious adverse events were reported. 
Conclusion: Eight week daily treatment with 1 mg R115866 resulted in a significant 
reduction in PASI from baseline to end of therapy. Additional improvement was seen 
after the 2-week follow-up period. The drug was well tolerated. R115866 merits further 
evaluation to optimize its clinical efficacy and safety profile in moderate to severe 
plaque type psoriasis. 
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Introduction 
R115866 (RambazoleTM) is identified as a new generation all-trans Retinoic Acid 
Metabolism Blocking Agent (RAMBA). The investigational drug is a novel tri-azole 
derivative with highly potent and selective cytochrome P-450 (CYP) inhibiting proper-
ties against hydroxylases involved in the metabolic inactivation pathway of all-trans-
retinoic acid (all-trans-RA). R115866 affects the catabolism of all-trans-RA at nanomo-
lar concentrations, whereas micromolar concentrations are needed to inhibit other 
CYPs. 
The rationale behind the use of a RAMBA is blocking the breakdown of the body’s own 
all-trans-RA by using a non-retinoid drug thereby augmenting endogenous intracellular 
all-trans-RA. Several animal experiments have documented the in vivo suppressive 
effects of R115866 on the all-trans-RA metabolism in rats.1 A single oral R115866 
treatment transiently increases endogenous all-trans-RA in the rat skin. In other animal 
models, like all-trans-RA, both oral and topical R115866 induce epidermal hyperplasia 
in mouse ear skin, exhibit the formation of a granular layer and transform the parakera-
totic type of keratinization to the orthokeratotic type in the scale regions of murine tail 
epidermis.2 R115866 inhibits both orally and topically the vaginal keratinization in 
estrogen-stimulated rats. By virtue of this property and the well-known modulating 
effects of all-trans-RA on epithelial growth and differentiation3-6, R115866 is poten-
tially useful for disorders associated with or due to an aberrant keratinization, such as 
plaque psoriasis. 
Phase I single (0.6 to 20 mg) and multiple [0.5, 2 and 4 mg twice daily (b.i.d), for one 
week] dose escalation trials with oral R115866 in healthy volunteers reveal a fast 
absorption of R115866 with peak plasma concentrations obtained at approximately one 
hour (h) after drug intake.7, 8 Elimination of R115866 occurs with a dominant half-life of 
1.1 to 2.1 h. Steady-state plasma concentrations of R115866 are reached within one day 
of multiple dosing and terminal half-lives after the last dose are in the order of 15 h. In 
the multiple dose study, mean through and peak plasma concentrations of R115866 on 
the last day fluctuated between 0.036 and 0.32 ng/ml for the 0.5 mg b.i.d. dose and 
between 0.13 and 1.6 ng/ml for the 2 mg b.i.d. dose. The peak plasma RA concentration 
averaged 2.06 ng/ml for placebo versus 2.86 and 3.52 ng/ml for 0.5 and 2 mg R115866 
b.i.d respectively and remained within or slightly above the normal biological range (1 
to 4 ng/ml) of all-trans-RA levels in human plasma as published in literature.9-12 
Compared to liarozole, a previous generation RAMBA, R115866 is a more potent (IC50 
in nM range) and selective CYP26 inhibitor hence expected to result in clinical efficacy 
at lower dosages and consequently in less adverse events. The increase in all-trans-RA 
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as observed in clinical trials with liarozole has been used to predict an active dose level 
of R115866 in terms of efficacy.13-15 
The main purpose of this study was to explore the efficacy, tolerability and safety of 
oral R115866 at a daily dose of 1 mg in patients with moderate to severe plaque-type 
psoriasis. The rationale for the short treatment period of 8 weeks was based on the 
available animal toxicity data with R115866 and the clinical efficacy data obtained with 
acitretin, the only oral retinoid approved for treating psoriasis in Europe and the U.S.16 
After 8 weeks of treatment a more than 50% improvement in PSI score [corrected 
Psoriasis Area Severity Index (PASI) score] was achieved in 50% of severe psoriasis 
patients treated with 10 mg, 40.5% with 25 mg and 53.8% with 50 mg acitretin. Based 
on these results and based on the mechanism of action of R115866, an 8 week treatment 
course with 1 mg daily was considered sufficient to reveal clinical efficacy. 
Patients and Methods 
Study design 
The study was a phase 2a, multicentre, open-label study to assess the efficacy, tolerabil-
ity and safety of oral R115866 in subjects with moderate to severe plaque-type psoria-
sis; PASI ≥ 5. Patients were enrolled in two study centers: the Department of Dermatol-
ogy of the University Hospital Maastricht and the Department of Dermatology of the 
Radboud University Nijmegen Medical Center, both in the Netherlands. The protocol 
has been reviewed and approved by each study center’s independent ethics committee 
and all patients provided written informed consent prior to study enrollment. All clinical 
investigations were conducted according to the Declaration of Helsinki principles. 
Treatment 
In this open-label study, patients were instructed to take two capsules of 0.5 mg 
R115866, total daily dose of 1 mg, in the morning with breakfast for a period of 8 
weeks. The 8-week treatment period was followed by a 2-week treatment-free follow-up 
period. The investigator could decide to decrease the dose to 0.5 mg once daily if 
necessary. At the visit days, patients were advised to be fasted for at least 8 h before 
blood sampling. Their medication had to be taken in the clinic with breakfast after 
collection of the pre-dose blood samples and ECG recordings. 
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Patient population 
Male patients and female patients (at least 2 years post-menopausal or undergone 
successful surgical sterilization at least 1 year before inclusion), 18 years or older and 
diagnosed with moderate to severe plaque type psoriasis (PASI score>5.0) were allowed 
to participate in this trial. Patients had to be, except for psoriasis, in good health accord-
ing to their history and physical examination. No clinically relevant abnormalities in the 
laboratory test results (hematology, biochemistry, endocrinology and urine analysis) at 
visit 1 and a signed written informed consent were required from all patients. The 
following medication wash-out periods before entering the study were requested: 
2 weeks for topical or ultraviolet treatment, 4 weeks for systemic treatment for psoriasis 
or vitamin A supplements (>1000µg/day). 
Main exclusion criteria included non-plaque type forms of psoriasis, concurrent in-
flammatory skin disease, co-existing serious disease, heart disorders, ECG abnormali-
ties, hyperlipidaemia, use of drugs that could interfere with either psoriasis or the study 
drug, previous use of any psoriasis biological agent, known intolerance to retinoids and 
the suspicion of alcohol abuse. 
Clinical evaluations 
Clinical evaluations were made at week 0 (baseline), week 1, 2, 4, and 8 of the treat-
ment phase and at week 10 (2 weeks post-treatment). The following efficacy measures 
were evaluated by the same investigator per site over the course of the study: 
Psoriasis area and severity index  
The PASI was used to evaluate the extent and severity of psoriasis. The PASI is a 
composite score ranging from 0 to 72 and varying in steps of 0.1 that includes assess-
ments of the extent of skin involvement, erythema, plaque elevation/induration, and 
desquamation. 17 
Overall evaluation of efficacy by investigator  
At each post-baseline visit, the investigator compared the patient’s overall disease 
severity to the overall disease severity at baseline. The overall evaluation of efficacy 
was graded on a 6-point scale ranging from 0=worse, 1=unchanged (< 10% improve-
ment), 2=slight improvement (±25%), 3=moderate improvement (±50%), 4=marked 
improvement (±75%) to 5=almost to complete clearance (90-100%). 
CHAPTER 8 
 176
Lesion severity assessment by investigator  
An assessment of the overall lesion severity was performed by the investigator after 
scoring the PASI based on the psoriasis signs of erythema, plaque induration/elevation 
and desquamation. The severity was graded on a 6-point scale ranging from 0 to 5 
(Table 8.1). 
 
Table 8.1 Overall lesion severity assessment scales 
Scale Description 
0 No plaque elevation above normal skin level, may have residual non-erythematous discoloration, 
no psoriatic scale 
1 Essentially flat with possible trace elevation, may have up to mild erythema, may have limited 
amount of very fine scales 
2 Slight but definite elevation of plaque above normal skin level, may have up to moderate 
erythema, fine scales with some lesions partially covered 
3 Moderate elevation with rounded or sloped edges to plaque, moderate erythema; somewhat 
coarser scales with most lesions partially covered 
4 Marked elevation with hard, sharp edges to plaque; severe erythema; coarse, thick scales with 
virtually all lesions covered and a rough surface 
5 Very marked elevation with very hard, sharp edges to plaque; very severe erythema; very coarse, 
thick scales with all lesions covered and a very rough surface 
Patient’s self-assessment of treatment  
A subjective overall evaluation of treatment was made by the patient relative to baseline 
using the following scale: 0=worse, 1=unchanged, 2=slight improvement, 3=moderate 
improvement, 4=marked improvement, 5=almost to complete clearance. 
Photographs 
In order to document efficacy, photographs of the whole body and of 3-4 designated 
areas, e.g. elbow, legs, trunk were taken at each center under standardized conditions. 
Pharmacokinetics/ pharmacodynamics 
Plasma levels of R115866 and all-trans-RA were measured throughout the trial. After 
collection of the pre-dose blood samples (only for all-trans-RA), a second blood sample 
was collected between 2-4.5 hours after drug intake for both all-trans-RA and R115866 
at each subsequent visit. At the follow-up visit, only all-trans-RA monitoring was 
performed. All plasma samples were analyzed using a validated liquid chromatography-
tandem mass spectrometry method with a lower limit of quantitation at 0.010 ng/ml for 
R115866 and 0.5 ng/ml for all-trans-RA. 
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Safety and tolerability evaluation 
Adverse events (AEs) were recorded throughout the study period. In addition, at every 
visit blood samples for hematology, endocrinology (luteinizing hormone, oestradiol, 
cortisol, aldosterone and testosterone) and biochemistry were taken. Urinalysis was only 
performed at screening. Cardiovascular safety was monitored at each visit by pre- and 
post-dose measurements of electrocardiograms (ECG), blood pressure and heart rate. 
Possible clinical signs of retinoic acid related cutaneous side effects i.e. xerosis, pruri-
tus, cheilitis, epistaxis, periungual granulomatous reaction, hair loss and fragile skin 
were evaluated and graded for severity (absent, mild, moderate or severe) at all visits. 
Statistics 
The intent-to-treat (ITT) population consisted of all patients who were assigned to 
treatment. The safety population was identical to the ITT population. Statistical analysis 
was carried out for both the ITT population and the complete cases (i.e. all patients 
whom completed treatment and had efficacy data at end of treatment) using the SAS 
Version 8.2 system for statistical analysis.18 Continuous data are summarized as median 
change from baseline and distribution-free 95% confidence intervals for the median. 
Statistical significance versus baseline values was assessed with the Wilcoxon signed 
rank test. Two-sided p-values less than or equal to 0.05 is considered to indicate statisti-
cal significance. 
Results 
Patients 
Of 28 patients that were screened, 19 were enrolled and treated with R115866 (ITT 
population). All patients were Caucasian of which 15 were males and 4 females. The 
mean (range) age was 49.6 years (25-76), mean body weight 91.1 kg (71-160), mean 
body mass index 29.4 kg/m2 (21.0-49.4) and mean PASI 13 (5.8-41.8). Five patients 
discontinued during the study. Reasons for discontinuation included lack of efficacy 
(n=2) and AEs (n=3). Fourteen patients completed the 8-week treatment and the 2-week 
follow-up. However, there are only 13 complete cases, since one patient is lacking 
efficacy data at the end of treatment (week 8). The flowchart is presented in Figure 8.1. 
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Clinical evaluations 
Psoriasis area and severity index  
Compared to baseline, a statistically significant reduction in PASI score was found at all 
time points evaluated except for week 4. An initial statistically significant reduction 
versus baseline was observed after one week of treatment with a median PASI reduction 
of 7.8% (P=0.001). The median reduction in PASI increased with treatment duration 
and amounted from 8.2% (P=0.038) after 2 weeks of treatment to 21% at the end of 
treatment (week 8; P=0.048) and further increased to 49% (P<0.001) at the end of the 2-
week follow-up period (week 10; P<0.001). At the end of treatment, 5/19 (26%) pa-
tients showed a reduction in PASI of at least 50% (Figures 8.2 and 8.3) compared to 
8/17 (47%) at the end of the follow-up period. Detailed information on the individual 
PASI and percentage PASI reduction per visit as compared to baseline is given in Table 
8.2. 
1 patient was excluded due to 
missing efficacy data at week 8 = 
end of treatment 
14 patients 
completed the 
study 
19 Patients Included  
Intent-to-treat population =Safety population 
Discontinued treatment = 5 
Due to: 
Adverse event, 3 
Lack of efficacy, 2 
Complete cases =13 
Figure 8.1 Patient disposition 
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Analysis of the complete cases revealed a statistically significant reduction in PASI 
score compared to baseline at all time points evaluated with a median PASI reduction of 
37% (P=0.002) at end of therapy further augmenting to 51% (P<0.001) after 2 weeks 
follow-up. At the end of treatment, 5/13 (38%) patients showed a PASI reduction of at 
least 50%. At the end of the follow-up period 7/13 (54%) and 9/13 (69%) patients had a 
reduction of at least 50% and 45% respectively. 
 
Figure 8.2 Plaque type psoriasis on lower leg of a patient (S206) before treatment (A) and after 8 weeks of 
treatment with 1 mg R115866 (B). See page 235 for colour figure. 
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Figure 8.3 Plaque type psoriasis on back and knee of a patient (S226) at baseline (A and C) and after 8 weeks 
of treatment with 1 mg R115866 (B and D). See page 236 for colour figure. 
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Table 8.2 Overview of individual PASI scores (% change from baseline) for every patient at every visit.  
Baseline Treatment Follow-up All patients 
N=19 
Week 0 Week 1 Week 2 Week 4 Week 8 Week 10 
S202 6.9 6.9 (0%) 6.8 (-1%) 6.8 (-1%) 6.6 (-4%) 5.6 (-19%) 
S204 7.7 7.1 (-8%) 7.1 (-8%) 7.5 (-3%) 6.1 (-21%) 4.9 (-36%) 
S205 16.6 14.5 (-13%) 14.6 (-12%) 11.6 (-30%) 7.2 (-57%) 8.6 (-48%) 
S206 19.2 18.6 (-3%) 17 (-12%) 13.2 (-31%) 6.8 (-65%) 0.8 (-96%) 
S207 9.6 9.6 (0%) 8.3 (-14%) 7.7 (-20%) 3.3 (-66%) 3.3 (-66%) 
S209 7.4 6.6 (-11%) 5.7 (-23%) 4.5 (-39%) 3 (-58%) 2.1 (-72%) 
S212 15.9 14.1 (-11%) 15.6 (-2%) 17 (+7%) 13.6 (-14%) 11.2 (-30%) 
S217 6.3 6.8 (+8%) 7.4 (+18%) 5.3 (-16%) 8.1 (+29%) 5.5 (-13%) 
S218 12 11.1 (-8%) 10.3 (-14%) 8.2 (-32%) 6.6 (-45%) 3.2 (-73%) 
S220 18 14.6 (-19%) 14.3 (-21%) 10.3 (-43%) 8.5 (-53%) 9.2 (-49%) 
S224 41.8 33.6 (-20%) 31.6 (-24%) 31.6 (-24%) 27.9 (-33%) 20.5 (-51%) 
S226 9.8 9.0 (-8%) 9.0 (-8%) 10.2 (+4%) 7.2 (-26%) 4.4 (-55%) 
S228 6.7 6.7 (0%) 6.4 (-4%) 5.7 (-15%) 4.2 (-37%) 2.5 (-63%) 
S221a 15.1 13.3 16.3 12.7 - 5.4 
S213 (28d)b 11.2 8.9 9.3 23.1 - 7.2 
S227 (14d)b 15.9 17.9 23.7 - - - 
S216 (9d)c 9.5 8.1 - - - 9.6 
S219 (39d)c 10.8 10.8 10.2 8.8 11.8 11.4 
S223 (2d)c 5.8 - - - - - 
Median 10.8 10.2 10.2 9.5 7.0 5.5 
Mean 13.0 12.1 12.3 11.5 8.6 6.8 
Min 5.8 6.6 5.7 4.5 3.0 0.8 
Max 41.8 33.6 31.6 31.6 27.7 20.5 
a Excluded from complete cases due to lack of efficacy data at week 8 
b Discontinuations due to insufficient therapeutic effect 
c Discontinuations due to AEs 
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Overall evaluation of efficacy by investigator  
A statistically significant improvement from week 4 of treatment onwards was shown, 
with increased improvement towards the end of treatment (P=0.004) and follow-up 
(P<0.001) (Table 8.3). At the end of treatment, 8 patients (44%) scored at least moder-
ate improvement, 4 scored slight improvement (23%) and 6 scored worse or unchanged 
(34%). At follow-up 11 patients (64%) were rated at least moderate improved. Two 
patients scored slight improvement (12%) and 4 patients scored unchanged (24%). 
 
Table 8.3 Overall evaluation of efficacy by the investigator—ITT population 
Treatment period (n=18)*** Follow-up (n=17)** 
Weeks (scheduled) 1 2 4 8 10 
Investigator assessment n % n % n % n % n % 
Worse 2 11 4 22 3 18 3 17 0 0 
Unchanged 11 61 7 39 4 22 3 17 4 24 
Slight improvement 5 28 7 39 9 50 4 22 2 12 
Moderate improvement 0 0 0 0 2 11 6 33 5 29 
Marked improvement 0 0 0 0 0 0 2 11 5 29 
Almost complete clearance 0 0 0 0 0 0 0 0 1 6 
p-value vs baseline* 0.453 0.549 0.037 0.004 <0.001 
*Wilcoxon signed rank test, two-sided p-value versus baseline 
** For patients S223 and S227 no follow-up score was recorded 
*** For S223 no last observation on this variable available. 
 
Lesion severity assessment by investigator  
(Table 8.4) A statistically significant reduction of the lesion severity score was obtained 
at the end of the treatment (P=0.016) and at follow-up (P<0.001). At baseline, no 
patients were rated with a score none or minimal versus 3 (16%) at end of treatment and 
8 (42%) at follow-up. Where 6 patients (32%) were scored severe at baseline, only 3 
(16%) had this score at end of treatment and 1 (6%) at follow-up. 
Patient self-assessment of treatment 
Patient self-assessment of treatment was statistically significant improved from week 1 
of treatment onwards (Table 8.5). During the course of the treatment and follow-up, 
none of the patients rated their disease as almost completely cleared. A moderate to 
marked improvement was rated in 3 patients after 4 weeks of treatment, in 8 patients at 
end of treatment and in 9 patients at follow-up. At the end of treatment, 4 patients (22%) 
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scored a slight improvement, 2 (11%) scored unchanged and 4 (22%) worse versus 3 
(18%), 3 (18%) and 2 (12%) respectively at follow-up. 
 
 
 
Table 8.4 Lesion severity score by the investigator—ITT population  
 
Baseline Treatment period (n=19) Follow-up (n=17)** 
Weeks  0 1 2 4 8 10 
Severity 
assessment n % n % n % n % n % n % 
None 0 0 0 0 0 0 0 0 0 0 1 6 
Minimal 0 0 0 0 0 0 0 0 3 16 7 41 
Mild 2 11 3 16 5 26 8 42 7 37 3 18 
Moderate 11 58 11 58 7 37 7 37 6 32 5 29 
Severe 6 32 5 26 7 37 4 21 3 16 1 6 
Very severe 0 0 0 0 0 0 0 0 0 0 0 0 
p-value * NA 0.500 0.750 0.055 0.016 <0.001 
* Wilcoxon signed rank test, two-sided p-value on shifts of scores vs baseline 
** For patients S223 and S227 no follow-up score was recorded 
 
 
Table 8.5 Patient’s self-assessment—ITT population 
 
Treatment period (n=18)*** Follow-up (n=17)** 
Weeks (scheduled) 1 2 4 8 10 
Patient self-assessment n % n % n % n % n % 
Worse 3 17 4 22 4 22 4 22 2 12 
Unchanged 4 22 2 11 2 11 2 11 3 18 
Slight improvement 9 50 9 50 9 50 4 22 3 18 
Moderate improvement 2 11 3 17 3 17 6 33 3 18 
Marked improvement 0 0 0 0 0 0 2 11 6 35 
Almost complete clearance 0 0 0 0 0 0 0 0 0 0 
p-value vs baseline* 0.037 0.035 0.035 0.007 0.002 
* Wilcoxon signed rank test, two-sided p-value on shifts of scores vs baseline 
** For patients S223 and S227 no follow-up score was recorded 
*** For S223 no last observation on this variable available. 
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Pharmacokinetics and -dynamics 
Figure 8.4 shows the R115866 plasma concentrations at all treatment visits, 2-4.5 hours 
(h) after drug intake which are to be considered post-peak levels since the Tmax after a 
single dose is 1-2 h. The maximum observed concentration of R115866 in plasma was 
1.390 ng/ml, the minimum was 0.140 ng/ml. The mean/median plasma concentrations 
of R115866 at 2 to 4.5 h after trial medication intake were comparable throughout the 8-
week treatment period and are listed in Table 8.6. 
 
Figure 8.4 Individual plasma concentrations of R115866 after trial medication intake (1 mg o.d.) 
 
 
Table 8.6 Post-peak plasma concentrations of R115866 after repeated oral dosage of 1 mg, once daily for 8 
weeks. 
R115866, ng/ml plasma (mean ± S.D.) 
Day 1  
(n=19) 
Day 7  
(n=12) 
Day 14 
(n=11) 
Day 28 
(n= 10) 
Day 56 
(n=13) 
0.408 ± 0.233 0.407 ± 0.260 0.494 ± 0.340 0.379 ± 0.184 0.359 ± 0.181 
 
0.0 
0.4 
0.8 
1.2 
1.6 
 0  1 2  3  4   5 
Time after dosing, h 
R115866, ng/mL plasma 
Day 1 Day 7 Day 14 Day 28 Day 56
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Figure 8.5 Plasma concentrations of RA pre- and post-dose during an 8 week treatment period with R115866 
1 mg o.d. ({: pre dose; U: post dose) and two weeks thereafter. 
 
Figure 8.5 shows the individual pre- and post-dose plasma concentrations of all-trans-
RA during the treatment period and at the end of follow-up period. Pre-dose all-trans-
RA concentrations remained constant during the whole study period. At all time points, 
in all treated patients, all-trans-RA plasma levels consistently increased (0.5-1.5 ng/ml) 
between 2 to 4.5 h after intake of 1 mg R115866. This increase was somewhat larger 
after the first dose (median difference=0.98 ng/ml), but was similar after 1, 2, 4 and 8 
weeks of treatment (median difference ranging from 0.50 to 0.62 ng/ml). All-trans-RA 
plasma levels measured before, during and after the treatment remained within the 
normal biological limits. 
Safety and tolerability evaluation 
R115866 treatment was overall well tolerated. The safety population includes all pa-
tients who were exposed to at least one dose of the trial medication (n=19). All AEs 
reported by more than 1 patient are listed in Table 8.7. In all patients, a total of 94 
adverse events (AEs) were recorded of which 31 (33%) were mild, 50 (53%) moderate 
and 13 (14%) severe. Severe AEs reported in more than 1 patient were pruritus (n =5) 
and xerosis (n=2), other severe AEs with one instance each were cheilitis, increased 
blood triglycerides, skin fragility, pain of skin and atrial fibrillation. For the individual 
0.0 
0.5 
1.0 
1.5 
2.0 
2.5 
3.0 
3.5 
14 21 28 35 42 49 56 63 70 
Days 
0 7 
RA, ng/mL plasma 
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AEs, cheilitis was most commonly (n=11) recorded and was scored ‘very likely’ or 
‘probably related’ to the trial medication. Other AEs reported as very likely or probably 
related to trial medication were pruritus (n=6), xerosis (n=6), increased triglycerides 
(n=7) and epistaxis (n=4). 
 
Table 8.7 Incidence of AEs reported for 2 or more patients (Per system organ class and regardless of severity 
and drug relatedness)—ITT population (n=19) 
System organ class 
Preferred term 
Number of AEs reported 
in >1 patient 
Patients 
n=19 (%) 
Total  71 19 (100) 
Skin and appendages disorders 37  16 (84.2) 
 Pruritus 16 12 (63.1) 
 Xerosis 12 10 (52.6) 
 Skin fragility 4 3 (15.8) 
 Hair disorder 3 3 (15.8) 
 Dry skin 2 2 (10.5) 
Gastrointestinal disorders 15  13 (68.4) 
 Cheilitis 13 11 (52.6) 
 Dry mouth 2 2 (10.5) 
Metabolic and nutritional disorders 11  10 (52.6) 
 Increase in blood triglycerides 11 10  
Central and peripheral nervous system disorders 3  2 (10.5) 
 Headache 3 2  
Vascular disorders 5  4 (21.1) 
 Epistaxis 5 4  
 
Three patients were withdrawn from the study due to adverse events. One patient [S223] 
discontinued after 2 days of treatment because of non-symptomatic atrial fibrillation at 
the ECG evaluation. However after further evaluation, it appeared that this condition 
was probably pre-existing and the relationship to the trial medication was considered 
very doubtful. Another patient [S216] discontinued treatment after 9 days because of 
aggravation of T-wave abnormalities on the ECG and suggestive for myocardial ische-
mia (possibly drug-related) although the patient presented himself in a good condition 
without any complaints or cardiac symptoms. This patient was included presenting 
already at baseline with an asymptomatic abnormal morphology of the T-wave which is 
considered a protocol deviation. A third patient [S219] was discontinued from treatment 
after 39 days due to ‘worsening pruritus’ (possibly drug-related) and ‘severe xerosis’ 
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(very likely drug-related). No deaths or serious adverse events were reported during the 
trial. 
No clinically relevant laboratory abnormalities were reported during the trial except for 
an increase in blood triglycerides. Six patients had above normal values for triglycerides 
already at baseline, i.e. before the first intake of R115866 and values remained above 
normal at several time points during treatment/follow-up. In 10 patients abnormal 
triglyceride levels were reported as adverse event. In one patient [S221] the study 
medication was reduced to 0.5 mg/day due to significant hypertriglyceridemia noticed 
after 3 weeks of treatment. 
No clinically relevant abnormal values were noted for the endocrinology parameters and 
no clinically significant changes in vital signs, weight and ECG-intervals were ob-
served. 
From the seven cutaneous retinoic acid-related symptoms evaluated at each visit, the 
most commonly reported symptoms at baseline were pruritus (n=13) and xerosis (n=9). 
Fragile skin and hair loss were reported in 3 and 2 patients, respectively, while periun-
gual granulomatous reaction, cheilitis and epistaxis were not observed at baseline. 
During treatment the incidence of patients reporting symptoms increased. The greatest 
shift from baseline was observed for cheilitis with no patients reporting the symptom at 
baseline versus 8 at the end of treatment. After 2 weeks follow-up, cheilitis was reported 
by 3 patients. Periungual granulomatous reaction was not reported at any time point. 
The majority of patients scored the cutaneous retinoic acid-related symptoms as mild to 
moderate. 
Discussion 
Eight weeks of therapy with R115866 at a 1 mg daily dose in patients with moderate to 
severe plaque-type psoriasis resulted in a statistically significant improvement versus 
baseline for all assessed efficacy variables at the end of the treatment phase (week 8), 
with a p-value less than 0.05 for both the analysis of the complete cases as well as the 
ITT-population. Importantly, the improvement continued and was even more pro-
nounced 2 weeks after the last drug intake indicating that treatment duration will likely 
have to go beyond 8 weeks in order to achieve optimal clinical efficacy. From the 
complete cases, 5/13 (38%) had at least 50% reduction of PASI at end of therapy and 
7/13 (54%) at follow-up compared to baseline. At least 45% reduction of PASI was 
achieved at follow-up in 9/13 patients (69%). These data are in line with data found in 
the literature on acitretin, the preferred systemic retinoid in the treatment of psoriasis for 
more than 10 years.19 In one study where treatment with acitretin was initiated at 
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50mg/day for 4 weeks followed by dose adjustment according to therapeutic response, 
44.5% of the patients reached a 50% improvement of PASI after 8 weeks.20 In a second 
study, where the initial dose was 40mg/day, 57% of the patients reached PASI 50 after 8 
weeks.21 
An oral daily dose of 1mg R115866 for 8 weeks was well tolerated. One patient [S221] 
had a dose reduction after 3 weeks of treatment due to severe hypertriglyceridemia. In 
this patient 0.5 mg R115866 daily was still efficacious: a PASI reduction of 64.2% was 
achieved after 2 weeks follow-up compared to baseline. Six out of nine screening 
failures in this study were due to hypertriglyceridemia and six patients that were in-
cluded in the trial had already triglyceride levels above normal values at baseline, before 
the first intake of the study medication. Elevated blood triglycerides or the susceptibility 
to have increases in blood triglycerides may be intrinsic to the psoriasis population since 
no abnormal triglyceride levels were recorded as an AE in a recent exploratory trial with 
R115866, 1 mg daily in 17 patients with moderate to severe facial acne vulgaris.22-25 
Recent work by Mallbris et al. in 200 patients with psoriasis at the onset of the disease 
supports the notion that lipid abnormalities in psoriasis are already present and probably 
genetically determined.26 However, this phenomenon needs further investigation and 
close monitoring. Cheilitis was repetitively seen between week 2 and 8 of the treatment 
phase in the majority of patients (70%) who responded well to treatment. This effect 
disappeared quickly after treatment. 
The body needs and therefore produces very little all-trans-RA. Blocking its breakdown 
will give only modest all-trans-RA elevations in specific target cells where all-trans-RA 
is metabolized by the retinoic acid 4-hydroxylase. The advantage of administering a 
RAMBA is that there is markedly less all-trans-RA accumulation and circulation in the 
body as compared to retinoids which need to be administered at high doses because the 
majority of the drug probably never reaches its target. The consequence is that a large 
amount of the administered retinoid ends up in the plasma and subsequently in other 
non-targeted tissue where it may be causing some of the undesirable effects (e.g. hepa-
totoxicity).27,28, 29 
Kinetic data in this trial were in line with the data obtained in the Phase I trials.7 The 
mean/median R115866 plasma concentrations, 2-4.5 hours after drug intake remained 
fairly constant throughout the trial, indicating that there is no accumulation. A modest 
and temporary effect of R115866 was seen on all-trans-RA plasma levels which re-
mained within physiological limits. The uptake of all-trans-RA from the circulation by 
the tissues will be far less when compared to administering oral retinoids.27,28 At all time 
points, increases in all-trans-RA were comparable except after the first dose where the 
increase was slightly higher. This could be explained by the fact that increases in all-
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trans-RA will lead to an up-regulation of 4-hydroxylase activity resulting in a higher 
catabolism of all-trans-RA.30 It is well-known that this negative feed-back mechanism is 
responsible for the reduced activity seen with retinoids after long-term treatment. The 
constant all-trans-RA plasma increases could indicate that this feed-back mechanism 
seems not to affect much the potential of R115866. Some retinoids like etretinate and 
acitretin also have the disadvantage of being stored in subcutaneous adipose tissue from 
which they are slowly released into the plasma. This is, in view of the teratogenic 
potential, a real burden for women of child-bearing age as they have to continue contra-
ception for 3 years after stopping therapy with the above mentioned drugs.31 R115866 is 
rapidly cleared from the body once treatment is stopped (within hours) which minimizes 
the waiting period to become pregnant significantly as compared to acitretin. 
As part of this clinical trial, the dynamics of epidermal proliferation, keratinization, 
lesional T-cell subsets and cells expressing NK-receptors were assessed in 6 patients. 
The data have been presented elsewhere.32 Briefly, it was shown that clinical efficacy of 
R115866 is primarily the result of restoring proliferation (Ki67, -63%; P<0.01)) and 
differentiation (keratin 10 expression: +29%; P<0.01) of epidermal keratinocytes as 
compared to baseline. Secondarily, a tendency toward reductions of relevant T-cell 
subsets and cells expressing NK-receptors was shown but was not yet significant after 8 
weeks of treatment. The positive, although not significant, immunological results 
obtained in this small subpopulation support again the concept that a longer treatment 
with R115866 will probably further improve clinical efficacy. Recent data from a 
biomarker expression study in skin with topical R115866 gel (0.07% and 0.35%) 
applied for 9 days in healthy volunteers exhibited not only an induction of cellular 
retinoic acid binding protein-2 and keratin 4 mRNA but also a reduction of IL-1α 
mRNA at the skin level.33 This observation, together with the above mentioned ten-
dency towards a reduction of T-cell subsets in psoriasis patients, suggests that R115866 
might also possess anti-inflammatory activities. However further study is needed to 
confirm these interesting but preliminary results. 
Conclusion 
The promising results from this exploratory study suggest that R115866 may be an 
effective and well tolerated treatment for patients with moderate to severe plaque-type 
psoriasis and warrant further investigation. A treatment duration extending 8 weeks may 
improve the therapeutic effect and may be needed to achieve optimal clinical efficacy. 
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Abstract 
Background: R115866 (RambazoleTM), a new generation all-trans Retinoic Acid 
Metabolism Blocking Agent (RAMBA), is a non-retinoid compound enhancing intracel-
lularly the endogenous levels of all-trans-retinoic acid (all-trans-RA) by blocking its 
catabolism. By virtue of this property and the proven positive effects of retinoids in the 
treatment of acne, R115866 could potentially be a useful drug for this complex skin 
disorder. 
Objective: To explore the therapeutic effect, safety and tolerability of systemic R115866 
in male patients with moderate to severe facial acne vulgaris (at least 15 papules and/or 
pustules and minimum 2 nodular-cystic lesions). 
Patients and methods: In this open label, single-arm, exploratory trial, 17 patients were 
treated once daily with 1 mg of R115866 for 12 weeks, followed by a 4-week treatment-
free follow-up period. Patients were monitored for efficacy, tolerability and safety. 
Results: Analysis of efficacy at the end of treatment (week 12; n=16) showed a mean 
reduction in inflammatory lesions of 77.4% (p<0.001), in non-inflammatory lesions of 
58.3% (p<0.001), and in total lesion count of 76% (p<0.001) as compared to baseline. 
All lesion counts were significantly reduced from week 4 onwards, except for the closed 
comedones and papules, which were significantly reduced from week 8 onwards. Only 
mild side-effects were reported occasionally. 
Conclusion: The data from this study indicate that oral daily treatment with 1 mg 
R115866 during 12 weeks in patients with moderate to severe facial acne vulgaris is 
efficacious and well tolerated. R115866 merits further investigation to assess the opti-
mal dose and its potential as a new therapy for this indication. 
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Introduction 
Limited to the sebaceous follicles of the head and upper trunk, acne vulgaris is a skin 
disorder with a very complex aetiology involving aberrant keratinization and/or des-
quamation of follicular epithelial cells, increased sebum production and excretion, and 
colonization of the follicle by Propionibacterium acnes which induces inflammation. 
The primary lesion in acne is the “microcomedone” that may evolve over time into a 
non-inflammatory lesion i.e. open comedone (blackhead) or closed comedone (white-
head) and further to an inflammatory lesion (pustule, papule or nodulocystic lesion).1,2 
Topical retinoids, as single therapy or in combination with antimicrobial therapy, have 
been recommended as the primary treatment for mild to moderate forms of acne vul-
garis. However irritation and corticosteroid resistance limit their use.3-5 
Oral isotretinoin (13-cis-retinoic acid), the only drug currently available affecting all 
before mentioned pathogenic factors of acne, is reserved for patients with moderate to 
severe inflammatory acne because of its side-effects profile i.e. teratogenicity, eleva-
tions in triglycerides, in liver enzymes and to a lesser degree in cholesterol levels.6-9 The 
high incidence of cutaneous retinoic acid (RA)-related side effects can sometimes be 
troublesome and lead to discontinuation of the treatment. So there is room for effective 
alternatives with a more favourable safety profile. 
R115866 is a triazole derivative identified as a new generation Retinoic Acid Metabo-
lism Blocking Agent (RAMBA). At nanomolar concentrations, R115866 exhibits highly 
potent and very selective cytochrome P-450 (CYP) inhibiting properties against hy-
droxylases involved in catabolism of all-trans-retinoic acid (all-trans-RA) like CYP26 
whereas micromolar concentrations are needed to inhibit other CYPs.10,11 By blocking 
the breakdown of endogenous all-trans-RA within the cells, RAMBAs transiently 
increase the cellular all-trans-RA levels. 
Several animal experiments have documented the in vivo suppressive effects of 
R115866 on all-trans-RA metabolism in rats. Single oral R115866 treatment was shown 
to transiently increase endogenous all-trans-RA in rat skin. Similar to all-trans-RA, 
both oral and topical R115866 exhibited a modulating effect on epithelial growth and 
differentiation in various animal models of keratinization.10 In addition, topical applica-
tion of R115866 has revealed a reduction of the utriculus size in rhino mouse back skin 
and also a dose-dependent reduction of mRNA of pro-inflammatory cytokines in the 
skin of healthy volunteers suggesting a possible anti-inflammatory activity.12,13 
By virtue of this pharmacodynamic property and the well-known modulating effects of 
all-trans-RA on both epidermal and sebocyte growth and differentiation, R115866 is 
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potentially of use for disorders where aberrant keratinisation is associated with aberrant 
sebum production/excretion, such as in acne vulgaris. 
The main purpose of this exploratory trial was to assess the efficacy, tolerability and 
safety of oral R115866 administered for 12 weeks at a daily dose of 1 mg in patients 
with moderate to severe facial acne vulgaris. 
Patients and Methods 
Study design 
This exploratory, multi-center, open-label study assessed the efficacy, tolerability and 
safety of oral R115866 in patients with moderate to severe facial acne vulgaris. Patients 
were enrolled in three study centers: a private practice in Dermatology in Vilvoorde, 
Belgium; the Department of Dermatology, Albert Schweitzer Hospital, Zwijndrecht, 
The Netherlands and the Department of Dermatology, Academic Hospital Jette, Free 
University of Brussels, Belgium. 
The protocol has been reviewed and approved by each study center’s independent ethics 
committee and all patients provided written informed consent prior to study enrollment. 
All clinical investigations were conducted according to the Declaration of Helsinki 
principles. 
Treatment 
Patients took two capsules of 0.5 mg R115866, total daily dose of 1 mg, in the morning 
with breakfast for a period of 12 weeks. At the visit days, patients were advised to be 
fasted for at least 8 h before blood sampling. Their medication had to be taken in the 
clinic with breakfast after collection of the pre-dose blood samples and electrocardio-
gram (ECG) recordings. The 12-week treatment period was followed by a 4-week 
treatment-free follow-up period. The investigator could decide to decrease the dose to 
0.5 mg once daily if necessary. No additional topical treatments were allowed. 
Patient population 
Healthy male patients between 16 and 50 years with at least 15 papules and/or pustules 
and a minimum of 2 nodular-cystic lesions were allowed to participate in this trial. 
Clinically relevant abnormalities in the laboratory test results (haematology, biochemis-
try, endocrinology and urine analysis) at screening were not accepted. All patients had 
to sign a written informed consent. Wash-out periods before entering the study were: 
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2 weeks for topical or ultraviolet (UV) treatment or excessive UV exposure and 4 weeks 
for previous systemic treatment of acne. Main exclusion criteria included other types of 
acne, concurrent inflammatory disease, co-existing serious disease, hyperlipidaemia, 
clinically relevant electrocardiogram (ECG) abnormalities, heart disorders, use of drugs 
that could interfere with either acne or the study drug, use of Vitamin A (>1000µg/day) 
or oral retinoids 6 months prior to screening, known intolerance to retinoids and the 
suspicion of alcohol or drug abuse. 
Clinical evaluations 
Clinical evaluations were performed by the same investigator per site over the course of 
the study at baseline, at week 4, 8 and 12 of the treatment and at the end of the follow-
up (week 16). 
Facial acne-related lesion count 
All acne-related lesions (open/closed comedones, papules, pustules and nodules) were 
counted by the investigator on the front, the left/right cheek, the chin and the nose. This 
resulted in a separate count per area of every lesion type (open/closed comedones, 
papules, pustules and nodules), in a total inflammatory (sum of papules, pustules and 
nodules), a total non-inflammatory (sum of open and closed comedones) and a total 
acne lesion count. A definition of the lesions is displayed in Table 9.1 
 
Table 9.1 Definition of the acne lesions. Any intermediate lesion was counted according to its major compo-
nent. Prominent follicles, small milia or trichostasis spinulosa are excluded from the count. Non inflamed 
lesions are not counted on the nose, at the edge of the nose and at the hairline. 
Lesion Description 
Comedones Non-inflamed lesions, small, discrete, raised areas of the skin, usually occurring in the 
opening of a hair follicle. The lesions are not red, but may be discoloured (blackheads = 
open comedones) or not (whiteheads = closed comedones).  
Papules Inflammatory superficial lesions, less than 5 mm in diameter, raised circular areas of the 
skin, red, containing no visible pus 
Pustules Inflammatory superficial lesions, less than 5 mm in diameter, raised circular areas of the 
skin, red, containing a visible central core of white or yellow purulent material 
Nodules Deep inflammatory lesions with a diameter of 5 mm or larger. They may become 
suppurative or hemorrhagic. Nodular lesions are commonly referred to as cysts. Palpation 
was used for detection, since some nodules are almost invisible, but easily palpable 
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Overall acne severity 
Both the investigator and the patient independently, evaluated the overall facial acne 
severity on a 5-point scale in which 0=none (clear, no inflammatory lesions), 
1=Minimal (very few or no inflammatory lesions present), 2=Mild (few to several 
papules or pustules, no nodules), 3=Moderate (several to many papules or pustules, few 
to several nodules), 4=Severe (numerous or extensive papules or pustules, many nod-
ules). 
Global assessment of effectiveness 
A subjective global evaluation of the patient’s overall disease severity relative to base-
line was made by both the investigator and the patient independently. The global as-
sessment of effectiveness was graded on a 6-point scale with 0=worse, 1=unchanged (< 
10% improvement), 2=slight improvement (±25%), 3=moderate improvement (±50%), 
4=marked improvement (±75%) and 5=Almost to complete clearance (90-100%). 
Photographs 
In order to document efficacy, photographs of the facial area were taken under standard-
ized conditions at each designated visit. 
Safety and tolerability evaluation 
Adverse events were recorded throughout the study period. Blood samples for haema-
tology, biochemistry and endocrinology (luteinising hormone, oestradiol, cortisol, 
aldosterone and testosterone) were taken at every visit. Urinalysis was only performed 
at screening. Cardiovascular safety was monitored at each visit. At all visits, possible 
clinical signs of cutaneous RA-related side effects (xerosis, pruritus, cheilitis, epistaxis, 
periungual granulomatous reaction, hair loss and fragile skin) were evaluated and 
graded for their severity (none, mild, moderate or severe). 
Statistics 
The intent-to-treat (ITT) population consisted of all patients who were assigned to 
treatment. The per-protocol (PP) population consisted of all enrolled patients that used 
trial medication for the specified period, that were evaluable at the end of the treatment 
period and that did not use other prohibited therapy during the entire trial period. The 
PP population was the primary population in the analysis of efficacy. The safety popula-
tion was identical to the ITT population. Statistical significance of changes in lesion 
counts and overall acne severity as compared to baseline values was assessed with the 
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Wilcoxon signed rank test. Global assessment of severity by investigator and patient 
were compared to “no change” (= score 1) as hypothesized outcome using the Wilcoxon 
signed rank test. Two-sided p-values less than or equal to 0.05 were considered to 
indicate statistical significance. All computations were carried out using the SAS 
Version 8.2 system for statistical analysis.14 
Results 
Patients 
Twenty patients were screened, 17 (male, Caucasian) enrolled and treated with 
R115866. There were 3 screening failures due to an insufficient number of lesions. 
Mean age (range) was 22.3 (13-36) years and mean weight 71.3 (55-97) kg. One patient 
discontinued the study due to lost of follow up after 4 weeks of treatment. Sixteen 
patients completed the entire study. 
Clinical evaluations 
The PP-population (n=16) was used to evaluate efficacy and is presented here. 
Facial acne-related lesion count 
Detailed information of each patient on the acne lesion counts and percentage reduction 
as compared to baseline is given in Tables 9.2 and 9.3, respectively. 
At baseline the mean (range) for the total acne lesion count was 81.3 (22-199), for total 
inflammatory lesion count 56.2 (15-170) and for total non-inflammatory lesion count 
25.1 (0-60). 
Compared to baseline, a statistically significant reduction was seen in both total non-
inflammatory (p=0.016) and total inflammatory lesion count (p=0.018) from week 4 of 
the treatment onwards and at all time points for the total acne lesion count (p≤0.001). 
The mean % reduction in total acne lesion count from baseline increased with treatment 
duration and amounted from 31.5% after 4 weeks of treatment to 76% at the end of 
treatment (week 12; p<0.001) to 77.2% at the end of the follow-up period (week 16; 
p<0.001). At the end of treatment, the mean % reduction in total inflammatory lesion 
count versus baseline was 77.4 % (p<0.001) with 6/16 (37.5%) patients showing at least 
90% reduction. The mean % reduction in total non- inflammatory lesion count versus 
baseline was 58.3% (p<0.001) with 5/16 (31.25%) patients showing at least 90% reduc-
tion. For all individual lesion types, a similar degree of lesion reduction was seen after 
12 weeks of treatment. 
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The mean % reduction of the acne lesions was still improving during the treatment free 
follow-up period reaching 77.2% (p<0.001) for total acne lesion count, 78.4% 
(p<0.001) for total inflammatory lesion count and 63.2% (p<0.001) for non-
inflammatory lesion count. 
 
Table 9.2 Summary of total non-inflammatory (N-ILC) and total inflammatory lesion count (ILC) per patient 
(n=16) at baseline, at week 4, 8 and 12 weeks of treatment with R115866 and at follow-up.  
 Baseline Treatment Follow-up 
Patient Week 0 Week 4 Week 8 Week 12 Week 16 
 N-ILC/ILC N-ILC/ILC N-ILC/ILC N-ILC/ILC N-ILC/ILC 
S402 29/170 29/11 31/28 29/5 10/11 
S403 37/84 19/29 21/34 17/23 15/56 
S405 60/35 39/43 22/22 14/13 19/12 
S419 40/75 45/77 52/94 28/37 24/36 
S420 29/56 18/33 0/2 0/3 0/3 
S421 0/22 0/11 0/9 0/0 0/0 
S422 16/30 0/3 0/1 0/1 0/4 
S423 23/40 0/12 0/4 0/1 0/2 
S424 10/15 0/30 0/2 0/3 0/1 
S425 4/19 3/18 0/4 0/0 0/0 
S561 48/45 35/36 17/31 10/15 0/5 
S562 21/51 11/47 11/53 12/25 19/19 
S563 13/36 13/46 11/31 6/16 6/19 
S564 26/63 24/56 7/32 9/25 18/21 
S565 31/62 5/40 7/26 15/14 3/3 
S567 14/96 31/58 30/50 17/24 15/20 
Mean 25.1/56.2 17.0/34.4 13.1/26.4 9.8/12.8 8.1/13.3 
SD 16.0/38.3 15.3/20.2 15.0/24.7 9.8/11.5 8.9/15.3 
Median 24.5/48.0 15.5/34.5 9.0/27.0 9.5/13.5 4.5/8.0 
Min 0/15 0/3 0/1 0/0 0/0 
Max 60/170 45/77 52/94 29/37 24/56 
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Table 9.3 Summary of lesion counts reduction (%) versus baseline at week 4, 8 and 12 of treatment and at 
follow-up. n=16 for each group, exact two-sided p-value from Wilcoxon signed rank test comparison with 
value at baseline. 
Week  
4 8 12 16 
Total Count of All Acne Lesions Mean 31.5 56.0 76.0 77.2 
 SD 35.3 35.3 19.2 22.4 
 Median 21.6 57.6 72.3 90.4 
 Min -20 -27 43 41 
 Max 93 98 100 100 
 P-value 0.001 <.001 <.001 <.001 
Total Count of Inflammatory lesions Mean 23.5 53.7 77.4 78.4 
 SD 49.1 36.2 18.3 21.0 
 Median 27.7 58.6 76.2 87.8 
 Min -100 -25 51 33 
 Max 94 97 100 100 
 P-value 0.018 <.001 <.001 <.001 
Total Count of Non-inflammatory lesions Mean 29.9 45.8 58.3 63.2 
 SD 55.6 60.2 39.8 38.7 
 Median 31.0 64.0 59.7 66.9 
 Min -121 -114 -21 -7 
 Max 100 100 100 100 
 P-value 0.016 0.009 <.001 <.001 
 
Overall acne severity 
The mean (range) investigator’s overall acne severity score at baseline was 3.3 (3-4) 
reaching 1.3 (0-3) at the end of treatment and 1.6 (0-3) at follow up. The mean (range) 
patients’ baseline score was 3.1 (2-4) reaching 1.3 (0-2) at the end of treatment and 1.2 
(0-2) at follow up. When compared to baseline, both investigator’s and patient’s overall 
acne severity scores improved significantly from week 4 onwards (p=0.002 and p<0.001 
respectively) reaching both p≤0.001 for subsequent visits. A summary is given in 
Table 9.4. 
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Table 9.4 Summary of physician’s and patient’s overall acne severity scores at baseline; end of treatment and 
at follow-up. 
 Physician’s Overall 
Acne Severity Score 
Patient’s Overall 
Acne Severity Score 
Scores* 0 1 2 3 4 0 1 2 3 4 
Baseline (n=16) 0 0 0 11 5 0 0 3 8 5 
End of treatment (Week 12, n=16) 2 8 5 1 0 2 8 6 0 0 
Follow-Up (Week 16, n=16) 3 5 4 4 0 5 3 8 0 0 
Results presented as number of patients. 
* 5-point rating scale: 0 = none, 1= Minimal, 2 = Mild, 3= Moderate, 4 = Severe 
 
Global assessment of effectiveness 
A statistically significant improvement of both the physician’s and the patient’s global 
efficacy score was obtained from week 4 onwards till the end of the treatment and 
follow-up (p<0.001). The mean (range) global efficacy score at the end of treatment was 
3.8 (1-5) when scored by the physician and 3.9 (2-5) when scored by the patient. At 
follow-up the scores were 3.6 (0-5) and 3.9 (0-5) when scored by the physician and the 
patient respectively. A summary is given in Table 9.5. 
 
Table 9.5 Summary of physician’s and patient’s global assessment of effectiveness (n=16) 
 Physician’s 
Global assessment of 
Effectiveness 
Patient’s 
Global assessment of 
Effectiveness 
Scores* 0 1 2 3 4 5 0 1 2 3 4 5 
Week 4 1 1 5 5 3 1 0 1 5 6 3 1 
Week 8 1 3 2 4 2 4 1 2 1 6 3 3 
End of treatment (Week 12) 0 1 0 6 4 5 0 0 1 4 6 5 
Follow-Up (Week 16) 1 1 1 3 4 6 1 0 1 3 3 8 
* Six-point rating scale: 0=worse, 1=unchanged (< 10% improvement), 2=slight improvement (±25%), 3=moderate 
improvement (±50%), 4=marked improvement (±75%) and 5=Almost to complete clearance (90-100%). 
 
Safety and tolerability evaluation 
R115866 treatment was well tolerated, a total of 16 adverse events (AEs) were recorded 
in 9/17 patients: 10 were mild, 5 moderate and 1 severe (eczema). Six AEs including the 
case of severe eczema were interpreted as not drug-related, 3 doubtful, 6 possibly drug-
related and 1 (mild stomach discomfort) as very likely related to treatment. AEs re-
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ported in more than one patient were dry skin (n=3), contact dermatitis (n=2), and 
eczema (n=2). All AEs were resolved at the end of the trial. No deaths or serious ad-
verse events were reported during the trial. 
No clinically relevant ECGs or laboratory abnormalities were reported and there was no 
abnormal evolution of test values in any of the investigated parameters. Elevation above 
normal values for triglycerides was observed in 3 patients during treatment but none 
were reported as AE. 
At baseline, no cutaneous RA-related side effects were reported. Periungual granuloma-
tous reaction was not observed at any time point. During treatment the RA-related side 
effects were scored as mild to moderate in the majority of patients. Comparison of 
severity scores during treatment with baseline revealed a significant aggravation of 
xerosis (4 and 8 weeks: p≤0.01; 12 weeks: p=0.008), cheilitis (4, 8 and 12 weeks: 
p≤0.01) and pruritus (4 weeks: p=0.031). All RA-related side effects had disappeared 
after 4 weeks treatment-free follow-up, except for xerosis (mild, n=1) and hair loss 
(mild, n=3). 
Discussion 
Oral treatment with R115866 at a daily dose of 1 mg for 12 weeks in patients with 
moderate to severe facial acne vulgaris resulted in a statistically significant improve-
ment for all assessed efficacy variables at the end of the treatment phase (Figures 9.1 
and 9.2). Importantly, the improvement was still pronounced 4 weeks after the last drug 
intake. This excellent treatment effect was observed for the individual lesion types and 
confirmed by the acne severity scores and the assessment of overall effectiveness by the 
investigator and the patients. 
In a double-blind randomized placebo-controlled study with oral tazarotene, which is in 
development for acne, a mean % reduction of non-inflammatory lesion count of 56% 
was achieved after 12 weeks of treatment.15 These data are in line with our data showing 
a 58.3% mean reduction of non-inflammatory lesion count after 12 weeks further 
improving to 63.2% at follow up. With 1 mg R115866, a 76% mean reduction of total 
count of papules and pustules was achieved after 12 weeks versus 50% and 52% for 
3mg and 6 mg oral tazarotene, respectively; the mean % reduction of the nodulocystic 
lesions was 81.3% for R115866 versus 65% and 71% for 3 mg and 6 mg oral tazaro-
tene.15 Our preliminary efficacy results suggest that R115866, compared to oral tazaro-
tene, has an equivalent potency towards improving the non-inflammatory lesions but 
may exhibit a greater efficacy of improving inflammatory lesions. The effect of 
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R115866 on the acne lesions was remarkable in its early onset of action as well as its 
final result. More studies in a larger population are needed to reproduce these findings. 
In this small patient group, R115866 was well tolerated with an acceptable safety 
profile. Elevated triglyceride levels, a side effect often seen after oral isotretinoin 
treatment, were reported in 3/17 patients but, because they were limited in nature (all 
less than twice the accepted upper normal limit), none have been reported as adverse 
event.6-9 Oral ingestion of retinoids at effective clinical doses results in a significant 
increase of the physiological retinoid levels in blood and consequently in tissue where it 
may be causing some of the undesirable effects (e.g. hepatotoxicity).16-22 R115866 does 
not add an exogenous retinoid load to the whole body; it selectively increases the 
intracellular levels of retinoic acid (RA) in those cell systems where CYP enzymes are 
present that specifically metabolize endogenous RA, like CYP 26.23-25 This targeted 
selective increase of all-trans-RA is expected to result in a better safety profile than that 
observed with oral retinoids. 
 
Figure 9.1 Healing of severe papular facial acne with some residual discolouring in the sub-mandibular area 
(A) before treatment and (B) after 12 weeks of treatment with 1mg R115866 daily. See page 237 for colour 
figure. 
B 
A 
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Figure 9.2 Case of moderate papulo-pustular acne almost completely cleared with minimal scarring after 12 
weeks of treatment with 1 mg R115866 daily: (A) before treatment, (B) after 12 weeks treatment. See page 
238 for colour figure. 
 
Conclusion 
The results in a limited number of patients with moderate to severe facial acne vulgaris 
indicate that R115866 could not only be an effective but also a well tolerated treatment 
with equally good effects on inflammatory and non-inflammatory lesions. Although the 
series of patients is small, it is worth mentioning that the side effects were low in 
incidence and severity. R115866 deserves further clinical investigation for dose and 
duration in facial acne vulgaris.  
Acknowledgements 
The authors wish to thank Luc Wouters for the statistical analysis. 
A 
B 
CHAPTER 9 
 206
References 
1. Zouboulis CC, Eady A, Philpott M, et al. What is the pathogenesis of acne? Exp Dermatol 2005; 14: 
143-52. 
2. Pawin H, Beylot C, Chivot M, et al. Physiopathology of acne vulgaris: recent data, new understanding of 
the treatments. Eur J Dermatol 2004; 14: 4-12. 
3. Gollnick H, Schramm M. Topical drug treatment in acne. Dermatology 1998; 196: 119-25. 
4. Eady EA. Bacterial resistance in acne. Dermatology 1998; 196: 59-66. 
5. Gollnick H, Cunliffe W, Berson D, et al. Management of acne: a report from a Global Alliance to 
Improve Outcomes in Acne. J Am Acad Dermatol 2003; 49: S1-37. 
6. Strauss JS, Rapini RP, Shalita AR, et al. Isotretinoin therapy for acne: results of a multicenter dose-
response study. J Am Acad Dermatol 1984; 10: 490-6. 
7. Orfanos CE, Zouboulis CC. Oral retinoids in the treatment of seborrhoea and acne. Dermatology 1998; 
196: 140-7. 
8. Kunynetz RA. A review of systemic retinoid therapy for acne and related conditions. Skin Therapy Lett 
2004; 9: 1-4. 
9. http://www.fda.gov/cder/foi/label/2005/018662s056lbl.pdf: Accutane (Oral isotretinoin capsules) 
prescribing information: accessed on July 31st 2006. 
10. Stoppie P, Borgers M, Borghgraef P, et al. R115866 Inhibits all-trans-retinoic acid metabolism and 
exerts retinoidal effects in rodents. J Pharmacol Exp Ther 2000; 293: 304-12. 
11. R115866 Investigational Drug Brochure; version 4.0.; Jun. 2006. Data on file at Barrier Therapeutics. 
12. Stoppie P, Van Wauwe J, Wouters L, et al. RambazoleTM, a potent inhibitor of all-trans-retinoic acid 
metabolism, applied topically to mouse tail skin exerts retinoid mimetic activity. J Invest Dermatol 2004; 
122: A70( #420) 
13. Cools M, Pavez-Lorie E, Borgers M, et al. Effect of topical R115866 (RambazoleTM) gel on the expres-
sion of biomarkers in the skin of healthy volunteers. J Invest Dermatol 2006; 126: S40 (#240). 
14. SAS version 8.2, SAS Institute, Cary, USA 
15. Tan JKL, Lew-Kaya D, Walker PS. Oral tazarotene reduces comedones. JAAD 2004; 50: P20 (#78) 
16. Hartman S, Brors O, Bock J, et al. Exposure to retinyl esters, retinol and retinoic acids in non-pregnant 
women following increasing single and repeated oral doses of vitamin A. Ann Nutr Metab 2005; 49: 
155-64. 
17. Tang G, Russell RM. 13-cis Retinoic acid is an endogenous compound in human serum. J Lipid Res 
1990; 31: 175-82. 
18. Wiegand U-W, Chou RC. Pharmacokinetics of oral isotretinoin. J Am Acad Dermatol 1998; 39: S8-S12. 
19. Kurlandsky SB, Gamble MV, Ramakrishnan R, et al. Plasma delivery of retinoic acid to tissues in the 
rat. J Biol Chem 1995; 270: 17850-7. 
20. Allen JG, Bloxham DP. The pharmacology and pharmacokinetics of the retinoids. Pharmacol Ther 1989; 
40: 1-27. 
21. David M, Hodak E, Lowe NJ. Adverse effects of retinoids. Medical Toxicology 1988; 3: 273-88. 
22. Penniston KL, Tanumihardjo SA. The acute and chronic toxic effects of vitamin A. Am J Clin Nutr 2006; 
83: 191-201. 
23. Napoli JL. Retinoic acid: its biosynthesis and metabolism. Prog Nucleic Acid Res Mol Biol 1999; 63: 
139-88. 
24. Napoli JL. Interactions of retinoid binding proteins and enzymes in retinoid metabolism. Biochim 
Biophys Acta 1999; 1440: 139-62. 
25. Petkovich PM. Retinoic acid metabolism. J Am Acad Dermatol 2001; 45: S136-42. 
 207 
 
10  
General Discussion 
 
 
 
CHAPTER 10 
 208
Hyperkeratotic disorders and RAMBAs 
All-trans-retinoic acid (all-trans-RA), the naturally occurring derivative of vitamin A is 
one of the principal endogenous compounds that controls growth and differentiation of 
epithelial tissue.1,2 In order to sustain normal structure and function, the epidermis of the 
skin, a keratinized epithelium, requires a certain quantity of all-trans-RA. Cells retrieve 
their all-trans-RA from the plasma, either directly or indirectly as vitamin A (retinol, 
ROL). Both endogenous compounds are ingested through the diet and are constitutively 
present in plasma at a concentration of 4-14nM for all-trans-RA and 2µM for ROL 
under normal dietary conditions.3-6 They are available to the epidermis from the vascu-
lature of the underlying dermis. Once permeated to the epidermis, ROL may serve as a 
substrate for all-trans-RA synthesis in situ.7 Inside the cells, all-trans-RA exerts most of 
its biological activities through binding to specific receptors (RAR-RXR), belonging to 
the superfamily of nuclear receptors.8,9 Nuclear receptors regulate transcription of genes 
by acting as ligand-inducible transcription factors. As such they can manage genes 
involved in processes as cell differentiation, cell proliferation, apoptosis etc. Today, the 
molecular mechanisms underlying the action of retinoids i.e. both the natural and 
synthetic compounds that share structural and/or functional similarity with vitamin A, 
are not yet fully understood. They can be antiproliferative in hyperproliferating systems, 
induce hyperproliferation in normal proliferating systems and they possess immuno-
modulating properties. The concentration of all-trans-RA within the cells is tightly 
regulated in part by specific catabolising microsomal cytochrome P450 enzymes i.e the 
CYP26 family which oxidizes all-trans-RA into 4-hydroxy-RA and further into 4-oxo-
RA. CYP2S1, another cytochrome P450 enzyme has also shown to be able to catabolise 
all-trans-RA in skin.10,11 
Since the discovery that vitamin A-deficiency leads to keratinizing metaplasia and 
hyperkeratosis, numerous studies have followed focusing on the metabolism and phar-
macological action of ‘retinoids’ in the skin which has led to the establishment of 
retinoid treatment for various skin diseases like psoriasis, ichthyosis and acne.12-14 
Although very effective, the use of oral retinoids is hampered by systemic toxicity i.e. 
long-lasting teratogenicity, hypertriglyceridaemia, hepatotoxicity, skeletal malforma-
tions, etc. Effective clinical doses of oral retinoids significantly increase the physiologi-
cal retinoid levels in the circulation and consequently, in the whole body where they 
may cause undesirable effects.15,16 Some retinoids are even stored in adipose tissue and 
cause chronic toxicity and birth defects for months after discontinuation of therapy.17 
Next to that, prolonged treatment with retinoids has proven to induce Cyp26A1-
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mediated catabolism which leads to reduced responsiveness, higher effective therapeutic 
doses and consequently more unwanted side-effects.18,19 
Hypothetically, the above mentioned problems could be circumvented by using a 
different clinical approach to administering retinoids, i.e. modulating the retinoic acid 
concentrations at the cellular level by using Retinoic Acid Metabolism Blocking Agents 
or RAMBAs. RAMBAs are compounds that block the cytochrome P450-dependent 
enzyme, retinoic acid 4-hydroxylase (CYP26), responsible for the intracellular catabo-
lism of all-trans-RA in specific target cells which leads to an increase of intracellular 
all-trans-RA concentration.20-23 Unlike existing therapies where high amounts of exoge-
nous retinoids, natural or synthetic, are administered to the body, a RAMBA modulates 
the body’s own production of all-trans-RA to achieve the same therapeutic effects.24 
Once treatment is stopped, a RAMBA is quickly eliminated from the body returning the 
intracellular metabolism of all-trans-RA back to normal and declining the elevated all-
trans-RA tissue levels.25 This targeted selective increase of all-trans-RA combined with 
the rapid clearance of the RAMBAs is expected to result in a better safety profile 
compared to oral retinoids.15,16 
Answering the question whether RAMBAs, in particular liarozole and R115866, could 
represent an effective and safer therapeutic approach for hyperkeratotic disorders like 
ichthyosis, psoriasis and acne was the main objective of this thesis. 
The first aim was to investigate the clinical use of liarozole in ichthyosis. Interest in 
liarozole, once in clinical development for psoriasis in the nineties, has now received a 
boost because of its orphan drug status for congenital ichthyosis in Europe and the 
US.26-28 Both topical and oral clinical use of liarozole in several ichthyosis subtypes 
(XRI, LI and CBIE) has been described in detail in chapters 5 and 6.  
The second aim was to explore the clinical efficacy, tolerability and safety of oral 
R115866, a more potential and selective RAMBA than liarozole, in psoriasis. The 
results of an 8 weeks study in 19 patients with moderate to severe plaque-type psoriasis 
have been presented in detail in chapter 8.  
The third aim, which was the most challenging one, was to explore the clinical efficacy, 
tolerability and safety of oral R115866 in moderate to severe facial acne vulgaris. The 
results of an open study in 17 patients with moderate to severe facial acne vulgaris have 
been presented in detail in chapter 9.  
This chapter will summarize and discuss the results of the above mentioned clinical 
studies as well as some future perspectives. At the end, some general considerations are 
discussed. 
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Liarozole, a new treatment option for severe ichthyosis? 
Today, although not approved in certain countries of the European Union and the US 
for this condition, acitretin is the most effective and the only systemic treatment avail-
able for most of the severe types of ichthyosis.29,30 However, while effective, acitretin is 
not well tolerated by the patients. The major issues are considerable RA-related cutane-
ous side effects, hypercholesterolaemia, hyperlipidaemia and the long-term teratogenic-
ity. Pre-menopausal women are advised not to become pregnant for at least 2 years 
following acitretin treatment.17 Due to the side-effect profile of acitretin, many patients 
prefer to go without systemic treatment.  Since no other drugs, systemic or topical, have 
been approved for congenital ichthyosis in EU or the US today; the only options left are 
the use of emollients, bathing, mechanical removal of the scales and other less effective 
methods which badly impact the quality of life. There is a clear need for safer and more 
effective agents for these orphan diseases.  
Clinical efficacy, tolerability and safety of oral and topical liarozole in severe ich-
thyosis 
In 1998, Lucker et al. provided the first evidence in an open study that oral liarozole 
was an effective treatment for severe ichthyosis. The overall response to treatment 
assessed by the investigator at the end of a 12 week treatment period with 300mg 
liarozole daily revealed an at least markedly improvement in all patients.31 The treat-
ment was well tolerated, adverse events (AEs) were reported in 11 out of 12 patients. 
The most frequently reported AEs were mild mucocutaneous RA-related side effects 
being cheilitis (10/12), pruritus (6/12) and xerosis (3/12). 
Over the years, the dose-finding studies with liarozole in the psoriasis population have 
shown that 75mg b.i.d. was the optimum dose and that any dose higher than 75mg b.i.d. 
didn’t give an appreciable better therapeutic effect and was less tolerated. Next to 
that, studies with synthetic retinoids have shown that the dose needed for therapeutic 
efficacy is similar for the various types of keratinisation disorders, including psoriasis 
and ichthyosis. Based on these data, the dose of oral liarozole was lowered to 75mg 
b.i.d. for the comparative study versus acitretin in ichthyosis described in chapter 6.  
The results of the double-blind comparative study suggest that oral liarozole at a daily 
dose of 150 mg is equally effective as a treatment for severe ichthyosis as acitretin 
(35mg daily) and shows a trend towards a more favourable tolerability profile. Overall 
scaling (sum of scaling at all locations, i.e. trunk, upper and lower limbs) had improved 
significantly from baseline (p<0.001) within both treatment groups. For overall ery-
thema and overall bullae, no significant changes from baseline were observed in any of 
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the treatment groups. The overall response to treatment when assessed by the investiga-
tor revealed at least marked improvement in 10/15 patients for the liarozole group and 
in 12/16 patients for the acitretin group. Both the number of adverse events and the 
incidence of hypertriglyceridaemia in this trial were lower in the liarozole group than in 
the acitretin group and will be further discussed below, however a larger trial will be 
needed to show statistical significance.  
To broaden the margin between efficacy and side-effects, a topical formulation was 
developed. In Chapter 5, the short- and long-term clinical efficacy and safety of topical 
liarozole 5% cream has been described in 12 patients with several ichthyosis subtypes 
(XRI, LI and CBIE). After a 4 weeks double-blind treatment versus placebo, a signifi-
cant unilateral improvement in extent and severity of skin lesions was observed in 
favour of the liarozole-treated side. The extent and severity of the lesions further im-
proved during the 6 weeks open phase and 72 weeks maintenance phase. At the end of 
the maintenance study, the overall assessment of the response to treatment rated by the 
investigator as well as the patient was considered to be “good/excellent” for 7 out of 8 
patients and 1 patient was completely cleared. Kinetic data from this study indicate 
some systemic absorption of topical liarozole in patients with NELI or CBIE and less 
with XRI. As no significant differences were found between these groups in the amount 
of liarozole used, the differences in liarozole plasma concentrations might be related to 
a different absorption caused by differences in skin barrier function amongst the sub-
types. This will need further investigation in a larger population. Clinical side effects 
were only minimal. Topical liarozole was well tolerated, even through the 72 weeks 
maintenance study with only 11 AEs reported in 7 out of 8 patients, all being mild and 
temporary. The most reported AE was ‘sticky feeling of the skin’ reported by 4 patients. 
Currently, the clinical data demonstrating the efficacy and safety of liarozole in the 
treatment of ichthyosis is limited. However, the present data gathered and the particular 
pharmacokinetics of liarozole indicate that the drug is an attractive candidate worth-
while developing for the treatment of severe ichthyosis.  
Future studies with liarozole in severe ichthyosis 
Dose-finding studies will be required to optimize both the efficacy and safety of topical 
and oral liarozole treatment. The major issue one encounters when performing clinical 
studies in an orphan disease like severe ichthyoses is finding enough patients. The low 
incidence and the genetic heterogeneity of the ichthyoses make recruitment very hard. 
Next to that, there is the fact that placebo-controlled studies lasting longer than 3 
months are not well accepted by the patients. An ongoing phase II/III study is evaluat-
ing the efficacy and safety of 2 doses of oral liarozole (75 mg and 150 mg once daily) 
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given during 12 weeks compared to placebo in patients with lamellar ichthyosis. The 
outcome of the study should clarify whether a once daily treatment regimen of liarozole 
also provides therapeutic activity while further improving the side effect profile of the 
drug.  
Oral R115866, a promising anti-psoriatic treatment? 
Despite the fact that many new therapies, like the biologicals, have been developed, 
retinoids as monotherapy or in combination with other treatment modalities remain a 
useful therapy for the treatment of psoriasis.32,33 Today, acitretin (Neotigason®, Sori-
atane®) is the only oral, and tazarotene (Zorac®, Tazorac®), the only topical retinoid, 
approved for psoriasis in most European countries and in the US.29,34-38 Oral tazarotene 
has completed Phase III studies but at the time of writing its manufacturer has received 
a non-approvable letter from the U.S. Food and Drug Administration.39 As mentioned 
before, the use of acitretin is also restricted in psoriasis due to its toxicity profile and its 
long-term teratogenicity.  
Whereas the first RAMBAs where non-selective CYP inhibitors, a thorough screening 
yielded a very selective and highly active retinoic acid 4-hydroxylase inhibitor namely 
R115866 (RambazoleTM).23 Similar to all-trans-RA, both oral and topical R115866 
exhibit modulating effects on epithelial growth and differentiation in various animal 
models of keratinisation which suggests a therapeutic potential in hyperkeratotic disor-
ders like psoriasis.23,40,41 Compared to liarozole, R115866 is a more potent (IC50 in nM 
range) and selective retinoic acid 4-hydroxylase inhibitor, hence expected to result in 
clinical efficacy at lower dosages and consequently in less adverse events.  
Clinical efficacy, tolerability and safety of oral R115866 in moderate to severe plaque 
type psoriasis 
The results of an 8 weeks exploratory study in patients with moderate to severe plaque-
type psoriasis, suggest that oral R115866 may be an effective and well tolerated treat-
ment which warrants further investigation, see chapter 8. Of the complete cases, 38% 
had at least PASI50 at end of treatment and 54% at follow-up. These data are in line 
with efficacy data found on acitretin, the preferred systemic retinoid in the treatment of 
psoriasis for more than 10 years.42 PASI 50 was reached after 8 weeks treatment with 
acitretin in 44.5% and 57% of the patients respectively treated with an initial dose of 
50mg/day and 40mg/day for 4 weeks followed by a dose adjustment according to 
therapeutic response.43,44 A treatment duration extending 8 weeks may be needed to 
achieve optimal clinical efficacy. 
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The most common adverse events with R115866 in this trial were pruritus, xerosis, 
cheilitis and an increase in blood triglycerides which will be discussed below.  
Kinetic data were in line with those obtained in healthy volunteers and revealed no 
accumulation of R115866 throughout the study and a rapid clearance (within hours) 
from the body once treatment was stopped.24 At all time points, increases in plasma all-
trans-RA levels remained within physiological limits and were comparable, except after 
the first dose, where the increase was slightly higher. This might indicate that the feed-
back mechanism responsible for the reduced activity seen with retinoids after long-term 
treatment does not seem to affect much the potential of R115866.  
Assessment of the dynamics of epidermal proliferation, keratinization, lesional T-cell 
subsets and cells expressing NK-receptors in only 6 patients (data have been presented 
elsewhere) revealed that clinical efficacy of R115866 is primarily the result of restoring 
proliferation and differentiation of epidermal keratinocytes.45 Also a tendency toward 
reduction of relevant T-cell subsets and cells expressing NK-receptors was shown 
suggesting that R115866 might possess anti-inflammatory activities and supporting the 
concept that a longer treatment with R115866 will probably further improve clinical 
efficacy.  
In conclusion, R115866 may be an effective and well tolerated treatment for patients 
with moderate to severe plaque-type psoriasis and warrant further investigation. 
Future studies with R115866 in psoriasis 
The preliminary data presented here suggest that R115866 has a potential as a treatment 
for plaque-type psoriasis. Additional controlled studies and dose-finding studies will be 
required to confirm the efficacy and establish the optimum treatment dose and safety. 
The fact that some non-responders in this exploratory study had a very high body mass 
index (e.g. 49.4) could indicate that a ‘dose by weight’ (mg/kg) regimen might be 
necessary. Next to that, the data point out that a longer treatment with R115866 will 
probably improve clinical efficacy so optimisation of the treatment duration is definitely 
necessary. Future clinical studies should include a quality of life survey and close 
monitoring of triglycerides. Also the possible anti-inflammatory activity of R115866 
needs further investigation. 
As R115866 seems to be a promising drug for the treatment of plaque type psoriasis, it 
could be worthwhile exploring the clinical efficacy of R115866 in other types of psoria-
sis like palmo-plantar psoriasis or even psoriatic arthritis. 
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Oral R115866, an effective treatment for facial acne? 
Although being the most effective treatment available for severe acne, the use of oral 
isotretinoin is restricted due to its side effect profile i.e. teratogenicity, elevations in 
triglycerides and liver enzymes and to a lesser degree cholesterol levels.46-49 Also the 
high incidence of cutaneous RA-related side effects can sometimes be troublesome and 
lead to discontinuation of the treatment. So there is room for alternatives with a more 
favourable safety profile.  
Next to its effect on epithelial growth and differentiation, oral R115866 also reduces the 
sebaceous gland size in hamsters. In addition, topical application of R115866 has 
revealed a reduction of the utriculus size in rhino mouse back skin (predictive for acne) 
and also a dose-dependent reduction of pro-inflammatory cytokines at the mRNA level 
like IL-1α in the skin of healthy volunteers, suggesting a possible anti-inflammatory 
activity.41,50 Based on these properties, R115866 was hypothesized to be effective in 
skin disorders such as acne vulgaris where an aberrant keratinization is combined with 
an excessive sebum production/excretion. 
Clinical efficacy, tolerability and safety of oral R115866 in moderate to severe facial 
acne vulgaris 
The results of an open exploratory trial in patients with moderate to severe facial acne 
vulgaris as presented in chapter 9, indicate that R115866 could indeed not only be an 
effective but also a well tolerated treatment with equally good effects on inflammatory 
and non-inflammatory lesions. A significant mean reduction in inflammatory lesions of 
77.4% (p<0.001), in non-inflammatory lesions of 58.3% (p<0.001), and in total lesion 
count of 76% (p<0.001) was observed at the end of treatment compared to baseline. The 
improvement was still pronounced 4 weeks after the last drug intake. This excellent 
treatment effect was confirmed by the acne severity scores and overall effectiveness 
scores by investigator and patients. In line with our data, a 56% mean reduction of non-
inflammatory lesions was achieved after 12 weeks of treatment with oral tazarotene, a 
synthetic retinoid in development for acne and psoriasis. However, the mean % reduc-
tion of total count of papules and pustules was 76% for R115866 versus 50% for 3mg 
and 52% for 6 mg tazarotene; the mean % reduction of the nodulocystic lesions were 
81.3% for R115866 versus 65% and 71% for 3 mg and 6 mg tazarotene.51 These pre-
liminary results suggest that R115866 is equipotent to oral tazarotene in improving the 
non-inflammatory lesions but may exhibit a greater efficacy in improving inflammatory 
lesions. Although the series of patients is small, it is worth mentioning that the reported 
side effects were low in incidence and severity. No elevated blood triglyceride levels 
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were reported as adverse event although they are often seen after oral isotretinoin 
treatment. 49  
In conclusion, oral R115866 deserves further clinical investigation to optimize dose and 
duration of treatment in patients with moderate to severe acne.  
Future studies with R115866 in facial acne vulgaris 
In order to further clarify the potential of oral R115866 in the treatment of moderate to 
severe facial acne vulgaris, larger clinical studies using a placebo- or active-controlled 
approach as well as dose-finding studies will be necessary. As topical R115866 revealed 
a reduction of the utriculus size in rhino mouse back skin (predictive for acne) and also 
a dose-dependent reduction of pro-inflammatory cytokines in the skin of healthy volun-
teers, another option would be to investigate the potential of topical R115866 in the 
milder forms of facial acne vulgaris. If such studies prove to be positive, one might 
think of using the combination of oral R115866 as a short-term first line therapy for the 
moderate to severe forms of acne followed by a maintenance treatment with topical 
R115866. 
General Considerations 
The major issues with the available oral retinoids today, as described above, are hyper-
lipidaemia and long-term teratogenicity (acitretin). How about the RAMBAs, liarozole 
and R115866? 
Hypertriglyceridaemia 
During acitretin treatment in psoriasis at a dose of 30 to 60 mg/day, a 35% increase in 
serum triglycerides was observed.44 A safety analysis of all the data gathered over the 
years in the psoriasis and ichthyosis clinical trials with liarozole showed a higher 
incidence (p=0.298) of hypertriglyceridaemia in the 150 mg liarozole group (10%) 
compared to the placebo (5%) but a significantly lower incidence compared to acitretin 
group (15%, p=0.036).52 Similar observations were found for hypercholesterolemia: 6% 
in the 150 mg liarozole group vs. 3% in the placebo (p>0.999, ns) and 9% in the 
acitretin group (p=0.034). Also for the ≥150 mg liarozole group, the incidence of 
hypertriglyceridaemia and hypercholesterolemia is significantly lower when compared 
to the acitretin group (p=0.002 and 0.005 respectively).  
In the open psoriasis study with oral R115866 (chapter 8), elevated triglycerides were 
reported as an adverse event in 10 out of 19 patients. Interestingly, 6 out of 9 screening 
failures in this study were due to pre-existent hypertriglyceridaemia and 6 patients that 
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were included had already triglyceride levels above normal values at baseline, so before 
the first intake of the study medication. The fact that no abnormal triglyceride levels 
were recorded as an AE in the open exploratory trial with R115866 in moderate to 
severe facial acne vulgaris adds evidence to the hypothesis that elevated blood triglyc-
erides or the susceptibility to have increases in blood triglycerides may be intrinsic to 
the psoriasis population.53-56 Recent work by Mallbris et al. in 200 patients with psoria-
sis at the onset of the disease supports the notion that lipid abnormalities in psoriasis are 
already present and probably genetically determined.57 However, this phenomenon 
needs further investigation and close monitoring.  
Long-term teratogenicity 
The main advantage of RAMBAs over acitretin lies in their inherent property towards 
long-term teratogenicity. Etretinate and acitretin have the disadvantage of being stored 
in subcutaneous adipose tissue from which they are slowly released into the plasma.  
This is, in view of the teratogenic potential, a real burden for women of child-bearing 
age as they are advised not to become pregnant for at least 2 (Europe) to 3 (US) years 
following acitretin treatment. Neither liarozole nor R115866 accumulate in plasma or 
tissues during treatment and both drugs are rapidly cleared from the body once treat-
ment is stopped (within hours) as shown in chapters 4 and 8.25,40,58 The elevated RA 
levels in plasma (still within physiological limits) and in tissue also rapidly return to 
baseline levels after discontinuation of the treatment which significantly minimizes the 
waiting period to become pregnant as compared to acitretin.17,24 
Conclusion 
The data presented in this thesis suggest that RAMBAs, compared to the oral retinoids 
available today, are at least equally effective treatments for hyperkeratotic disorders and 
they display a trend towards a more favourable safety profile. However, larger and 
longer studies will be needed to confirm these preliminary results. 
Retinoids possess a remarkable range of activities and clinical uses. Other cutaneous 
disorders previously shown to be responsive to retinoids such as photoaging, dyspig-
mentation, actinic keratosis, etc. are likely to respond positively to RAMBAs too. As 
more insight is gained into the mechanism of action of retinoids and their intracellular 
metabolism, more opportunities will arise for RAMBAs. The latter form the object of a 
series of ongoing studies and research projects for the forthcoming years.  
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Summary 
 
 
 
 
 
 
The outer layers of the human skin (epidermis) serve as the first line of defence between 
the internal body organs and the environment; it is a mechanical barrier that protects 
from pathogens, irritants and allergens whilst regulating the loss of water. Disturbance 
of the barrier can lead to significant water loss, the penetration of microbes and aller-
gens and to the onset of inflammation. In order to produce and maintain that barrier 
function, the epidermis is a dynamic, continually renewing structure with a homeostasis 
that is carefully regulated. It is a stratifying epithelium consisting of stacked layers of 
keratinocytes connected by protein bridges called desmosomes. At the bottom, in the 
basal layers, are cells that continually divide and thereby regenerate the skin. As cells 
move outwards from the basal layer, they differentiate into their terminal state and 
desquamate. During this maturation process the physiology, chemical composition, 
shape and orientation of the keratinocytes changes. Under various pathophysiologic 
conditions, these orderly processes of growth and differentiation become disturbed and 
may lead to hyperkeratotic skin disorders like ichthyosis, psoriasis and acne. These 
three main hyperkeratotic disorders, their current and future treatment options are 
introduced in Chapter 1.  
Hyperkeratosis (aberrant scaling) is mostly the result of an abnormal cell turnover 
caused by changes in the keratinocyte life-cycle, which may or may not be immune-
mediated. The best known example is psoriasis, where hyperkeratosis is associated with 
aberrant differentiation and inflammation caused by the release of cytokines into the 
epidermis by keratinocytes and lymphocytes. Hyperkeratosis is also one of the factors 
involved in the pathogenesis of acne. The keratinocytes lining the inside of a hair 
follicle normally detach from the lining, attach to the growing hair and die, while 
converting themselves into corneocytes and forming the hair cuticle. In 
hyperkeratinization, a number of these cells convert too fast, clumping together instead 
of attaching to the cuticle. When such a clump of cells blocks the follicle exit, it 
contributes to acne. Genetic abnormalities in structural cytoskeleton proteins or in 
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enzymes responsible for the formation of the cornified cell envelope or the metabolism 
of the intercellular lipids are among the main causes of keratinization disorders such as 
ichthyosis. These, however, are relatively rare.  
All-trans-retinoic acid (all-trans-RA), the naturally occurring derivative of vitamin A is 
one of the principal endogenous compounds that controls growth and differentiation of 
epithelial tissue. Since the discovery that vitamin A-deficiency leads to keratinizing 
metaplasia and hyperkeratosis, numerous studies have focused on the metabolism and 
pharmacological action of ‘retinoids’ in the skin which has led to the establishment of 
retinoid treatment for various skin diseases like psoriasis, ichthyosis and acne. The 
retinoids comprises the natural and synthetic compounds that share structural and/or 
functional similarity with vitamin A. 
Although very effective, the use of oral retinoids is hampered by systemic toxicity and 
topical retinoids have not been proved a successful alternative because of skin irritation. 
A different clinical approach to administering retinoids is to modulate the retinoic acid 
concentrations at the cellular level by using a Retinoic Acid Metabolism Blocking 
Agent or RAMBA. RAMBAs (e.g. liarozole, R115866) are compounds that block a 
cytochrome P450-dependent enzyme i.e. the retinoic acid 4-hydroxylase (CYP26) 
responsible for the intracellular catabolism of all-trans-RA in specific target cells.  This 
targeted selective increase in all-trans-RA is expected to result in a good therapeutic 
effect and a better safety profile compared to oral retinoids. The main objective of this 
work is to answer the question whether RAMBAs, liarozole and R115866 in particular, 
could represent an effective and safer therapeutic approach for hyperkeratotic disorders 
like ichthyosis, psoriasis and acne.The history and the mechanism of action of both the 
retinoids and the RAMBAs are elaborated in Chapter 1. 
Chapter 2 describes the effect of 3 generations RAMBAs (ketoconazole, liarozole and 
R115866) on cell proliferation and viability of 3 major skin cell types i.e. keratinocytes, 
fibroblasts and endothelial cells. The in vitro comparison points out a different sensitiv-
ity of the cell types towards the RAMBAs with the keratinocytes being the most sensi-
tive. In the light of a future topical development, the effect of R115866 on cell viability 
and skin permeability has been studied in vitro using human reconstituted epidermis as 
an alternative for animal testing. R115866 is found to be devoid of enhancing the 
permeation of H3-water through reconstructed skin epidermis or inducing morphologi-
cal changes, see Chapter 3.  
Interest in liarozole, the first RAMBA once in clinical development in the nineties for 
psoriasis and ichthyosis, has today received a boost because of its orphan drug status for 
congenital ichthyosis in Europe and the US. A review of liarozole’s in vivo pharmacol-
ogy related to dermatology is presented in Chapter 4 whilst the next two chapters cover 
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its clinical use in several ichthyosis subtypes (XRI, LI and CBIE). The short (10 weeks) 
and long-term (72 weeks) clinical efficacy and safety of topical liarozole 5% cream is 
described in Chapter 5. After a 4 weeks double-blind treatment versus placebo, a signifi-
cant unilateral improvement in extent and severity of skin lesions was observed in favour of 
the liarozole-treated side. The lesions further improved during the following 6 weeks open 
phase and 72 weeks open maintenance phase. Clinical side effects were only minimal and 
the treatment was well tolerated. These clinical findings justify consideration of liarozole 
cream as a front-line treatment for ichthyosis. 
The results of a 12 week double-blind comparative trial between oral liarozole and 
acitretin, the only drug approved today for the treatment of congenital ichthyosis are 
discussed in Chapter 6.  The data suggest that oral liarozole at a daily dose of 150 mg is 
equally effective as 35 mg acitretin daily but shows a trend towards a more favourable 
tolerability profile. Both the number of adverse events and the incidence of hypertriglyceri-
daemia in this trial are lower in the liarozole than in the acitretin group; however a larger 
trial will be needed to show statistical significance.  
The clinical use of retinoids and RAMBAs in psoriasis is reviewed in Chapter 7. 
Specific information on the pharmacology and pharmacokinetics of R115866, the most 
selective and specific RAMBA, is also provided here.  
Chapter 8 discusses the results of an 8 week exploratory study with oral R115866, 1 
mg daily in patients with moderate to severe plaque-type psoriasis. Of the complete 
cases, 38% had at least PASI50 at end of treatment and 54% at follow-up which is 
comparable to efficacy data found on acitretin, the preferred systemic retinoid in the 
treatment of psoriasis for more than 10 years. A treatment duration extending 8 weeks 
may be needed to achieve optimal clinical efficacy. The kinetic data from this study 
reveal no accumulation of R115866 and a rapidly clearance from the body once treat-
ment is stopped (within hours) which could significantly minimize the ‘safe time’ to 
conceive as compared to acitretin (2 years in EU). Throughout the study, the increases 
in plasma all-trans-RA levels remain within physiological limits. The data from this 
study suggest that R115866 may be an effective and well tolerated treatment for plaque 
type psoriasis which warrants further investigation.  
Chapter 9 presents a 12-week exploratory study with oral R115866, 1 mg daily in 
patients with moderate to severe facial acne vulgaris. The data indicate that R115866 
could not only be an effective but also a well tolerated treatment for this skin disorder 
with equally good effects on inflammatory and non-inflammatory lesions. A significant 
mean reduction in inflammatory lesions of 77.4% (p<0.001), in non-inflammatory 
lesions of 58.3% (p<0.001), and in total lesion count of 76% (p<0.001) is observed at 
the end of treatment compared to baseline. This improvement is still pronounced 4 
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weeks after the last drug intake. Although the series of patients is small, it is worth 
mentioning that the reported side effects are low in incidence and severity and no 
elevated blood triglyceride levels are reported as adverse event.General considerations 
and future perspectives related to the treatment of hyperkeratotic disorders with RAM-
BAs are dealt with in Chapter 10.  
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Samenvatting 
 
 
 
 
 
 
 
De buitenste lagen van de huid, de epidermis, vormen een mechanische barrière tussen 
onze interne organen en de omgeving waarin we leven. Ze biedt bescherming tegen 
pathogenen, irriterende producten en allergenen terwijl ze het waterverlies regelt. 
Wanneer de epidermis beschadigd wordt, komt de barrièrefunctie in gevaar wat kan 
leiden tot waterverlies, het binnendringen van kiemen en allergenen en uiteindelijk tot 
ontstekingen. Om er voor te zorgen dat de barrièrefunctie intact blijft, wordt de epider-
mis voortdurend vernieuwd op een zorgvuldig gereguleerde manier. Het is een gestrati-
fieerd epithelium d.w.z. het is opgebouwd uit verschillende lagen cellen met name 
keratinocyten, die met elkaar verbonden zijn door eiwitbruggen of desmosomen. De 
onderste of basale laag  bevat cellen die zich continu delen en zodoende de epidermis 
hernieuwen. Vanuit deze basale lagen schuiven de cellen op naar bovenliggende lagen 
waar ze differentiëren tot verhoornde cellen (corneocyten) en uiteindelijk afschilferen. 
Tijdens dit maturatie- of rijpings-proces verandert niet alleen de fysiologie en de chemi-
sche compositie maar ook de vorm en de oriëntatie van de keratinocyten. 
Onder bepaalde patho-fysiologische condities kan dit netjes geordend proces van groei 
en differentiatie verstoord worden en leiden tot hyperkeratiniserende huidziekten zoals 
ichthyosis, psoriasis en acne. In hoofdstuk 1 worden deze 3 belangrijke hyperkeratoti-
sche huidziekten samen met hun huidige en toekomstige behandelingen geïntroduceerd. 
Hyperkeratinisatie (overmatige hoorn/schilfervorming), is meestal het gevolg van een 
abnormale celvernieuwing veroorzaakt door veranderingen in de levenscyclus van de 
keratinocyten, al dan niet gestuurd door het immuunsysteem. Het meest bekende voor-
beeld hiervan is psoriasis waar de hyperkeratosis samengaat met een aberante prolifera-
tie/differentiatie en inflammatie die veroorzaakt wordt door de vrijstelling van cytokines 
in de epidermis door keratinocyten en lymfocyten. Hoewel niet onmiddellijk zichtbaar 
is hyperkeratinisatie ook één van de factoren betrokken in de pathogenese van acne. In 
normale omstandigheden komen de keratinocyten die zich aan de binnenkant van de 
haarfollikel bevinden los, hechten zich vast aan het groeiende haar en sterven af. Bij 
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hyperkeratinisatie komt een groot deel van deze keratinocyten te snel los en klitten ze 
samen tot een klompje. Hierdoor treedt er een vernauwing op van de follikels waardoor 
de afvloeiing van talg wordt belemmerd en de ontwikkeling van acne wordt bewerkstel-
ligd. Genetische afwijkingen in structurele eiwitten van het cytoskelet of in enzymen 
verantwoordelijk voor de vorming van de cornified envelope of het metaboliseren van 
de intracellulaire vetten liggen aan de basis van keratinisatiestoornissen zoals de icht-
hyosis, die eerder zeldzaam zijn. 
All-trans-vitamine A zuur, een natuurlijk derivaat van vitamine A, is één van de belang-
rijkste endogene moleculen verantwoordelijk voor de groei en differentiatie van epithe-
liale weefsels. Sinds de ontdekking dat een tekort aan vitamine A o.a. leidt tot hyperke-
ratinisatie is er heel wat onderzoek geweest naar het metabolisme en het farmacologisch 
effect van vitamine A in de huid. Dit heeft geleid tot het ontwikkelen van tal van retino-
iden (= natuurlijke en synthetische stoffen die structureel en/of functioneel verwant zijn 
met vitamine A) voor de behandeling van verschillende huidziekten als ichthyosis, 
psoriasis and acne. Hoewel ze heel efficiënt werken is het gebruik van orale retinoïden 
beperkt door een aantal storende neveneffecten. Topische retinoïden zijn minder toxisch 
maar hebben dan weer het nadeel dat ze irriterend zijn waardoor ze tot op heden nog 
geen volwaardig alternatief kunnen bieden. 
Een alternatieve aanpak om retinoïden toe te dienen is de concentratie van het natuurlij-
ke vitamine A zuur binnenin de cellen te verhogen door gebruik te maken van een 
Retinoic Acid Metabolism Blocking Agent of RAMBA. RAMBAs, zoals liarozole en 
R115866, zijn chemische stoffen die een bepaald enzyme blokkeren nl. het vitamine A 
zuur-4-hydroxylase, een cytochroom P450 afhankelijk enzyme dat verantwoordelijk is 
voor de afbraak van het vitamine A zuur in bepaalde cellen van het lichaam. Door het 
endogene all-trans-vitamine A zuur op een doelgerichte en selectieve manier te verho-
gen wordt niet alleen een betere doeltreffendheid maar vooral een beter veiligheidspro-
fiel verwacht in vergelijking tot orale retinoïden. Het hoofddoel van dit werk is het 
beantwoorden van de vraag of de RAMBAs, en met name liarozole en R115866, niet 
alleen een doeltreffende maar ook een veilige behandeling zouden kunnen zijn voor 
hyperkeratotische huidziekten zoals ichthyosis, psoriasis en acne.   
De geschiedenis van de ontwikkeling van de retinoïden en de RAMBAs alsook hun 
werkingsmechanisme is samengevat in hoofdstuk 1. 
In hoofdstuk 2 wordt het effect van 3 generaties RAMBAs (ketoconazole, liarozole en 
R115866) beschreven op celproliferatie en celviabiliteit en dit in de 3 voornaamste 
huidceltypes nl. keratinocyten, fibroblasten en endotheelcellen. De in vitro resultaten 
tonen aan dat de verschillende celtypes een verschillende gevoeligheid hebben t.o.v. de 
RAMBAs waarbij de keratinocyten de meest gevoelige zijn. Gezien de toekomstige 
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ontwikkeling van R115866 als een topische geneesmiddel werd in hoofdstuk 3 het 
effect op celviabiliteit en huidpermeabiliteit bestudeerd in vitro gebruikmakend van 
menselijk gereconstrueerde epidermis als alternatief voor dierproeven. R115866 blijkt 
noch de doorlaatbaarheid van getritieerd water doorheen gereconstrueerde epidermis te 
beïnvloeden noch een effect te hebben op de morfologie. 
Liarozole, de eerste RAMBA ooit in klinische ontwikkeling voor de behandeling van 
psoriasis in de jaren negentig heeft vandaag terug alle aandacht wegens het verkrijgen 
van de status van weesgeneesmiddel voor congenitale ichthyosis, zowel in Europa als in 
de U.S. De in vivo farmacologie van liarozole met betrekking tot dermatologie is sa-
mengevat in hoofdstuk 4, terwijl de volgende 2 hoofdstukken het klinisch gebruik van 
liarozole bespreken in verschillende ichthyosis subtypes zoals XRI, LI en CBIE.  
De klinische efficiëntie en veiligheid van topische liarozole crème zowel op korte (10 
weken) als lange (72 weken) termijn wordt beschreven in hoofdstuk 5. Na een 4 weken 
dubbel-blinde behandeling met 5% liarozole crème vs. placebo is er een unilaterale 
significante verbetering  te zien van de huidletsels aan de zijde behandeld met liarozole. 
De huidletsels verminderen verder tijdens de daaropvolgende 6 weken open en de 72 
weken onderhoudsbehandeling met liarozole crème. De neveneffecten zijn minimaal en 
de behandeling wordt goed verdragen. De klinische data bemoedigen een verdere 
ontwikkeling van liarozole crème als eerstelijnsbehandeling voor ichthyosis. 
Hoofdstuk 6 behandelt de resultaten van een dubbel blinde studie waar orale liarozole 
wordt vergeleken met acitretin, het enige goedgekeurde geneesmiddel voor de behande-
ling van congenitale ichthyosis. De data suggereren dat een behandeling van 12 weken 
met liarozole (150 mg per dag) even efficiënt is als acitretin (35 mg per dag) maar dat 
liarozole een beter veiligheidsprofiel vertoont. Zowel het aantal nevenwerkingen als het 
aantal keren dat bij patiënten hypertriglyceridemie optreedt is lager in de liarozole groep 
dan in de acitretin groep maar gezien het beperkt aantal patiënten kon geen statistische 
significantie worden aangetoond. 
Hoofdstuk 7 geeft een overzicht van het klinisch gebruik van retinoïden en RAMBAs 
in psoriasis. In dit hoofdstuk wordt ook dieper ingegaan op de farmacologie en de 
farmakokinetiek van R115866, de meest selectieve en specifieke RAMBA op dit mo-
ment.  
De resultaten van een exploratieve klinische studie met oraal R115866, 1 mg per dag 
gedurende 8 weken in patiënten met moderate tot severe plaque psoriasis worden 
besproken in hoofdstuk 8. Achtendertig procent van de patiënten die de volledige 
studie hebben doorlopen zien een verbetering van hun PASI van minstens 50% op het 
einde van de behandeling (week 8). Bij follow-up (week 10) zijn het er 54% wat verge-
lijkbaar is met de efficaciteitsdata van acitretin, sinds 10 jaar het meest gebruikte retino-
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id voor de behandeling van psoriasis. Een behandeling van meer dan 8 weken zal 
waarschijnlijk nodig zijn om een grotere doeltreffendheid te bekomen. De kinetische 
data in deze studie tonen aan dat er geen opstapeling is van R115866 en dat na de laatste 
inname de molecule heel snel (binnen enkele uren) uit het lichaam verwijderd is. Dit 
betekent dat de sperperiode om zwanger te worden enorm kan worden gereduceerd in 
vergelijking met acitretin (2 jaar in Europa). Tijdens de behandeling blijven de verho-
gingen van all-trans-vitamine A zuur spiegels in het plasma binnen de fysiologische 
grenzen. De data van deze studie suggereren dat R115866 een doeltreffende en goed 
verdraagbare behandeling zou kunnen zijn voor plaque psoriasis wat uitnodigt voor 
verder onderzoek. 
In hoofdstuk 9 worden de resultaten voorgesteld van een 12 week durende exploratieve 
studie met oraal R115866, 1mg per dag in moderate to severe acne vulgaris in het 
aangezicht. R115866 blijkt niet alleen een doeltreffende maar ook een goed verdraagba-
re behandeling te zijn voor deze huidziekte. R115866 grijpt aan op zowel de inflamma-
toire als niet-inflammatoire letsels. Op het eind van de behandeling wordt ten opzichte 
van de baseline een gemiddelde reductie behaald van 77% (p<0.001) op de inflamma-
toire letsels, van 58% (p<0.001) op de niet inflammatoire letsels en van 76% (p<0.001) 
op de som van alle letsels samen. Vier weken na de laatste inname van R115866 is deze 
reductie nog steeds aanwezig. Ondanks het feit dat het hier om een kleine patiënten-
groep gaat is het toch noodzakelijk om er op te wijzen dat zowel het aantal als de 
intensiteit van de nevenwerkingen in deze studie heel laag is en dat er geen verhoogde 
triglyceriden als een nevenwerking zijn gerapporteerd. 
De algemene bevindingen en de toekomstplannen met betrekking tot het behandelen 
van hyperkeratotische huidziekten met RAMBAs zijn samengevat in hoofdstuk 10. 
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Colour Figures 
 
Figure 3.4 Light microscopical images of RHE treated with (a) Control (b) R115866, 10-5M and (c) R116010, 
10-5 M. 
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Figure 5.3 NELI patient: a) before treatment, exhibiting large brown scales covering a substantial part of the 
skin surface; b) at the end of the double-blind treatment, showing marked improvement at the liarozole treated 
side (left side of the person), whereas improvement at the cream-base treated side (right side of the person) is 
only small; c) after 6 weeks double-blind and 4 weeks open liarozole treatment, improvement is marked on both 
sides. At the previously cream-base treated right side, minimal scaling is still visible. 
 
 
a b c 
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Figure 6.4 A patient with lamellar ichthyosis with the typical phenotype consisting of large brown scales 
covering the arm: (a) before treatment and (b) after 2 weeks of treatment with 75 mg liarozole twice daily. 
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Figure 6.5 Typical hyperkeratosis in the neck of a patient with X-linked recessive ichthyosis which is giving 
the so-called ‘dirty look’ present before treatment with liarozole (a). Scaling is almost completely absent after 
treatment with liarozole (b). 
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Figure 7.1 Clinical response to acitretin (1mg/kg/day) in a patient with generalised pustular psoriasis 
(a) before and (b) after 4 weeks of treatment 
b a 
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Figure 7.3 Clinical response to R115866 (1mg/ day) in a patient with moderate to severe plaque type psoriasis 
(a) before treatment and (b) after 10 weeks i.e. 8 week treatment + 2 weeks treatment free follow-up. 
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Figure 8.2 Plaque type psoriasis on lower leg of a patient (S206) before treatment (A) and after 8 weeks of 
treatment with 1 mg R115866 (B). 
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Figure 8.3 Plaque type psoriasis on back and knee of a patient (S226) at baseline (A and C) and after 8 weeks 
of treatment with 1 mg R115866 (B and D). 
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Figure 9.1 Healing of severe papular facial acne with some residual discolouring in the sub-mandibular area 
(A) before treatment and (B) after 12 weeks of treatment with 1mg R115866 daily. 
B 
A 
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Figure 9.2 Case of moderate papulo-pustular acne almost completely cleared with minimal scarring after 12 
weeks of treatment with 1 mg R115866 daily: (A) before treatment, (B) after 12 weeks treatment. 
A 
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Fiji Mermaid by Takeshi Yamada  
 
 
 
 
 
 
Takeshi Yamada, born in 1960, developed a fascination for the city’s intricate culture 
and development as he grew up in Osaka, the third largest city in Japan. He moved to 
the United States when he was 23 years old, and lived in big cities such as Oakland, 
California; Baltimore, Maryland; Ann Arbor, Michigan; New Orleans, Louisiana; 
Chicago, Illinois and Brooklyn, NY, where he lives now. The similarities and differ-
ences among cities always fascinated him and therefore, he produced artworks based on 
what he saw, photographed, researched, interviewed and felt about the unique character-
istics of cities, such as the city’s physical, social, material, architectural and cultural 
development and people including their origin, evolution, costumes, beliefs, folkways, 
etc. in comparison to other cities. In this sense, he regards himself as a “Visual Anthro-
pologist”.  With these unique artworks, as one of the most active and respected visual 
artists in America, he had over 350 fine art exhibitions including 40 solo art exhibitions 
internationally including Spain, The Netherlands, Japan and the United States.    
His current series of super-realism artworks entitled “Museum of World Wonders: 
Coney Island Sideshow and Cabinet of Curiosities” reflect his investigation of the 
unique and distinctive culture where he lives in the Coney Island area of Brooklyn, NY.  
This special culture is called Coney Island Circus Sideshow.  His series of artworks are 
simulations and re-interpretations of this rapidly disappearing unique and distinctive 
form of modern American pop culture, which originated and blossomed in Coney Island 
when Steeple Chase Park opened in 1879.  He was particularly inspired by the series of 
artworks on display at the circus sideshow tents, which are called “gaffs”.  “Gaffs” are 
man-made objects simulating artifacts of wonder and oddities (some are completely 
fictional, such as “Fiji Mermaid” and “Jackalope”), with details great enough to fool the 
eyes and mind of the audience. His Circus Sideshow Gaffs celebrate the curiosity and 
passion of humanity, which never ceases to seek things of mystery and wonder of the 
universe. With these in mind, he created over 500 one-of-a-kind gaffs including Chu-
pacabra, Fiji Mermaids, Giant Sea Serpents, Two-Headed Babies, Shrunken Human 
Head, Fossilized Fairies, Nuclear Radiation Giant Stag Beetles, Hairy Trout, King 
Piranhas, Mongolian Giant Death Worms, Two-headed Snakes, Four-legged Turkeys, 
Giant Vampire Bats, Chinese Flesh-Eating Mushrooms, Two-headed and Six-fingered 
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Alchemist, artifacts of the Dreamland Fire of 1911 in Coney Island, relics of ancient 
civilizations, and alien artifacts/specimens collected by the Area 51 US Military Base, 
among others.  Some of his gaffs reflect his investigation of today’s technologies, and 
they are created with a digital camera, computer and photo-quality 7-color printer. 
Takeshi Yamada regards his artworks as a “Visual Encyclopedia” equipped with a 
comprehensive description of each artwork, documentations and cross-cultural anthro-
pological research behind them.  It is his hope that his artworks are vehicles to please 
the eyes, uplift the spirit, stir the imagination and express conviction.  It is his desire to 
promote a greater understanding and appreciation of the importance of the global nature 
of the world, its people and the bonds that mutually bind them.  It is his sincere wish 
that his creativity and its products contribute to the advancement of the glorious culture 
based on the sanctity of life and true humanism. 
Traditionally, a mermaid is a legendary/mythological creature with a female human 
head and torso and the tail of a fish, which inhabits the water. If it's male, it's called a 
merman. From the dawn of the humanity, across the world, sightings of mermaids are 
reported and documented. In Japan, Ningyo (人魚, human-fish) is an animal with top-
half is human and bottom-half is a fish. Ningyo can be male or female. There are many 
stories, legends, and mythologies of mermaids associated with Buddhism and Shintoism 
in Japan. There are many stories of mermaids helping or saving people. Some of the 
mummified mermaids are also enshrined at Buddhism temples as divine deity. Ningyo 
shinko (religion of mermaid) can be found many cities in Japan. The oldest record of 
mermaid in Japan is dated 619 AD in Nihonshoki (Historical Record of Japan) at the 
time of Suiko Emperor. Kuinji Temple in Fukui Prefecture is said to be the place of 
death of a woman (Buddhist nun called Yaobikuni, in her later life) who lived 800 years 
after eating the flesh of a mermaid, which was thought to have wondrous properties that 
could bring about immortality. Incidentally, a Japanese anime about this magical power 
of mermaid’s flesh was recently released in America (bi-lingual format). It is entitled 
“Mermaid Forest: Quest for Death”. It is a story of a boy who ate the flesh of mermaid 
became immortal, and lost being alone because people around him grow old and die one 
after another. He started his journey to find another mermaid, hoping to get her help to 
become mortal again.    
In 2004, Takeshi Yamada created a three-dimensional life-like life-size super realistic 
large mermaid (49x12x8 inch). Part of the Fiji Mermaid is presented on the cover of this 
work. For Yamada, the mummified mermaid is the ultimate expression of humanity’s 
curious mind to seek out mysteries and wonders of the universe.  
More information of Takeshi Yamada and his artwork can be found on the web at 
http://sideshowworld.com/SSA-15.html 
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Na mijn afstudeerstage op de  Life Sciences, Janssen Research Foundation, België, nu 
bijna 14 jaar geleden, werd mij door Prof. M. Borgers gevraagd of ik als AIO aan de 
Universiteit Maastricht nog enkele jaren verder wou studeren. Ik vond het een geweldig 
idee maar om allerhande redenen heb ik na veel twijfelen het aanbod afgeslagen. Er 
werd mij o.a. een boeiende job aangeboden  binnen de Janssen Research Foundation op 
de afdeling neuropsychofarmacologie. Het omvatte vooral basisonderzoek, een combi-
natie van electrofysiologie en moleculaire biologie. Ondanks dat het onderzoek ontzet-
tend gevarieerd was met veel interne en externe samenwerking en ik heel leuke colle-
ga’s had, was ik toch niet helemaal tevreden. Door de vele contacten met PhD studenten 
werd ik er mij van bewust dat er diep van binnen nog een sluimerend verlangen zat om 
een PhD te halen.  
Uiteindelijk werd de stap gezet, opnieuw gestimuleerd door Prof. M. Borgers, mijn 
promotor. Marcel, jij hebt van in het begin af aan in mij geloofd en nooit opgegeven. 
Bedankt voor dit jarenlange vertrouwen, voor je hulp en voor alles wat je mij hebt 
geleerd. Samen met Prof. Frans Ramaekers en Prof. Peter Steijlen, eveneens mijn 
promotoren, heb je er voor gezorgd dat ik de kans kreeg om te promoveren aan de 
Universiteit Maastricht. Frans en Peter, bedankt voor de begeleiding, het wetenschappe-
lijk advies en het vertrouwen. Jullie hebben steeds moeite gedaan om mij zoveel moge-
lijk te betrekken bij het universitair gebeuren en mij te integreren in jullie beide vak-
groepen waardoor ik steeds het gevoel had een interne AIO te zijn. Ik was altijd welkom 
en kon steeds op alle hulp en advies rekenen. Ook Dr. Maurice van Steensel, mijn co-
promotor heeft hiertoe bijgedragen. Maurice, bedankt voor jouw begeleiding, voor het 
kritisch doornemen van de manuscripten en voor je vriendschap. Het was altijd leuk en 
interessant te brainstormen over wetenschappelijke experimenten en nieuwe proof-of-
concept studies met de RAMBAs. Samen met Peter heb je mij als ‘niet dermatoloog’ 
ingeleid in de wereld van de geno-dermatologie en mijn interesse hiervoor aangewak-
kerd. Beste Frans, jou wil ik samen met Francine Teng nog even speciaal bedanken voor 
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de organisatorische basis zoals het plannen en modereren van de meetings, bijhouden 
van timelines, de brieven en voor zoveel meer... Thank you for watching over me! 
Marcel, jij hebt mij eveneens voorgesteld aan Dr. Geert Cauwenbergh waardoor ik de 
kans kreeg dit werk te voltooien binnen Barrier Therapeutics waarvoor mijn blijvende 
erkentelijkheid.  Het was niet alleen een grote maar vooral een zeer boeiende uitdaging: 
een nieuwe job, een PhD, de overstap van hersenen naar huid en van preklinisch naar 
klinisch onderzoek, een start-up bedrijf,... Het was heel druk, heel spannend maar 
ontzettend leerrijk. Jullie onuitputtelijk enthousiasme, positieve instelling, kennis en 
bruisende ideeën werkten ongelooflijk stimulerend. Jullie passie voor de RAMBAs was 
heel besmettelijk. Geert en Marcel, bedankt voor deze unieke ervaring!  
Ook Nicole Eyben wil ik bedanken want zonder haar vertrouwen, haar hulp en steun 
zou dit boekje er ook niet geweest zijn. Nicole, bedankt!  
Verder wil ik iedereen die op welke wijze dan ook heeft bijgedragen aan de totstandko-
ming van dit boekje bedanken. De leden van de beoordelingscommissie Prof. Dr. J.P.M. 
Geraedts, Prof. Dr. M.J.A.P. Daemen, Prof. Dr. H. Degreef, Prof. Dr. A.P. Oranje en 
Prof. Dr. H. van Loveren voor het kritisch doornemen van dit proefschrift. 
Al mijn collega’s bij Barrier Therapeutics voor het team-work, de wetenschappelijke 
discussies, de input, etc....maar vooral voor het begrip, de leuke momenten en de morele 
steun. In het bijzonder wil ik een woord van dank richten tot Kim Franssen en Dr. Paul 
Stoppie voor de hulp bij het preklinische werk en verder tot Johan Mertens, Luc Wou-
ters, Dr. Paul Stoppie, Dr. Marina Cools en Dr. Koen van Rossem voor de input bij de 
klinische studies en publicaties rond R115866. Dr. Lieve Vandeplassche wil ik bedan-
ken voor de begeleiding, de liarozole discussies, het kritisch doorlezen van de manu-
scripten maar ook voor de steun. Lieve, jij hebt mij heel veel bijgebracht op vlak van 
klinisch onderzoek, dank u wel! Dr. Geert Van Minnebruggen wil ik bedanken voor het 
overnemen van mijn werk tijdens deze laatste dagen, bedankt Geert. 
Alle dermatologen, hun medische teams en de patiënten die hebben meegewerkt aan de 
klinische studies. Dank aan Dr. C. Blanchet-Bardon, Dr. I. Boersma, Dr. H.J. Boven-
schen, Dr. M. Coel, Dr. J.P. Hachem, Dr. G.P.H. Lucker, Prof. Dr. D. Roseeuw, Prof. 
Dr. P.C.M. van de Kerkhof, Dr. M.A.M van Steensel, Prof. Dr. P.M. Steijlen en Dr. 
C.A. Thissen voor de goeie en leuke samenwerking. Bedankt voor de leerrijke protocol-
besprekingen, jullie advies en het kritisch nalezen van de manuscripten. 
Alle medewerkers van de vakgroep Moleculaire Celbiologie en Dermatologie van de 
Universiteit Maastricht en de medewerkers van Maia Scientific. In het bijzonder Franci-
ne, Marie-Hélène, Mieke, Fons, Ronald, Myriam, Michel, Valerie, Reno, Bieke, Marc, 
Luc en Johan: bedankt voor jullie gastvrijheid, voor het wetenschappelijk advies, de 
samenwerking in het lab en vooral voor jullie vriendschap.  
DANKWOORD 
 243 
 
 
 
Christel 
 
Alle excollega’s bij Johnson & Johnson Pharmaceutical Research and Development 
alsook iedereen die heeft bijgedragen tot mijn wetenschappelijke ontwikkeling en tot de 
ontwikkeling van de RAMBAs. 
David Borgers voor de grafische hulp bij het maken van de posters en manuscripten. 
Datawyse voor het drukken van dit boekje and I would like to thank Mr. Yamada 
Takeshi for allowing the use of his copyrighted picture of the beautiful Fiji Mermaid on 
the cover of my thesis. 
Mijn paranimfen: Kim Franssen en Leen Raeymaekers, jullie weten wel waarom ik 
jullie persé aan mijn zijde wilde! Thanks! 
Mijn ouders, broer en zussen, familie, schoonfamilie en vrienden voor hun liefde, 
morele steun en interesse. Ik beloof dat ik vanaf nu terug wat meer tijd voor jullie zal 
vrijmaken! Ik heb jullie vaak gemist! Uit het oog betekent niet uit het hart!  
Frank, dat geldt ook voor jou want je hebt veel tijd zonder mij moeten doorbrengen wat 
niet altijd gemakkelijk was. Dankzij jou en dankzij onze vele rondreizen in Afrika en 
Latijns-Amerika heb ik geleerd te relativeren en te beseffen dat het leven mild voor mij 
is geweest en nog steeds is, bedankt.  
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Christel J. Verfaille werd geboren in Menen, België op 19 maart 1969. Nadat zij  haar 
diploma van algemeen secundair onderwijs in de richting Latijn-Wetenschappen be-
haalde aan het Sint-Aloysiuscollege in Menen is ze naar Gent getrokken waar ze aan de 
Hogelschool Sint-Lieven de opleiding Farmaceutische en Biologische Technieken heeft 
gevolgd. De 6 maand-durende praktijkstage horende bij deze opleiding heeft ze vol-
bracht op de afdeling Eiwitzuivering, Innogenetics N.V. in België waar ze de zuivering 
van recombinant humaan keratinocyt groei factor m.b.v. metaalaffiniteitschromatograp-
hy heeft geoptimaliseerd. In datzelfde jaar vervolgde zij haar studie aan de Hogeschool 
West-Brabant in Nederland waar ze in 1993 afstudeerde met grootste onderscheiding als 
medisch ingenieur. Het daarbij horende afstudeerproject “Morfologische karakterisatie 
van gastro-intestinale motiliteitsstoornissen.” heeft ze volbracht op de afdeling Life 
Sciences van de Janssen Research Foundation, Beerse, België . 
Christel begon haar professionele carrière in oktober 1993 bij Johnson and Johnson 
Pharmaceutical Research and Development, een afdeling van Janssen Pharmaceutica 
nv, Beerse, België waar ze gedurende 9 jaar heeft gewerkt op de afdeling CNS. De 
eerste 7 jaar (1993-2000) was ze betrokken bij verschillende basisresearch projecten, 
ook buiten CNS. Ze heeft zich voornamelijk toelegd op de expressieklonering van 
receptoren en ionenkanalen in Xenopus laevis oocyten gebruik makend van de ‘2-
electrode voltage clamp’ techniek en ontwikkelde een expertise in electrofysiologie and 
moleculaire biologie. Van 2000-2002 werkte ze aan projecten rond neurodegeneratie, 
stress en depressie en verbreedde ze haar expertise in diermodellen, morfologie (neuro-
pathologie en neurodegeneratieve processen), histologie, immunohistochemie en recep-
torbinding-autoradiografie.  
Sinds augustus 2002 is Christel werkzaam bij Barrier Therapeutics, een jong farmaceu-
tisch bedrijf dat zich toespitst op de ontwikkeling van geneesmiddelen voor de dermato-
logie. Als project director heeft ze zich de voorbije jaren toegelegd op zowel de prekli-
nische als klinische ontwikkeling van de Retinoic Acid Metabolism Blocking Agents 
(RAMBAs) met name liarozole en R115866.  Naast haar job was Christel vanaf augus-
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tus 2002 tot november 2006 aangesteld als externe Assistent in Opleiding aan de afde-
lingen moleculaire celbiologie en dermatologie van de universiteit Maastricht o.l.v. 
Prof. M. Borgers, Prof. F.C. Ramaekers en Prof. P.M. Steijlen. Een deel van haar werk 
met de RAMBAs, wat volledig werd gefinancieerd door Barrier Therapeutics, vormt het 
onderwerp van deze PhD thesis. 
Door de jaren heen heeft ze verschillende studenten opgeleid en begeleid en heeft ze 
deelgenomen aan menig nationale en internationale congressen. 
CURRICULUM VITAE 
 247 
About the author 
Christel J Verfaille was born in Menen, Belgium on March 19th 1969. After completing 
her secondary school (Latin-Sciences) at the Sint-Aloysius College in Menen she went 
to Ghent where she obtained a Bachelors degree in Pharmaceutical and Biological 
Techniques at the Hogeschool St. Lieven. She received practical training at the depart-
ment of Protein Purification, Innogenetics nv, Belgium where she optimized the purifi-
cation of recombinant human Keratinocyte Growth Factor using metal-affinity-
chromatography. She continued her education in the Netherlands at the Hogeschool 
West-Brabant where she graduated in 1993 as an engineer in Medical Sciences. She 
completed a 6-month practical training at the department of Life Sciences, Janssen 
Research Foundation focussing on the morphological characterisation of gastro-
intestinal disorders. 
Christel started her professional carrier in October 1993 at the department of CNS, 
Johnson and Johnson Pharmaceutical Research and Development, a division of Janssen 
Pharmaceutica nv, Beerse, Belgium where she worked for 9 years. The first 7 years 
(1993-2000) she was involved in various basic research projects (also outside the CNS 
field) focusing on the ‘Expression cloning of receptors and ionchannels in Xenopus 
laevis oocytes using the 2-electrode voltage clamp technique’. During that time she 
developed an expertise in electrophysiology and molecular biology.  
From 2000-2002, she worked on projects in the field of neurodegeneration, stress and 
depression and gained expertise in animal models, morphology (neuropathology-
neurodegeneration processes), histology, immunohistochemistry and receptorbinding-
autoradiography.  
Since august 2002, she joined Barrier Therapeutics, a young pharmaceutical company 
that develops and commercializes products in the field of dermatology. There she was 
appointed project director focussing on the preclinical and clinical development of the 
Retinoic Acid Metabolism Blocking Agents (RAMBAs) e.g. liarozole and R115866. Next 
to her job, she worked as an external PhD student from August 2002 till November 
2006 at the departments of Molecular Cell Biology and Dermatology at the University 
of Maastricht under the supervision of Prof. M. Borgers, Prof. F.C. Ramaekers and 
Prof. P.M. Steijlen. Part of her work on the RAMBAs, which has been financially 
supported by Barrier Therapeutics, formed the basis of her research project which 
resulted in this thesis. 
Over the years she trained and supervised undergraduate/graduate students and at-
tended national and international meetings. 
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